This document is the approved product information for Jakavi, with the changes since the previous procedure affecting the product information (EMA/VR/0000252914) tracked.

For more information, see the European Medicines Agency’s website: <https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi>

**ANNEX I**

**SUMMARY OF PRODUCT CHARACTERISTICS**

**1. NAME OF THE MEDICINAL PRODUCT**

Jakavi 5 mg tablets

Jakavi 10 mg tablets

Jakavi 15 mg tablets

Jakavi 20 mg tablets

**2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Jakavi 5 mg tablets

Each tablet contains 5 mg ruxolitinib (as phosphate).

*Excipient with known effect*

Each tablet contains 71.45 mg lactose monohydrate.

Jakavi 10 mg tablets

Each tablet contains 10 mg ruxolitinib (as phosphate).

*Excipient with known effect*

Each tablet contains 142.90 mg lactose monohydrate.

Jakavi 15 mg tablets

Each tablet contains 15 mg ruxolitinib (as phosphate).

*Excipient with known effect*

Each tablet contains 214.35 mg lactose monohydrate.

Jakavi 20 mg tablets

Each tablet contains 20 mg ruxolitinib (as phosphate).

*Excipient with known effect*

Each tablet contains 285.80 mg lactose monohydrate.

For the full list of excipients, see section 6.1.

**3. PHARMACEUTICAL FORM**

Tablet.

Jakavi 5 mg tablets

Round curved white to almost white tablets of approximately 7.5 mm in diameter with “NVR” debossed on one side and “L5” debossed on the other side.

Jakavi 10 mg tablets

Round curved white to almost white tablets of approximately 9.3 mm in diameter with “NVR” debossed on one side and “L10” debossed on the other side.

Jakavi 15 mg tablets

Ovaloid curved white to almost white tablets of approximately 15.0 x 7.0 mm with “NVR” debossed on one side and “L15” debossed on the other side.

Jakavi 20 mg tablets

Elongated curved white to almost white tablets of approximately 16.5 x 7.4 mm with “NVR” debossed one one side and “L20” debossed on the other side.

**4. CLINICAL PARTICULARS**

**4.1 Therapeutic indications**

Myelofibrosis (MF)

Jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.

Polycythaemia vera (PV)

Jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.

Graft versus host disease (GvHD)

*Acute GvHD*

Jakavi is indicated for the treatment of adults and paediatric patients aged 28 days and older with acute graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.1).

*Chronic GvHD*

Jakavi is indicated for the treatment of adults and paediatric patients aged 6 months and older with chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.1).

**4.2 Posology and method of administration**

Jakavi treatment should only be initiated by a physician experienced in the administration of anti-cancer medicinal products.

A complete blood cell count, including a white blood cell count differential, must be performed before initiating therapy with Jakavi.

Complete blood count, including a white blood cell count differential, should be monitored every 2 to 4 weeks until Jakavi doses are stabilised, and then as clinically indicated (see section 4.4).

Posology

*Starting dose*

*Myelofibrosis (MF)*

The recommended starting dose of Jakavi in MF is based on platelet counts (see Table 1):

**Table 1 Starting doses in myelofibrosis**

| **Platelet count** | **Starting dose** |
| --- | --- |
| Greater than 200 000/mm3 | 20 mg twice daily |
| 100 000 to 200 000/mm3 | 15 mg twice daily |
| 75 000 to less than 100 000/mm3 | 10 mg twice daily |
| 50 000 to less than 75 000/mm3 | 5 mg twice daily |

*Polycythaemia vera (PV)*

The recommended starting dose of Jakavi in PV is 10 mg twice daily.

*Graft versus host disease (GvHD)*

The recommended starting dose of Jakavi in acute and chronic GvHD is based on age (see Tables 2 and 3):

**Table 2** **Starting doses in acute graft versus host disease**

|  |  |
| --- | --- |
| **Age group** | **Starting dose** |
| 12 years old and above | 10 mg twice daily |
| 6 years to less than 12 years old | 5 mg twice daily |
| 28 days to less than 6 years old | 8 mg/m2 twice daily |

**Table 3** **Starting doses in chronic graft versus host disease**

|  |  |
| --- | --- |
| **Age group** | **Starting dose** |
| 12 years old and above | 10 mg twice daily |
| 6 years to less than 12 years old | 5 mg twice daily |
| 6 months to less than 6 years old | 8 mg/m2 twice daily |

These starting doses in GvHD can be administered using either the tablet for patients who can swallow tablets whole or the oral solution.

Jakavi can be added to corticosteroids and/or calcineurin inhibitors (CNIs).

*Dose modifications*

Doses may be titrated based on efficacy and safety.

*Myelofibrosis and polycythaemia vera*

If efficacy is considered insufficient and blood counts are adequate, doses may be increased by a maximum of 5 mg twice daily, up to the maximum dose of 25 mg twice daily.

The starting dose should not be increased within the first four weeks of treatment and thereafter no more frequently than at 2-week intervals.

Treatment should be discontinued for platelet counts less than 50 000/mm3 or absolute neutrophil counts less than 500/mm3. In PV, treatment should also be interrupted when haemoglobin is below 8 g/dl. After recovery of blood counts above these levels, dosing may be re-started at 5 mg twice daily and gradually increased based on careful monitoring of complete blood cell count, including a white blood cell count differential.

Dose reductions should be considered if the platelet count decreases during treatment as outlined in Table 4, with the goal of avoiding dose interruptions for thrombocytopenia.

**Table 4 Dosing recommendation for MF patients with thrombocytopenia**

|  |  |
| --- | --- |
|  | **Dose at time of platelet decline** |
|  | 25 mgtwice daily | 20 mgtwice daily | 15 mgtwice daily | 10 mgtwice daily | 5 mgtwice daily |
| **Platelet count** | **New dose** |
| 100 000 to <125 000/mm3 | 20 mgtwice daily | 15 mgtwice daily | No change | No change | No change |
| 75 000 to <100 000/mm3 | 10 mgtwice daily | 10 mgtwice daily | 10 mgtwice daily | No change | No change |
| 50 000 to <75 000/mm3 | 5 mgtwice daily | 5 mgtwice daily | 5 mgtwice daily | 5 mgtwice daily | No change |
| Less than 50 000/mm3 | Hold | Hold | Hold | Hold | Hold |

In PV, dose reductions should also be considered if haemoglobin decreases below 12 g/dl and is recommended if it decreases below 10 g/dl.

*Graft versus host disease*

Dose reductions and temporary interruptions of treatment may be needed in GvHD-patients with thrombocytopenia, neutropenia, or elevated total bilirubin after standard supportive therapy including growth-factors, anti-infective therapies and transfusions. One dose level reduction step is recommended (10 mg twice daily to 5 mg twice daily or 5 mg twice daily to 5 mg once daily). In patients who are unable to tolerate Jakavi at a dose of 5 mg once daily, treatment should be interrupted. Detailed dosing recommendations are provided in Table 5.

**Table 5 Dosing recommendations during ruxolitinib therapy for GvHD patients with thrombocytopenia, neutropenia or elevated total bilirubin**

|  |  |
| --- | --- |
| **Laboratory parameter** | **Dosing recommendation** |
| Platelet count <20 000/mm3 | Reduce Jakavi by one dose level. If platelet count ≥20 000/mm3 within seven days, dose may be increased to initial dose level, otherwise maintain reduced dose. |
| Platelet count <15 000/mm3 | Hold Jakavi until platelet count ≥20 000/mm3, then resume at one lower dose level. |
| Absolute neutrophil count (ANC) ≥500/mm3 to <750/mm3 | Reduce Jakavi by one dose level. Resume at initial dose level if ANC >1 000/mm3. |
| Absolute neutrophil count <500/mm3 | Hold Jakavi until ANC >500/mm3, then resume at one lower dose level. If ANC >1 000/mm3,dosing may resume at initial dose level. |
| Total bilirubin elevation not caused by GvHD (no liver GvHD) | >3.0 to 5.0 x upper limit of normal (ULN): Continue Jakavi at one lower dose level until ≤3.0 x ULN. |
| >5.0 to 10.0 x ULN: Hold Jakavi up to 14 days until total bilirubin ≤3.0 x ULN. If total bilirubin ≤3.0 x ULN dosing may resume at current dose. If not ≤3.0 x ULN after 14 days, resume at one lower dose level. |
| >10.0 x ULN: Hold Jakavi until total bilirubin ≤3.0 x ULN, then resume at one lower dose level. |
| Total bilirubin elevation caused by GvHD (liver GvHD) | >3.0 x ULN: Continue Jakavi at one lower dose level until total bilirubin ≤3.0 x ULN. |

*Dose adjustment with concomitant strong CYP3A4 inhibitors or dual CYP2C9/3A4 inhibitors*

When ruxolitinib is administered with strong CYP3A4 inhibitors or dual inhibitors of CYP2C9 and CYP3A4 enzymes (e.g. fluconazole) the unit dose of ruxolitinib should be reduced by approximately 50%, to be administered twice daily (see sections 4.4 and 4.5). The concomitant use of ruxolitinib with fluconazole doses greater than 200 mg daily should be avoided.

*Special populations*

*Renal impairment*

No specific dose adjustment is needed in patients with mild or moderate renal impairment.

In patients with severe renal impairment (creatinine clearance less than 30 ml/min) the recommended starting dose based on platelet count for MF, PV and GvHD patients should be reduced by approximately 50% to be administered twice daily. Patients should be carefully monitored with regard to safety and efficacy during ruxolitinib treatment (see section 4.4).

There are limited data to determine the best dosing options for patients with end-stage renal disease (ESRD) on haemodialysis. Pharmacokinetic/pharmacodynamic simulations based on available data in this population suggest that the starting dose for MF patients with ESRD on haemodialysis is a single dose of 15 to 20 mg or two doses of 10 mg given 12 hours apart, to be administered post-dialysis and only on the day of haemodialysis. A single dose of 15 mg is recommended for MF patients with platelet count between 100 000/mm3 and 200 000/mm3. A single dose of 20 mg or two doses of 10 mg given 12 hours apart is recommended for MF patients with platelet count of >200 000/mm3. Subsequent doses (single administration or two doses of 10 mg given 12 hours apart) should be administered only on haemodialysis days following each dialysis session.

The recommended starting dose for PV patients with ESRD on haemodialysis is a single dose of 10 mg or two doses of 5 mg given 12 hours apart, to be administered post-dialysis and only on the day of haemodialysis. These dose recommendations are based on simulations and any dose modification in ESRD should be followed by careful monitoring of safety and efficacy in individual patients. No data is available for dosing patients who are undergoing peritoneal dialysis or continuous venovenous haemofiltration (see section 5.2).

There are no data for GvHD patients with ESRD.

*Hepatic impairment*

In MF patients with any hepatic impairment the recommended starting dose based on platelet count should be reduced by approximately 50% to be administered twice daily. Subsequent doses should be adjusted based on careful monitoring of safety and efficacy. The recommended starting dose is 5 mg twice daily for PV patients. Ruxolitinib dose can be titrated to reduce the risk of cytopenia (see section 4.4).

In patients with mild, moderate or severe hepatic impairment not related to GvHD, the starting dose of ruxolitinib should be reduced by 50% (see section 5.2).

In patients with GvHD liver involvement and an increase of total bilirubin to >3 x ULN, blood counts should be monitored more frequently for toxicity and a dose reduction by one dose level is recommended.

*Elderly patients (≥65 years)*

No additional dose adjustments are recommended for elderly patients.

*Paediatric population*

The safety and efficacy of Jakavi in children and adolescents aged up to 18 years with MF and PV have not been established. No data are available (see section 5.1).

*Treatment discontinuation*

Treatment of MF and PV may be continued as long as the benefit-risk assessment remains positive. However the treatment should be discontinued after 6 months if there has been no reduction in spleen size or improvement in symptoms since initiation of therapy.

It is recommended that, for patients who have demonstrated some degree of clinical improvement, ruxolitinib therapy be discontinued if they sustain an increase in their spleen length of 40% compared with baseline size (roughly equivalent to a 25% increase in spleen volume) and no longer have tangible improvement in disease-related symptoms.

In GvHD, tapering of Jakavi may be considered in patients with a response and after having discontinued corticosteroids. A 50% dose reduction of Jakavi every two months is recommended. If signs or symptoms of GvHD reoccur during or after the taper of Jakavi, re-escalation of treatment should be considered.

Method of administration

Jakavi is to be taken orally, with or without food.

If a dose is missed, the patient should not take an additional dose, but should take the next usual prescribed dose.

**4.3 Contraindications**

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Pregnancy and lactation.

**4.4 Special warnings and precautions for use**

Myelosuppression

Treatment with Jakavi can cause haematological adverse drug reactions, including thrombocytopenia, anaemia and neutropenia. A complete blood count, including a white blood cell count differential, must be performed before initiating therapy with Jakavi. Treatment should be discontinued in MF patients with platelet count less than 50 000/mm3 or absoute neutrophil count less than 500/mm3 (see section 4.2).

It has been observed that MF patients with low platelet counts (<200 000/mm3) at the start of therapy are more likely to develop thrombocytopenia during treatment.

Thrombocytopenia is generally reversible and is usually managed by reducing the dose or temporarily withholding Jakavi (see sections 4.2 and 4.8). However, platelet transfusions may be required as clinically indicated.

Patients developing anaemia may require blood transfusions. Dose modifications or interruption for patients developing anaemia may also need to be considered.

Patients with a haemoglobin level below 10.0 g/dl at the beginning of the treatment have a higher risk of developing a haemoglobin level below 8.0 g/dl during treatment compared to patients with a higher baseline haemoglobin level (79.3% versus 30.1%). More frequent monitoring of haematology parameters and of clinical signs and symptoms of Jakavi-related adverse drug reactions is recommended for patients with baseline haemoglobin below 10.0 g/dl.

Neutropenia (absolute neutrophil count <500) was generally reversible and was managed by temporarily withholding Jakavi (see sections 4.2 and 4.8).

Complete blood counts should be monitored as clinically indicated and dose adjusted as required (see sections 4.2 and 4.8).

Infections

Serious bacterial, mycobacterial, fungal, viral and other opportunistic infections have occurred in patients treated with Jakavi. Patients should be assessed for the risk of developing serious infections. Physicians should carefully observe patients receiving Jakavi for signs and symptoms of infections and initiate appropriate treatment promptly. Treatment with Jakavi should not be started until active serious infections have resolved.

Tuberculosis has been reported in patients receiving Jakavi. Before starting treatment, patients should be evaluated for active and inactive (“latent”) tuberculosis, as per local recommendations. This can include medical history, possible previous contact with tuberculosis, and/or appropriate screening such as lung x-ray, tuberculin test and/or interferon-gamma release assay, as applicable. Prescribers are reminded of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or immunocompromised.

Hepatitis B viral load (HBV-DNA titre) increases, with and without associated elevations in alanine aminotransferaseand aspartate aminotransferase, have been reported in patients with chronic HBV infections taking Jakavi. It is recommended to screen for HBV prior to commencing treatment with Jakavi. Patients with chronic HBV infection should be treated and monitored according to clinical guidelines.

Herpes zoster

Physicians should educate patients about early signs and symptoms of herpes zoster, advising that treatment should be sought as early as possible.

Progressive multifocal leukoencephalopathy

Progressive multifocal leukoencephalopathy (PML) has been reported with Jakavi treatment. Physicians should be particularly alert to symptoms suggestive of PML that patients may not notice (e.g., cognitive, neurological or psychiatric symptoms or signs). Patients should be monitored for any of these new or worsening symptoms or signs, and if such symptoms/signs occur, referral to a neurologist and appropriate diagnostic measures for PML should be considered. If PML is suspected, further dosing must be suspended until PML has been excluded.

Lipid abnormalities/elevations

Treatment with Jakavi has been associated with increases in lipid parameters including total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides. Lipid monitoring and treatment of dyslipidaemia according to clinical guidelines is recommended.

Major adverse cardiac events (MACE)

In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in rheumatoid arthritis patients 50 years of age and older with at least one additional cardiovascular risk factor, a higher rate of MACE, defined as cardiovascular death, non-fatal myocardial infarction (MI) and non-fatal stroke, was observed with tofacitinib compared to tumour necrosis factor (TNF) inhibitors.

MACE have been reported in patients receiving Jakavi. Prior to initiating or continuing therapy with Jakavi, the benefits and risks for the individual patient should be considered particularly in patients 65 years of age and older, patients who are current or past long-time smokers, and patients with a history of atherosclerotic cardiovascular disease or other cardiovascular risk factors.

Thrombosis

In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in rheumatoid arthritis patients 50 years of age and older with at least one additional cardiovascular risk factor, a dose dependent higher rate of venous thromboembolic events (VTE) including deep venous thrombosis (DVT) and pulmonary embolism (PE) was observed with tofacitinib compared to TNF inhibitors.

Events of deep venous thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients receiving Jakavi. In patients with MF and PV treated with Jakavi in clinical studies, the rates of thromboembolic events were similar in Jakavi and control-treated patients.

Prior to initiating or continuing therapy with Jakavi, the benefits and risks for the individual patient should be considered, particularly in patients with cardiovascular risk factors (see also section 4.4 “Major adverse cardiovascular events (MACE)”).

Patients with symptoms of thrombosis should be promptly evaluated and treated appropriately.

Second primary malignancies

In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in rheumatoid arthritis patients 50 years of age and older with at least one additional cardiovascular risk factor, a higher rate of malignancies, particularly lung cancer, lymphoma, and non-melanoma skin cancer (NMSC) was observed with tofacitinib compared to TNF inhibitors.

Lymphoma and other malignancies have been reported in patients receiving JAK inhibitors, including Jakavi.

Non-melanoma skin cancers (NMSCs), including basal cell, squamous cell, and Merkel cell carcinoma, have been reported in patients treated with ruxolitinib. Most of the MF and PV patients had histories of extended treatment with hydroxyurea and prior NMSC or pre-malignant skin lesions. Periodic skin examination is recommended for patients who are at increased risk for skin cancer.

Special populations

*Renal impairment*

The starting dose of Jakavi should be reduced in patients with severe renal impairment. For patients with end-stage renal disease on haemodialysis the starting dose should be based on platelet counts for MF patients, while the recommended starting dose is a single dose of 10 mg for PV patients (see section 4.2). Subsequent doses (single dose of 20 mg or two doses of 10 mg given 12 hours apart in MF patients; single dose of 10 mg or two doses of 5 mg given 12 hours apart in PV patients) should be administered only on haemodialysis days following each dialysis session. Additional dose modifications should be made with careful monitoring of safety and efficacy. In GvHD patients with severe renal impairment, the starting dose of Jakavi should be reduced by approximately 50% (see sections 4.2 and 5.2).

*Hepatic impairment*

The starting dose of Jakavi should be reduced by approximately 50% in MF and PV patients with hepatic impairment. Further dose modifications should be based on the safety and efficacy of the medicinal product. In GvHD patients with hepatic impairment not related to GvHD, the starting dose of Jakavi should be reduced by approximately 50% (see sections 4.2 and 5.2).

Patients diagnosed with hepatic impairment while receiving ruxolitinib should have complete blood counts, including a white blood cell count differential, monitored at least every one to two weeks for the first 6 weeks after initiation of therapy with ruxolitinib and as clinically indicated thereafter once their liver function and blood counts have been stabilised.

Interactions

If Jakavi is to be co-administered with strong CYP3A4 inhibitors or dual inhibitors of CYP3A4 and CYP2C9 enzymes (e.g. fluconazole), the unit dose of Jakavi should be reduced by approximately 50%, to be administered twice daily (see sections 4.2 and 4.5).

More frequent monitoring (e.g. twice a week) of haematology parameters and of clinical signs and symptoms of ruxolitinib-related adverse drug reactions is recommended while on strong CYP3A4 inhibitors or dual inhibitors of CYP2C9 and CYP3A4 enzymes.

The concomitant use of cytoreductive therapies with Jakavi was associated with manageable cytopenias (see section 4.2 for dose modifications during cytopenias).

Withdrawal effects

Following interruption or discontinuation of Jakavi, symptoms of MF may return over a period of approximately one week. There have been cases of patients discontinuing Jakavi who experienced severe adverse events, particularly in the presence of acute intercurrent illness. It has not been established whether abrupt discontinuation of Jakavi contributed to these events. Unless abrupt discontinuation is required, gradual tapering of the dose of Jakavi may be considered, although the utility of the tapering is unproven.

Excipients with known effect

Jakavi contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.

This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.

**4.5 Interaction with other medicinal products and other forms of interaction**

Interaction studies have only been performed in adults.

Ruxolitinib is eliminated through metabolism catalysed by CYP3A4 and CYP2C9. Thus, medicinal products inhibiting these enzymes can give rise to increased ruxolitinib exposure.

Interactions resulting in dose reduction of ruxolitinib

*CYP3A4 inhibitors*

*Strong CYP3A4 inhibitors (such as, but not limited to, boceprevir, clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, saquinavir, telaprevir, telithromycin, voriconazole)*

In healthy subjects co-administration of ruxolitinib (10 mg single dose) with a strong CYP3A4 inhibitor, ketoconazole, resulted in ruxolitinib Cmax and AUC that were higher by 33% and 91%, respectively, than with ruxolitinib alone. The half-life was prolonged from 3.7 to 6.0 hours with concurrent ketoconazole administration.

When administering ruxolitinib with strong CYP3A4 inhibitors the unit dose of ruxolitinib should be reduced by approximately 50%, to be administered twice daily.

Patients should be closely monitored (e.g. twice weekly) for cytopenias and dose titrated based on safety and efficacy (see section 4.2).

*Dual CYP2C9 and CYP3A4 inhibitors*

In healthy subjects co-administration of ruxolitinib (10 mg single dose) with a dual CYP2C9 and CYP3A4 inhibitor, fluconazole, resulted in ruxolitinib Cmax and AUC that were higher by 47% and 232%, respectively, than with ruxolitinib alone.

50% dose reduction should be considered when using medicinal products which are dual inhibitors of CYP2C9 and CYP3A4 enzymes (e.g. fluconazole). Avoid the concomitant use of ruxolitinib with fluconazole doses greater than 200 mg daily.

Enzyme inducers

*CYP3A4 inducers (such as, but not limited to, avasimibe, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin (rifampicin), St.John’s wort (Hypericum perforatum))*

Patients should be closely monitored and the dose titrated based on safety and efficacy (see section 4.2).

In healthy subjects given ruxolitinib (50 mg single dose) following the potent CYP3A4 inducer rifampicin (600 mg daily dose for 10 days), ruxolitinib AUC was 70% lower than after administration of ruxolitinib alone. The exposure of ruxolitinib active metabolites was unchanged. Overall, the ruxolitinib pharmacodynamic activity was similar, suggesting the CYP3A4 induction resulted in minimal effect on the pharmacodynamics. However, this could be related to the high ruxolitinib dose resulting in pharmacodynamic effects near Emax. It is possible that in the individual patient, an increase of the ruxolitinib dose is needed when initiating treatment with a strong enzyme inducer.

Other interactions to be considered affecting ruxolitinib

*Mild or moderate CYP3A4 inhibitors (such as, but not limited to, ciprofloxacin, erythromycin, amprenavir, atazanavir, diltiazem, cimetidine)*

In healthy subjects co-administration of ruxolitinib (10 mg single dose) with erythromycin 500 mg twice daily for four days resulted in ruxolitinib Cmax and AUC that were higher by 8% and 27%, respectively, than with ruxolitinib alone.

No dose adjustment is recommended when ruxolitinib is co-administered with mild or moderate CYP3A4 inhibitors (e.g. erythromycin). However, patients should be closely monitored for cytopenias when initiating therapy with a moderate CYP3A4 inhibitor.

Effects of ruxolitinib on other medicinal products

*Substances transported by P-glycoprotein or other transporters*

Ruxolitinib may inhibit P-glycoprotein and breast cancer resistance protein (BCRP) in the intestine. This may result in increased sytemic exposure of substrates of these transporters, such as dabigatran etexilate, ciclosporin, rosuvastatin and potentially digoxin. Therapeutic drug monitoring (TDM) or clinical monitoring of the affected substance is advised.

It is possible that the potential inhibition of P-gp and BCRP in the intestine can be minimised if the time between administrations is kept apart as long as possible.

A study in healthy subjects indicated that ruxolitinib did not inhibit the metabolism of the oral CYP3A4 substrate midazolam. Therefore, no increase in exposure of CYP3A4 substrates is anticipated when combining them with ruxolitinib. Another study in healthy subjects indicated that ruxolitinib does not affect the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel. Therefore, it is not anticipated that the contraceptive efficacy of this combination will be compromised by co-administration of ruxolitinib.

**4.6 Fertility, pregnancy and lactation**

Pregnancy

There are no data from the use of Jakavi in pregnant women.

Animal studies have shown that ruxolitinib is embryotoxic and foetotoxic. Teratogenicity was not observed in rats or rabbits. However, the exposure margins compared to the highest clinical dose were low and the results are therefore of limited relevance for humans (see section 5.3). The potential risk for humans is unknown. As a precautionary measure, the use of Jakavi during pregnancy is contraindicated (see section 4.3).

Women of childbearing potential/Contraception

Women of child-bearing potential should use effective contraception during the treatment with Jakavi. In case pregnancy should occur during treatment with Jakavi, a risk/benefit evaluation must be carried out on an individual basis with careful counselling regarding potential risks to the foetus (see section 5.3).

Breast-feeding

Jakavi must not be used during breast-feeding (see section 4.3) and breast-feeding should therefore be discontinued when treatment is started. It is unknown whether ruxolitinib and/or its metabolites are excreted in human milk. A risk to the breast-fed child cannot be excluded. Available pharmacodynamic/toxicological data in animals have shown excretion of ruxolitinib and its metabolites in milk (see section 5.3).

Fertility

There are no human data on the effect of ruxolitinib on fertility. In animal studies, no effect on fertility was observed.

**4.7 Effects on ability to drive and use machines**

Jakavi has no or negligible sedating effect. However, patients who experience dizziness after the intake of Jakavi should refrain from driving or using machines.

**4.8 Undesirable effects**

Summary of the safety profile

*Myelofibrosis*

The most frequently reported adverse drug reactions were thrombocytopenia and anaemia.

Haematological adverse drug reactions (any Common Terminology Criteria for Adverse Events [CTCAE] grade) included anaemia (83.8%), thrombocytopenia (80.5%) and neutropenia (20.8%).

Anaemia, thrombocytopenia and neutropenia are dose-related effects.

The three most frequent non-haematological adverse drug reactions were bruising (33.3%), other bleeding (including epistaxis, post-procedural haemorrhage and haematuria) (24.3%) and dizziness (21.9%).

The three most frequent non-haematological laboratory abnormalities identified as adverse reactions were increased alanine aminotransferase (40.7%), increased aspartate aminotransferase (31.5%) and hypertriglyceridaemia (25.2%). In phase 3 clinical studies in MF, neither CTCAE grade 3 or 4 hypertriglyceridaemia or increased aspartate aminotransferase, nor CTCAE grade 4 increased alanine aminotransferase or hypercholesterolaemia were observed.

Discontinuation due to adverse events, regardless of causality, was observed in 30.0% of patients.

*Polycythaemia vera*

The most frequently reported adverse drug reactions were anaemia and increased alanine aminotransferase.

Haematological adverse reactions (any CTCAE grade) included anaemia (61.8%), thrombocytopenia (25.0%) and neutropenia (5.3%). Anaemia and thrombocytopenia CTCAE grade 3 or 4 were reported in 2.9% and 2.6% of the patients, respectively.

The three most frequent non-haematological adverse reactions were weight gain (20.3%), dizziness (19.4%) and headache (17.9%).

The three most frequent non-haematological laboratory abnormalities (any CTCAE grade) identified as adverse reactions were increased alanine aminotransferase (45.3%), increased aspartate aminotransferase (42.6%), and hypercholesterolaemia (34.7%). No CTCAE grade 4 increased alanine aminotransferase or hypercholesterolaemia, and one CTCAE grade 4 increased aspartate aminotransferase were observed.

Discontinuation due to adverse events, regardless of causality, was observed in 19.4% of patients.

*Acute GvHD*

The most frequently reported adverse drug reactions in REACH2 (adult and adolescent patients) were thrombocytopenia, anaemia, neutropenia, increased alanine aminotransferase and increased aspartate aminotransferase. The most frequently reported adverse drug reactions in the pool of paediatric patients (adolescents from REACH2 and paediatric patients from REACH4) were anaemia, neutropenia, increased alanine aminotransferase, hypercholesterolaemia and thrombocytopenia.

Haematological laboratory abnormalities identified as adverse drug reactions in REACH2 (adult and adolescent patients) and in the pool of paediatric patients (REACH2 and REACH4) included thrombocytopenia (85.2% and 55.1%), anaemia (75.0% and 70.8%) and neutropenia (65.1% and 70.0%), respectively. Grade 3 anaemia was reported in 47.7% of patients in REACH2 and in 45.8% of patients in the paediatric pool. Grade 3 and 4 thrombocytopenia were reported in 31.3% and 47.7% of patients in REACH2 and in 14.6% and 22.4% of patients in the paediatric pool, respectively. Grade 3 and 4 neutropenia were reported in 17.9% and 20.6% of patients in REACH2 and in 32.0% and 22.0% of patients in the paediatric pool, respectively.

The most frequent non-haematological adverse drug reactions in REACH2 (adult and adolescent patients) and in the pool of paediatric patients (REACH2 and REACH4) were cytomegalovirus (CMV) infection (32.3% and 31.4%), sepsis (25.4% and 9.8%), urinary tract infections (17.9% and 9.8%), hypertension (13.4% and 17.6%) and nausea (16.4% and 3.9%), respectively.

The most frequent non-haematological laboratory abnormalities identified as adverse drug reactions in REACH2 (adult and adolescent patients) and in the pool of paediatric patients (REACH2 and REACH4) were increased alanine aminotransferase (54.9% and 63.3%), increased aspartate aminotransferase (52.3% and 50.0%) and hypercholesterolaemia (49.2% and 61.2%), respectively. The majority were of grade 1 and 2, however grade 3 increased alanine aminotransferase was reported in 17.6% of patients in REACH2 and 27.3% of patients in the paediatric pool.

Discontinuation due to adverse events, regardless of causality, was observed in 29.4% of patients in REACH2 and in 21.6% of patients in the paediatric pool.

*Chronic GvHD*

The most frequently reported adverse drug reactions in REACH3 (adult and adolescent patients) were anaemia, hypercholesterolemia and increased aspartate aminotransferase. The most frequently reported adverse drug reactions in the pool of paediatric patients (adolescents from REACH3 and paediatric patients from REACH5) were neutropenia, hypercholesterolaemia and increased alanine aminotransferase.

Haematological laboratory abnormalities identified as adverse drug reactions in REACH3 (adult and adolescent patients) and in the pool of paediatric patients (REACH3 and REACH5) included anaemia (68.6% and 49.1%), neutropenia (36.2% and 59.3%), and thrombocytopenia (34.4% and 35.2%), respectively. Grade 3 anaemia was reported in 14.8% of patients in REACH3 and in 17.0% of patients in the paediatric pool. Grade 3 and 4 neutropenia were reported in 9.5% and 6.7% of patients in REACH3 and in 17.3% and 11.1% of patients in the paediatric pool, respectively. Grade 3 and 4 thrombocytopenia were reported in 5.9% and 10.7% of adult and adolescent patients in REACH3 and in 7.7% and 11.1% of patients in the paediatric pool, respectively.

The most frequent non-haematological adverse drug reactions in REACH3 (adult and adolescent patients) and in the pool of paediatric patients (REACH3 and REACH5) were hypertension (15.0% and 14.5%) and headache (10.2% and 18.2%), respectively.

The most frequent non-haematological laboratory abnormalities identified as adverse drug reactions in REACH3 (adult and adolescent patients) and in the pool of paediatric patients (REACH3 and REACH5) were hypercholesterolaemia (52.3% and 54.9%), increased aspartate aminotransferase (52.2% and 45.5%) and increased alanine aminotransferase (43.1% and 50.9%). The majority were grade 1 and 2, however grade 3 laboratory abnormalities reported in the pool of paediatric patients included increased alanine aminotransferase (14.9%) and increased aspartate aminotransferase (11.5%).

Discontinuation due to adverse events, regardless of causality, was observed in 18.1% of patients in REACH3 and in 14.5% of patients in the paediatric pool.

Tabulated list of adverse reactions

The safety of Jakavi in MF patients was evaluated using the long-term follow-up data from two phase 3 studies (COMFORT-I and COMFORT-II) including data from patients initially randomised to ruxolitinib (n=301) and patients who received ruxolitinib after crossing over from control treatments (n=156). The median exposure upon which the adverse drug reaction frequency categories for MF patients are based was 30.5 months (range 0.3 to 68.1 months).

The safety of Jakavi in PV patients was evaluated using the long-term follow-up data from two phase 3 studies (RESPONSE, RESPONSE 2) including data from patients initially randomised to ruxolitinib (n=184) and patients who received ruxolitinib after crossing over from control treatments (n=156). The median exposure upon which the adverse drug reaction frequency categories for PV patients are based was 41.7 months (range 0.03 to 59.7 months).

The safety of Jakavi in acute GvHD patients was evaluated in the phase 3 study REACH2 and in the phase 2 study REACH4. REACH2 included data from 201 patients ≥12 years of age initially randomised to Jakavi (n=152) and patients who received Jakavi after crossing over from the best available therapy (BAT) arm (n=49). The median exposure upon which the adverse drug reaction frequency categories were based was 8.9 weeks (range 0.3 to 66.1 weeks). In the pool of paediatric patients ≥2 years of age (6 patients in REACH2 and 45 patients in REACH4), the median exposure was 16.7 weeks (range 1.1 to 48.9 weeks).

The safety of Jakavi in chronic GvHD patients was evaluated in the phase 3 study REACH3 and in the phase 2 study REACH5. REACH3 included data from 226 patients ≥12 years of age initially randomised to Jakavi (n=165) and patients who received Jakavi after crossing over from BAT (n=61). The median exposure upon which the adverse drug reaction frequency categories were based was 41.4 weeks (range 0.7 to 127.3 weeks). In the pool of paediatric patients ≥2 years of age (10 patients in REACH3 and 45 patients in REACH5), the median exposure was 57.1 weeks (range 2.1 to 155.4 weeks).

In the clinical study programme the severity of adverse drug reactions was assessed based on the CTCAE, defining grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening or disabling, grade 5=death.

Adverse drug reactions from clinical studies in MF and PV (Table 6) and in acute and chronic GvHD (Table 7) are listed by MedDRA system organ class. Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first. In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1 000 to <1/100); rare (≥1/10 000 to <1/1 000); very rare (<1/10 000); not known (cannot be estimated from the available data).

**Table 6 Frequency category of adverse drug reactions reported in the phase 3 studies in MF and PV**

|  |  |  |
| --- | --- | --- |
| **Adverse drug reaction** | **Frequency category for MF patients** | **Frequency category for PV patients** |
| **Infections and infestations** |
| Urinary tract infectionsd | Very common | Very common |
| Herpes zosterd | Very common | Very common |
| Pneumonia | Very common | Common |
| Sepsis | Common | Uncommon |
| Tuberculosis | Uncommon | Not knowne |
| HBV reactivation | Not knowne | Uncommon |
| **Blood and lymphatic system disordersa,d** |
| Anaemiaa |  |  |
| CTCAEc grade 4(<6.5g/dl) | Very common | Uncommon |
| CTCAEc grade 3(<8.0 – 6.5g/dl) | Very common | Common |
| Any CTCAEc grade | Very common | Very common |
| Thrombocytopeniaa |  |  |
| CTCAEc grade 4(<25 000/mm3) | Common | Uncommon |
| CTCAEc grade 3(50 000 – 25 000/mm3) | Very common | Common |
| Any CTCAEc grade | Very common | Very common |
| Neutropeniaa |  |  |
| CTCAEc grade 4(<500/mm3) | Common | Uncommon |
| CTCAEc grade 3(<1 000 – 500/mm3) | Common | Uncommon |
| Any CTCAEc grade | Very common | Common |
| Pancytopeniaa,b | Common | Common |
| Bleeding (any bleeding including intracranial, and gastrointestinal bleeding, bruising and other bleeding) | Very common | Very common |
| Bruising | Very common | Very common |
| Gastrointestinal bleeding | Very common | Common |
| Intracranial bleeding | Common | Uncommon |
| Other bleeding (including epistaxis, post-procedural haemorrhage and haematuria) | Very common | Very common |
| **Metabolism and nutrition disorders** |
| Hypercholesterolaemiaaany CTCAEc grade | Very common | Very common |
| Hypertriglyceridaemiaaany CTCAEc grade | Very common | Very common |
| Weight gain | Very common | Very common |
| **Nervous system disorders** |
| Dizziness | Very common | Very common |
| Headache | Very common | Very common |
| **Gastrointestinal disorders** |
| Elevated lipase, any CTCAEc grade | Very common | Very common |
| Constipation | Very common | Very common |
| Flatulence | Common | Common |
| **Hepatobiliary disorders** |
| Increased alanine aminotransferasea |  |  |
| CTCAEc grade 3(> 5x – 20 x ULN) | Common | Common |
| Any CTCAEc grade | Very common | Very common |
| Increased aspartate aminotransferasea |  |  |
| Any CTCAEc grade | Very common | Very common |
| **Vascular disorders** |
| Hypertension | Very common | Very common |
| a Frequency is based on new or worsened laboratory abnormalities compared to baseline. |
| b Pancytopenia is defined as haemoglobin level <100 g/l, platelet count <100x109/l, and neutrophil count <1.5x109/l (or low white blood cell count of grade 2 if neutrophil count is missing), simultaneously in the same lab assessment |
| c Common Terminology Criteria for Adverse Events (CTCAE) version 3.0; grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening |
| d These adverse drug reactions are discussed in the text. |
| e Adverse drug reaction derived from post-marketing experience |

Upon discontinuation, MF patients may experience a return of MF symptoms such as fatigue, bone pain, fever, pruritus, night sweats, symptomatic splenomegaly and weight loss. In clinical studies in MF the total symptom score for MF symptoms gradually returned to baseline value within 7 days after dose discontinuation (see section 4.4).

**Table 7 Frequency category of adverse drug reactions reported in clinical studies in GvHD**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Acute GvHD (REACH2)** | **Acute GvHD (Paediatric pool)** | **Chronic GvHD (REACH3)** | **Chronic GvHD (Paediatric pool)** |
| **Adverse drug reaction** | **Frequency category** | **Frequency category** | **Frequency category** | **Frequency category** |
| **Infections and infestations** |
| CMV infections | Very common | Very common | Common | Common |
|  CTCAE3 grade ≥3 | Very common | Common | Common | N/A5 |
| Sepsis | Very common | Common | -6 | -6 |
|  CTCAE grade ≥34 | Very common | Common | -6 | -6 |
| Urinary tract infections | Very common | Common | Common | Common |
|  CTCAE grade ≥3 | Common | Common | Common | Common |
| BK virus infections | -6 | -6 | Common | Common |
|  CTCAE grade ≥3 | -6 | -6 | Uncommon | N/A5 |
| **Blood and lymphatic system disorders** |
| Thrombocytopenia1 | Very common | Very common | Very common | Very common |
|  CTCAE grade 3 | Very common | Very common | Common | Common |
|  CTCAE grade 4 | Very common | Very common | Very common | Very common |
| Anaemia1 | Very common | Very common | Very common | Very common |
|  CTCAE grade 3 | Very common | Very common | Very common | Very common |
| Neutropenia1 | Very common | Very common | Very common | Very common |
|  CTCAE grade 3 | Very common | Very common | Common | Very common |
|  CTCAE grade 4 | Very common | Very common | Common | Very common |
| Pancytopenia1,2 | Very common | Very common | -6 | -6 |
| **Metabolism and nutrition disorders** |
| Hypercholesterolaemia1 | Very common | Very common | Very common | Very common |
|  CTCAE grade 3 | Common | N/A5 | Common | Common |
|  CTCAE grade 4 | Common | N/A5 | Uncommon | Common |
| Weight gain | -6 | -6 | Common | Common |
|  CTCAE grade ≥3 | -6 | -6 | N/A5 | Common |
| **Nervous system disorders** |
| Headache | Common | Common | Very common | Very common |
|  CTCAE grade ≥3 | Uncommon | N/A5 | Common | Common |
| **Vascular disorders** |
| Hypertension | Very common | Very common | Very common | Very common |
|  CTCAE grade ≥3 | Common | Very common | Common | Common |
| **Gastrointestinal disorders** |
| Increased lipase1 | -6 | -6 | Very common | Very common |
|  CTCAE grade 3 | -6 | -6 | Common | Common |
|  CTCAE grade 4 | -6 | -6 | Uncommon | Common |
| Increased amylase1 | -6 | -6 | Very common | Very common |
|  CTCAE grade 3 | -6 | -6 | Common | Common |
|  CTCAE grade 4 | -6 | -6 | Common | N/A5 |
| Nausea | Very common | Common | -6 | -6 |
|  CTCAE grade ≥3 | Uncommon | N/A5 | -6 | -6 |
| Constipation | -6 | -6 | Common | Common |
|  CTCAE grade ≥3 | -6 | -6 | N/A5 | N/A5 |
| **Hepatobiliary disorders** |
| Increased alanine aminotransferase1 | Very common | Very common | Very common | Very common |
|  CTCAE grade 3 | Very common | Very common | Common | Very common |
|  CTCAE grade 4 | Common | N/A5 | Uncommon | Common |
| Increased aspartate aminotransferase1 | Very common | Very common | Very common | Very common |
|  CTCAE grade 3 | Common | Common | Common | Very common |
|  CTCAE grade 4 | N/A5 | N/A5 | Uncommon | N/A5 |
| **Musculoskeletal and connective tissue disorders** |
| Increased blood creatine phosphokinase1 | -6 | -6 | Very common | Very common |
|  CTCAE grade 3 | -6 | -6 | Common | N/A5 |
|  CTCAE grade 4 | -6 | -6 | Common | N/A5 |
| **Renal and urinary disorders** |
| Increased blood creatinine1 | -6 | -6 | Very common | Common |
|  CTCAE grade 3 | -6 | -6 | Common | N/A5 |
|  CTCAE grade 4 | -6 | -6 | N/A5 | N/A5 |
| 1 Frequency is based on new or worsened laboratory abnormalities compared to baseline.2 Pancytopenia is defined as haemoglobin level <100 g/l, platelet count <100 x 109/l, and neutrophil count <1.5 x 109/l (or low white blood cell count of grade 2 if neutrophil count is missing), simultaneously in the same laboratory assessment.3 CTCAE Version 4.03.4 Grade ≥3 sepsis includes 20 (10%) grade 5 events in REACH2. There were no grade 5 events in the paediatric pool.5 Not applicable: no cases reported6 “-”: not an identified adverse drug reaction in this indication |

Description of selected adverse drug reactions

*Anaemia*

In phase 3 clinical studies in MF, median time to onset of first CTCAE grade 2 or higher anaemia was 1.5 months. One patient (0.3%) discontinued treatment because of anaemia.

In patients receiving ruxolitinib mean decreases in haemoglobin reached a nadir of approximately 10 g/litre below baseline after 8 to 12 weeks of therapy and then gradually recovered to reach a new steady state that was approximately 5 g/litre below baseline. This pattern was observed in patients regardless of whether they had received transfusion during therapy.

In the randomised, placebo-controlled study COMFORT-I 60.6% of Jakavi-treated MF patients and 37.7% of placebo-treated MF patients received red blood cell transfusions during randomised treatment. In the COMFORT-II study the rate of packed red blood cell transfusions was 53.4% in the Jakavi arm and 41.1% in the best available therapy arm.

In the randomised period of the pivotal studies, anaemia was less frequent in PV patients than in MF patients (40.8% versus 82.4%). In the PV population, the CTCAE grade 3 and 4 events were reported in 2.7%, while in the MF patients the frequency was 42.56%.

In the phase 3 acute (REACH2) and chronic (REACH3) GvHD studies, anaemia (all grades) was reported in 75.0% and 68.6% of patients, CTCAE grade 3 was reported in 47.7% and 14.8% of patients, respectively. In paediatric patients with acute and chronic GvHD, anaemia (all grades) was reported in 70.8% and 49.1% of patients, CTCAE grade 3 was reported in 45.8% and 17.0% of patients, respectively.

*Thrombocytopenia*

In the phase 3 clinical studies in MF, in patients who developed grade 3 or 4 thrombocytopenia, the median time to onset was approximately 8 weeks. Thrombocytopenia was generally reversible with dose reduction or dose interruption. The median time to recovery of platelet counts above 50 000/mm3 was 14 days. During the randomised period, platelet transfusions were administered to 4.7% of patients receiving ruxolitinib and to 4.0% of patients receiving control regimens. Discontinuation of treatment because of thrombocytopenia occurred in 0.7% of patients receiving ruxolitinib and 0.9% of patients receiving control regimens. Patients with a platelet count of 100 000/mm3 to 200 000/mm3 before starting ruxolitinib had a higher frequency of grade 3 or 4 thrombocytopenia compared to patients with platelet count >200 000/mm3 (64.2% versus 38.5%).

In the randomised period of the pivotal studies, the rate of patients experiencing thrombocytopenia was lower in PV (16.8%) patients compared to MF (69.8%) patients. The frequency of severe (i.e. CTCAE grade 3 and 4) thrombocytopenia was lower in PV (2.7%) than in MF (11.6%) patients.

In the phase 3 acute GvHD study (REACH2), grade 3 and 4 thrombocytopenia was observed in 31.3% and 47.7% of patients, respectively. In the phase 3 chronic GvHD study (REACH3), grade 3 and 4 thrombocytopenia was lower (5.9% and 10.7%) than in acute GvHD. The frequency of grade 3 (14.6%) and 4 (22.4%) thrombocytopenia in paediatric patients with acute GvHD was lower than in REACH2. In paediatric patients with chronic GvHD, grade 3 and 4 thrombocytopenia was lower (7.7% and 11.1%) than in paediatric patients with acute GvHD.

*Neutropenia*

In the phase 3 clinical studies in MF, in patients who developed grade 3 or 4 neutropenia, the median time to onset was 12 weeks. During the randomised period, dose holding or reductions due to neutropenia were reported in 1.0% of patients, and 0.3% of patients discontinued treatment because of neutropenia.

In the randomised period of the phase 3 studies in PV patients, neutropenia was reported in 1.6% of patients exposed to ruxolitinib compared to 7% in reference treatments. In the ruxolitinib arm one patient developed CTCAE grade 4 neutropenia. An extended follow-up of patients treated with ruxolitinib showed 2 patients reporting CTCAE grade 4 neutropenia.

In the phase 3 acute GvHD study (REACH2), grade 3 and 4 neutropenia was observed in 17.9% and 20.6% of patients, respectively. In the phase 3 chronic GvHD study (REACH3), grade 3 and 4 neutropenia was lower (9.5% and 6.7%) than in acute GvHD. In paediatric patients, the frequency of grade 3 and 4 neutropenia was 32.0% and 22.0%, respectively, in acute GvHD and 17.3% and 11.1%, respectively, in chronic GvHD.

*Bleeding*

In the phase 3 pivotal studies in MF bleeding events (including intracranial and gastrointestinal, bruising and other bleeding events) were reported in 32.6% of patients exposed to ruxolitinib and 23.2% of patients exposed to the reference treatments (placebo or best available therapy). The frequency of grade 3 to 4 events was similar for patients treated with ruxolitinib or reference treatments (4.7% versus 3.1%). Most of the patients with bleeding events during the treatment reported bruising (65.3%). Bruising events were more frequently reported in patients taking ruxolitinib compared with the reference treatments (21.3% versus 11.6%). Intracranial bleeding was reported in 1% of patients exposed to ruxolitinib and 0.9% exposed to reference treatments. Gastrointestinal bleeding was reported in 5.0% of patients exposed to ruxolitinib compared to 3.1% exposed to reference treatments. Other bleeding events (including events such as epistaxis, post-procedural haemorrhage and haematuria) were reported in 13.3% of patients treated with ruxolitinib and 10.3% treated with reference treatments.

During the long-term follow-up of phase 3 clinical studies in MF, the cumulative frequency of bleeding events increased proportionally to the increase in the follow-up time. Bruising events were the most frequently reported bleeding events (33.3%). Intracranial and gastrointestinal bleeding events were reported in 1.3% and 10.1% of patients respectively.

In the comparative period of phase 3 studies in PV patients, bleeding events (including intracranial and gastrointestinal, bruising and other bleeding events) were reported in 16.8% of patients treated with ruxolitinib, 15.3% of patients receiving best available therapy in RESPONSE study and 12.0% of patients receiving best available therapy in RESPONSE 2 study. Bruising was reported in 10.3% of patients treated with ruxolitinib, 8.1% of patients receiving best available therapy in RESPONSE study and 2.7% of patients receiving best available therapy in RESPONSE 2 study. No intracranial bleeding or gastrointestinal haemorrhage events were reported in patients receiving ruxolitinib. One patient treated with ruxolitinib experienced a grade 3 bleeding event (post-procedural bleeding); no grade 4 bleeding was reported. Other bleeding events (including events such as epistaxis, post-procedural haemorrhage, gingival bleeding) were reported in 8.7% of patients treated with ruxolitinib, 6.3% of patients treated with best available therapy in RESPONSE study and 6.7% of patients treated with best available therapy in RESPONSE 2 study.

During the long-term follow-up of phase 3 studies in PV, the cumulative frequency of bleeding events increased proportionally to the increase in the follow-up time. Bruising events were the most frequently reported bleeding events (17.4%). Intracranial and gastrointestinal bleeding events were reported in 0.3% and 3.5% of patients respectively.

In the comparative period of the phase 3 acute GvHD study (REACH2), bleeding events were reported in 25.0% and 22.0% of patients in the ruxolitinib and BAT arms respectively. The sub-groups of bleeding events were generally similar between treatment arms: bruising events (5.9% in ruxolitinib vs. 6.7% in BAT arm), gastrointestinal events (9.2% vs. 6.7%) and other haemorrhage events (13.2% vs. 10.7%). Intracranial bleeding events were reported in 0.7% of patients in the BAT arm and in no patients in the ruxolitinib arm. In paediatric patients, the frequency of bleeding events was 23.5%. Events reported in ≥5% of patients were cystitis haemorrhagic and epistaxis (5.9% each). No intracranial bleeding events were reported in paediatric patients.

In the comparative period of the phase 3 chronic GvHD study (REACH3), bleeding events were reported in 11.5% and 14.6% of patients in the ruxolitinib and BAT arms respectively. The sub-groups of bleeding events were generally similar between treatment arms: bruising events (4.2% in ruxolitinib vs. 2.5% in BAT arm), gastrointestinal events (1.2% vs. 3.2%) and other haemorrhage events (6.7% vs. 10.1%). In paediatric patients, the frequency of bleeding events was 9.1%. The reported events were epistaxis, haematochezia, haematoma, post-procedural haemorrhage, and skin haemorrhage (1.8% each). No intracranial bleeding events were reported in patients with chronic GvHD.

*Infections*

In the phase 3 pivotal studies in MF, grade 3 or 4 urinary tract infection was reported in 1.0% of patients, herpes zoster in 4.3% and tuberculosis in 1.0%. In phase 3 clinical studies sepsis was reported in 3.0% of patients. An extended follow-up of patients treated with ruxolitinib showed no trends towards an increase in the rate of sepsis over time.

In the randomised period of the phase 3 studies in PV patients, one (0.5%) CTCAE grade 3 and no grade 4 urinary tract infection was reported. The rate of herpes zoster was similar in PV (4.3%) patients and MF (4.0%) patients. There was one report of CTCAE grade 3 post-herpetic neuralgia amongst the PV patients. Pneumonia was reported in 0.5% of patients treated with ruxolitinib compared to 1.6% of patients in reference treatments. No patients in the ruxolitinib arm reported sepsis or tuberculosis.

During long-term follow-up of phase 3 studies in PV, frequently reported infections were urinary tract infections (11.8%), herpes zoster (14.7%) and pneumonia (7.1%). Sepsis was reported in 0.6% of patients. No patients reported tuberculosis in long-term follow-up.

In the phase 3 acute GvHD study (REACH2), during the *comparative period*, urinary tract infections were reported in 9.9% (grade ≥3, 3.3%) of patients in the ruxolitinib arm compared to 10.7% (grade ≥3, 6.0%) in the BAT arm. CMV infections were reported in 28.3% (grade ≥3, 9.3%) of patients in the ruxolitinib arm compared to 24.0% (grade ≥3, 10.0%) in the BAT arm. Sepsis events were reported in 12.5% (grade ≥3, 11.1%) of patients in the ruxolitinib arm compared to 8.7% (grade ≥3, 6.0%) in the BAT arm. BK virus infection was reported only in the ruxolitinib arm in 3 patients with one grade 3 event. During *extended follow-up* of patients treated with ruxolitinib, urinary tract infections were reported in 17.9% (grade ≥3, 6.5%) of patients and CMV infections were reported in 32.3% (grade ≥3, 11.4%) of patients. CMV infection with organ involvement was seen in very few patients; CMV colitis, CMV enteritis and CMV gastrointestinal infection of any grade were reported in four, two and one patients, respectively. Sepsis events, including septic shock, of any grade were reported in 25.4% (grade ≥3, 21.9%) of patients. Urinary tract infections and sepsis events were reported with lower frequency in paediatric patients with acute GvHD (9.8% each) compared to adult and adolescent patients. CMV infections were reported in 31.4% of paediatric patients (grade 3, 5.9%).

In the phase 3 chronic GvHD study (REACH3), during the *comparative period*, urinary tract infections were reported in 8.5% (grade ≥3, 1.2%) of patients in the ruxolitinib arm compared to 6.3% (grade ≥3, 1.3%) in the BAT arm. BK virus infection was reported in 5.5% (grade ≥3, 0.6%) of patients in the ruxolitinib arm compared to 1.3% in the BAT arm. CMV infections were reported in 9.1% (grade ≥3, 1.8%) of patients in the ruxolitinib arm compared to 10.8% (grade ≥3, 1.9%) in the BAT arm. Sepsis events were reported in 2.4% (grade ≥3, 2.4%) of patients in the ruxolitinib arm compared to 6.3% (grade ≥3, 5.7%) in the BAT arm. During *extended follow-up* of patients treated with ruxolitinib, urinary tract infections and BK virus infections were reported in 9.3% (grade ≥3, 1.3%) and 4.9% (grade ≥3, 0.4%) of patients, respectively. CMV infections and sepsis events were reported in 8.8% (grade ≥3, 1.3%) and 3.5% (grade ≥3, 3.5%) of patients, respectively. In paediatric patients with chronic GvHD, urinary tract infections were reported in 5.5% (grade 3, 1.8%) of patients and BK virus infection was reported in 1.8% (no grade ≥3) of patients. CMV infections occurred in 7.3% (no grade ≥3) of patients.

*Elevated lipase*

In the randomised period of the RESPONSE study, the worsening of lipase values was higher in the ruxolitinib arm compared to the control arm, mainly due to the differences among grade 1 elevations (18.2% vs 8.1%). Grade ≥2 elevations were similar between treatment arms. In RESPONSE 2, the frequencies were comparable between the ruxolitinib and the control arm (10.8% vs 8%). During long-term follow-up of phase 3 PV studies, 7.4% and 0.9% of patients reported grade 3 and grade 4 elevation of lipase values. No concurrent signs and symptoms of pancreatitis with elevated lipase values were reported in these patients.

In phase 3 studies in MF, high lipase values were reported in 18.7% and 19.3% of patients in the ruxolitinib arms compared to 16.6% and 14.0% in the control arms in COMFORT-I and COMFORT-II studies, respectively. In patients with elevated lipase values, no concurrent signs and symptoms of pancreatitis were reported.

In the *comparative period* of the phase 3 acute GvHD study (REACH2), new or worsened lipase values were reported in 19.7% of patients in the ruxolitinib arm compared to 12.5% in the BAT arm; corresponding grade 3 (3.1% vs 5.1%) and grade 4 (0% vs 0.8%) increases were similar. During *extended follow-up* of patients treated with ruxolitinib, increased lipase values were reported in 32.2% of patients; grade 3 and 4 were reported in 8.7% and 2.2% of patients respectively. Elevated lipase was reported in 20.4% of paediatric patients (grade 3 and 4: 8.5% and 4.1%, respectively).

In the *comparative period* of the phase 3 chronic GvHD study (REACH3), new or worsened lipase values were reported in 32.1% of patients in the ruxolitinib arm compared to 23.5% in the BAT arm; corresponding grade 3 (10.6% vs 6.2%) and grade 4 (0.6% vs 0%) increases were similar. During *extended follow-up* of patients treated with ruxolitinib, increased lipase values were reported in 35.9% of patients; grade 3 and 4 were observed in 9.5% and 0.4% of patients, respectively. Elevated lipase was reported with lower frequency (20.4%, grade 3 and 4: 3.8% and 1.9%, respectively) in paediatric patients.

*Increased systolic blood pressure*

In the phase 3 pivotal clinical studies in MF an increase in systolic blood pressure of 20 mmHg or more from baseline was recorded in 31.5% of patients on at least one visit compared with 19.5% of the control-treated patients. In COMFORT-I (MF patients) the mean increase from baseline in systolic BP was 0 to 2 mmHg on ruxolitinib versus a decrease of 2 to 5 mmHg in the placebo arm. In COMFORT-II mean values showed little difference between the ruxolitinib-treated and the control-treated MF patients.

In the randomised period of the pivotal study in PV patients, the mean systolic blood pressure increased by 0.65 mmHg in the ruxolitinib arm versus a decrease of 2 mmHg in the BAT arm.

Special populations

*Paediatric patients*

A total of 106 patients aged 2 to <18 years with GvHD were analysed for safety: 51 patients (45 patients in REACH4 and 6 patients in REACH2) in acute GvHD studies and 55 patients (45 patients in REACH5 and 10 patients in REACH3) in the chronic GvHD studies. The safety profile observed in paediatric patients who received treatment with ruxolitinib was similar to that observed in adult patients.

*Elderly*

A total of 29 patients in study REACH2 and 25 patients in REACH3 aged >65 years and treated with ruxolitinib were analysed for safety. Overall, no new safety concerns were identified and the safety profile in patients >65 years old is generally consistent with that of patients aged 18 to 65 years old.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in [Appendix V](https://www.ema.europa.eu/documents/template-form/qrd-appendix-v-adverse-drug-reaction-reporting-details_en.docx).

**4.9 Overdose**

There is no known antidote for overdoses with Jakavi. Single doses up to 200 mg have been given with acceptable acute tolerability. Higher than recommended repeat doses are associated with increased myelosuppression including leukopenia, anaemia and thrombocytopenia. Appropriate supportive treatment should be given.

Haemodialysis is not expected to enhance the elimination of ruxolitinib.

**5. PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitors, ATC code: L01EJ01

Mechanism of action

Ruxolitinib is a selective inhibitor of the Janus Associated Kinases (JAKs) JAK1 and JAK2 (IC50 values of 3.3 nM and 2.8 nM for JAK1 and JAK2 enzymes, respectively). These mediate the signalling of a number of cytokines and growth factors that are important for haematopoiesis and immune function.

MF and PV are myeloproliferative neoplasms known to be associated with dysregulated JAK1 and JAK2 signalling. The basis for the dysregulation is believed to include high levels of circulating cytokines that activate the JAK-STAT pathway, gain-of-function mutations such as JAK2V617F, and silencing of negative regulatory mechanisms. MF patients exhibit dysregulated JAK signalling regardless of JAK2V617F mutation status. Activating mutations in JAK2 (V617F or exon 12) are found in >95% of PV patients.

Ruxolitinib inhibits JAK-STAT signalling and cell proliferation of cytokine-dependent cellular models of haematological malignancies, as well as of Ba/F3 cells rendered cytokine-independent by expressing the JAK2V617F mutated protein, with IC50 ranging from 80 to 320 nM.

JAK-STAT signalling pathways play a role in regulating the development, proliferation, and activation of several immune cell types important for GvHD pathogenesis.

Pharmacodynamic effects

Ruxolitinib inhibits cytokine-induced STAT3 phosphorylation in whole blood from healthy subjects, MF patients and PV patients. Ruxolitinib resulted in maximal inhibition of STAT3 phosphorylation 2 hours after dosing which returned to near baseline by 8 hours in both healthy subjects and MF patients, indicating no accumulation of either parent or active metabolites.

Baseline elevations in inflammatory markers associated with constitutional symptoms such as TNFα, IL-6 and CRP in subjects with MF were decreased following treatment with ruxolitinib. MF patients did not become refractory to the pharmacodynamic effects of ruxolitinib treatment over time. Similarly, patients with PV also presented with baseline elevations in inflammatory markers and these markers were decreased following treatment with ruxolitinib.

In a thorough QT study in healthy subjects, there was no indication of a QT/QTc prolonging effect of ruxolitinib in single doses up to a supratherapeutic dose of 200 mg, indicating that ruxolitinib has no effect on cardiac repolarisation.

Clinical efficacy and safety

*Myelofibrosis*

Two randomised phase 3 studies (COMFORT-I and COMFORT-II) were conducted in patients with MF (primary MF, post-polycythaemia vera MF or post-essential thrombocythaemia MF). In both studies, patients had palpable splenomegaly at least 5 cm below the costal margin and risk category of intermediate-2 or high risk based on the International Working Group (IWG) Consensus Criteria. The starting dose of Jakavi was based on platelet count. Patients with platelet counts ≤100 000/mm3 were not eligible for enrolment in COMFORT studies but 69 patients were enrolled in the EXPAND study, a Phase Ib, open label, dose-finding study in patients with MF (primary MF, post-polycythaemia vera MF or post-essential thrombocythaemia MF) and baseline platelet counts ≥50 000 and <100 000/mm3.

COMFORT-I was a double-blind, randomised, placebo-controlled study in 309 patients who were refractory to or were not candidates for available therapy. The primary efficacy endpoint was proportion of subjects achieving ≥35% reduction from baseline in spleen volume at week 24 as measured by Magnetic Resonance Imaging (MRI) or Computed Tomography (CT).

Secondary endpoints included duration of maintenance of a ≥35% reduction from baseline in spleen volume, proportion of patients who had ≥50% reduction in total symptom score, changes in total symptom scores from baseline to week 24, as measured by the modified MF Symptom Assessment Form (MFSAF) v2.0 diary, and overall survival.

COMFORT-II was an open-label, randomised study in 219 patients. Patients were randomised 2:1 to ruxolitinib versus best available therapy. In the best available therapy arm, 47% of patients received hydroxyurea and 16% of patients received glucocorticoids. The primary efficacy endpoint was proportion of patients achieving ≥35% reduction from baseline in spleen volume at week 48 as measured by MRI or CT.

Secondary endpoints included proportion of patients achieving a ≥35% reduction of spleen volume from baseline at week 24 and duration of maintenance of a ≥35% reduction from baseline spleen volume.

In COMFORT-I and COMFORT-II, patient baseline demographics and disease characteristics were comparable between the treatment arms.

**Table 8 Percentage of patients with ≥35% reduction from baseline in spleen volume at week 24 in COMFORT-I and at week 48 in COMFORT-II (ITT)**

|  |  |  |
| --- | --- | --- |
|  | COMFORT-I | COMFORT-II |
|  | Jakavi(N=155) | Placebo(N=153) | Jakavi(N=144) | Best available therapy(N=72) |
| Time points | Week 24 | Week 48 |
| Number (%) of subjects with spleen volume reduced by ≥35% | 65 (41.9) | 1 (0.7) | 41 (28.5) | 0 |
| 95% confidence intervals | 34.1, 50.1 | 0, 3.6 | 21.3, 36.6 | 0.0, 5.0 |
| p-value | <0.0001 | <0.0001 |

A significantly higher proportion of patients in the Jakavi group achieved ≥35% reduction from baseline in spleen volume (Table 8) regardless of the presence or absence of the JAK2V617F mutation (Table 9) or the disease subtype (primary MF, post-polycythaemia vera MF, post-essential thrombocythaemia MF).

**Table 9** **Percentage of patients with ≥35% reduction from baseline in spleen volume by JAK mutation status (safety set)**

|  |  |  |
| --- | --- | --- |
|  | COMFORT-I | COMFORT-II |
|  | Jakavi | Placebo | Jakavi | Best available therapy |
| JAK mutation status | Positive(N=113)n (%) | Negative(N=40)n (%) | Positive(N=121)n (%) | Negative(N=27)n (%) | Positive(N=110)n (%) | Negative(N=35)n (%) | Positive(N=49)n (%) | Negative(N=20)n (%) |
| Number (%) of subjects with spleen volume reduced by ≥35% | 54 (47.8) | 11 (27.5) | 1(0.8) | 0 | 36 (32.7) | 5(14.3) | 0 | 0 |
| Time point | After 24 weeks | After 48 weeks |

The probability of maintaining spleen response (≥35% reduction) to Jakavi for at least 24 weeks was 89% in COMFORT-I and 87% in COMFORT-II; 52% maintained spleen responses for at least 48 weeks in COMFORT-II.

In COMFORT-I, 45.9% subjects in the Jakavi group achieved a ≥50% improvement from baseline in the week 24 total symptom score (measured using MFSAF diary v2.0), as compared to 5.3% in the placebo group (p<0.0001 using chi-square test). The mean change in the global health status at week 24, as measured by EORTC QLQ C30 was +12.3 for Jakavi and ‑3.4 for placebo (p<0.0001).

In COMFORT-I, after a median follow-up of 34.3 months, the death rate in patients randomised to the ruxolitinib arm was 27.1% versus 35.1% in patients randomised to placebo; HR 0.687; 95% CI 0.459, 1.029; p=0.0668.

In COMFORT-I, after a median follow–up of 61.7 months, the death rate in patients randomised to the ruxolitinib arm was 44.5% (69 of 155 patients) versus 53.2% (82 of 154) in patients randomised to placebo. There was a 31% reduction in the risk of death in the ruxolitinib arm as compared to placebo (HR 0.69; 95% CI 0.50, 0.96; p=0.025).

In COMFORT-II, after a median follow-up of 34.7 months, the death rate in patients randomised to ruxolitinib was 19.9% versus 30.1% in patients randomised to best available treatment (BAT); HR 0.48; 95% CI 0.28, 0.85; p=0.009. In both studies, the lower death rates noted in the ruxolitinib arm were predominantly driven by the results obtained in the post polycythaemia vera and post essential thrombocythaemia subgroups.

In COMFORT-II, after a median follow-up of 55.9 months, the death rate in patients randomised to the ruxolitinib arm was 40.4% (59 of 146 patients) versus 47.9% (35 of 73 patients) in patients randomized to best available therapy (BAT). There was a 33% reduction in risk of death in the ruxolitinib arm compared to the BAT arm (HR 0.67; 95% CI 0.44, 1.02; p=0.062).

*Polycythaemia vera*

A randomised, open-label, active-controlled phase 3 study (RESPONSE) was conducted in 222 patients with PV who were resistant to or intolerant of hydroxyurea defined based on the European LeukemiaNet (ELN) international working group published criteria. 110 patients were randomised to the ruxolitinib arm and 112 patients to the BAT arm. The starting dose of Jakavi was 10 mg twice daily. Doses were then adjusted in individual patients based on tolerability and efficacy with a maximum dose of 25 mg twice daily. BAT was selected by the investigator on a patient-by-patient basis and included hydroxyurea (59.5%), interferon/pegylated interferon (11.7%), anagrelide (7.2%), pipobroman (1.8%) and observation (15.3%).

Baseline demographics and disease characteristics were comparable between the two treatments arms. The median age was 60 years (range 33 to 90 years). Patients in the ruxolitinib arm had PV diagnosis for a median of 8.2 years and had previously received hydroxyurea for a median of approximately 3 years. Most patients (>80%) had received at least two phlebotomies in the last 24 weeks prior to screening. Comparative data regarding long-term survival and incidence of disease complications is missing.

The primary composite endpoint was the proportion of patients achieving both an absence of phlebotomy eligibility (HCT control) and a ≥35% reduction in spleen volume from baseline at week 32. Phlebotomy eligibility was defined as a confirmed HCT of >45%, i.e. at least 3 percentage points higher than the HCT obtained at baseline or a confirmed HCT of >48%, depending on which was lower. Key secondary endpoints included the proportion of patients who achieved the primary endpoint and remained free from progression at week 48, as well as the proportion of patients achieving complete haematological remission at week 32.

The study met its primary objective and a higher proportion of patients in the Jakavi group achieved the primary composite endpoint and each of its individual components. Significantly more patients treated with Jakavi (23%) achieved a primary response (p<0.0001) compared to BAT (0.9%). Haematocrit control was achieved in 60% of patients in the Jakavi arm compared to 18.8% in the BAT arm and a ≥35% reduction in spleen volume was achieved in 40% of patients in the Jakavi arm compared to 0.9% in the BAT arm (Figure 1).

Both key secondary endpoints were also met. The proportion of patients achieving a complete haematological remission was 23.6% on Jakavi compared to 8.0% on BAT (p=0.0013) and the proportion of patients achieving a durable primary response at week 48 was 20% on Jakavi and 0.9% on BAT (p<0.0001).

**Figure 1** **Patients achieving the primary endpoint and components of the primary endpoint at week 32**

Symptom burden was assessed using the MPN-SAF total symptom score (TSS) electronic patient diary, which consisted of 14 questions. At week 32, 49% and 64% of patients treated with ruxolitinib achieved a ≥50% reduction in TSS-14 and TSS-5, respectively, compared to only 5% and 11% of patients on BAT.

Treatment benefit perception was measured by the Patient Global Impression of Change (PGIC) questionnaire. 66% of patients treated with ruxolitinib compared to 19% treated with BAT reported an improvement as early as four weeks after beginning treatment. Improvement in perception of treatment benefit was also higher in patients treated with ruxolitinib at week 32 (78% versus 33%).

Additional analyses from the RESPONSE study to assess durability of response were conducted at week 80 and week 256 following randomisation. Out of 25 patients who had achieved primary response at week 32, 3 patients had progressed by week 80 and 6 patients by week 256. The probability to have maintained a response from week 32 up to week 80 and week 256 was 92% and 74%, respectively (see Table 10).

**Table 10 Durability of primary response in the RESPONSE study**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Week 32 | Week 80 | Week 256 |
| Primary response achieved at week 32\*n/N (%) | 25/110 (23%) | n/a | n/a |
| Patients maintaining primary response | n/a | 22/25 | 19/25 |
| Probability of maintaining primary response | n/a | 92% | 74% |
| \* According to the primary response composite endpoint criteria: absence of phlebotomy eligibility (HCT control) and a ≥35% reduction in spleen volume from baseline.n/a: not applicable |

A second randomised, open label, active-controlled phase 3b study (RESPONSE 2) was conducted in 149 PV patients who were resistant to, or intolerant of, hydroxyurea but without palpable splenomegaly. The primary endpoint defined as the proportion of patients achieving HCT control (absence of phlebotomy eligibility) at week 28 was met (62.2% in the Jakavi arm versus 18.7% in the BAT arm). The key secondary endpoint defined as the proportion of patients achieving complete haematological remission at week 28 was also met (23.0% in the Jakavi arm versus 5.3% in the BAT arm).

*Graft-versus-host disease*

Two randomised phase 3, open-label, multi-centre studies investigated Jakavi in patients 12 years of age and older with acute GvHD (REACH2) and chronic GvHD (REACH3) after allogeneic haematopoietic stem cell transplantation (alloSCT) and insufficient response to corticosteroids and/or other systemic therapies. The starting dose of Jakavi was 10 mg twice daily.

*Acute graft-versus-host disease*

In REACH2, 309 patients with grade II to IV corticosteroid-refractory, acute GvHD were randomised 1:1 to Jakavi or BAT. Patients were stratified by severity of acute GvHD at the time of randomisation. Corticosteroid refractoriness was determined when patients had progression after at least 3 days, failed to achieve a response after 7 days or failed corticosteroid taper.

BAT was selected by the investigator on a patient-by-patient basis and included anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mesenchymal stromal cells (MSC), low dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, or infliximab.

In addition to Jakavi or BAT, patients could have received standard allogeneic stem cell transplantation supportive care including anti-infective medicinal products and transfusion support. Ruxolitinib was added to continued use of corticosteroids and/or calcineurin inhibitors (CNIs) such as cyclosporine or tacrolimus and/or topical or inhaled corticosteroid therapies per institutional guidelines.

Patients who received one prior systemic treatment other than corticosteroids and CNI for acute GvHD were eligible for inclusion in the study. In addition to corticosteroids and CNI, prior systemic medicinal product for acute GvHD was allowed to continue only if used for acute GvHD prophylaxis (i.e. started before the acute GvHD diagnosis) as per common medical practice.

Patients on BAT could cross over to ruxolitinib after day 28 if they met the following criteria:

* Failed to meet the primary endpoint response definition (complete response [CR] or partial response [PR]) at day 28; OR
* Lost the response thereafter and met criteria for progression, mixed response, or no response, necessitating new additional systemic immunosuppressive treatment for acute GvHD, AND
* Did not have signs/symptoms of chronic GvHD.

Tapering of Jakavi was allowed after the day 56 visit for patients with treatment response.

Baseline demographics and disease characteristics were balanced between the two treatment arms. The median age was 54 years (range 12 to 73 years). The study included 2.9% adolescent, 59.2% male and 68.9% white patients. The majority of enrolled patients had malignant underlying disease.

The severity of acute GvHD was grade II in 34% and 34%, grade III in 46% and 47%, and grade IV in 20% and 19% of the Jakavi and BAT arms, respectively.

The reasons for patients’ insufficient response to corticosteroids in the Jakavi and BAT arms were i) failure in achieving a response after 7 days of corticosteroid treatment (46.8% and 40.6%, respectively), ii) failure of corticosteroid taper (30.5% and 31.6%, respectively) or iii) disease progression after 3 days of treatment (22.7% and 27.7%, respectively).

Among all patients, the most common organs involved in acute GvHD were skin (54.0%) and lower gastrointestinal tract (68.3%). More patients in the Jakavi arm had acute GvHD involving skin (60.4%) and liver (23.4%), compared to the BAT arm (skin: 47.7% and liver: 16.1%).

The most frequently used prior systemic acute GvHD therapies were corticosteroids+CNIs (49.4% in the Jakavi arm and 49.0% in the BAT arm).

The primary endpoint was the overall response rate (ORR) on day 28, defined as the proportion of patients in each arm with a complete response (CR) or a partial response (PR) without the requirement of additional systemic therapies for an earlier progression, mixed response or non-response based on investigator assessment following the criteria by Harris et al. (2016).

The key secondary endpoint was the proportion of patients who achieved a CR or PR at day 28 and maintained a CR or PR at day 56.

REACH2 met its primary objective. ORR at day 28 of treatment was higher in the Jakavi arm (62.3%) compared to the BAT arm (39.4%). There was a statistically significant difference between the treatment arms (stratified Cochrane-Mantel-Haenszel test p<0.0001, two-sided, OR: 2.64; 95% CI: 1.65, 4.22).

There was also a higher proportion of complete responders in the Jakavi arm (34.4%) compared to BAT arm (19.4%).

Day-28 ORR was 76% for grade II GvHD, 56% for grade III GvHD, and 53% for grade IV GvHD in the Jakavi arm, and 51% for grade II GvHD, 38% for grade III GvHD, and 23% for grade IV GvHD in the BAT arm.

Among the non-responders at day 28 in the Jakavi and BAT arms, 2.6% and 8.4% had disease progression, respectively.

Overall results are presented in Table 11.

**Table 11 Overall response rate at day 28 in REACH2**

|  |  |  |
| --- | --- | --- |
|  | **Jakavi****N=154** | **BAT****N=155** |
|  | **n (%)** | **95% CI** | **n (%)** | **95% CI** |
| Overall response | 96 (62.3) | 54.2, 70.0 | 61 (39.4) | 31.6, 47.5 |
| OR (95% CI) | 2.64 (1.65, 4.22) |
| p-value (2-sided) | p <0.0001 |
| Complete response | 53 (34.4) | 30 (19.4) |
| Partial response | 43 (27.9) | 31 (20.0) |

The study met its key secondary endpoint based on the primary data analysis. Durable ORR at day 56 was 39.6% (95% CI: 31.8, 47.8) in the Jakavi arm and 21.9% (95% CI: 15.7, 29.3) in the BAT arm. There was a statistically significant difference between the two treatment arms (OR: 2.38; 95% CI: 1.43, 3.94; p=0.0007). The proportion of patients with a CR was 26.6% in the Jakavi arm versus 16.1% in the BAT arm. Overall, 49 patients (31.6%) originally randomised to the BAT arm crossed over to the Jakavi arm.

*Chronic graft-versus-host disease*

In REACH3, 329 patients with moderate or severe corticosteroid-refractory, chronic GvHD were randomised 1:1 to Jakavi or BAT. Patients were stratified by severity of chronic GvHD at the time of randomisation. Corticosteroid refractoriness was determined when patients had lack of response or disease progression after 7 days, or had disease persistence for 4 weeks or failed corticosteroid taper twice.

BAT was selected by the investigator on a patient-by-patient basis and included extracorporeal photopheresis (ECP), low dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib, or ibrutinib.

In addition to Jakavi or BAT, patients could have received standard allogeneic stem cell transplantation supportive care including anti-infective medicinal products and transfusion support. Continued use of corticosteroids and CNIs such as cyclosporine or tacrolimus and topical or inhaled corticosteroid therapies were allowed per institutional guidelines.

Patients who received one prior systemic treatment other than corticosteroids and/or CNI for chronic GvHD were eligible for inclusion in the study. In addition to corticosteroids and CNI, prior systemic medicinal product for chronic GvHD was allowed to continue only if used for chronic GvHD prophylaxis (i.e. started before the chronic GvHD diagnosis) as per common medical practice.

Patients on BAT could cross over to ruxolitinib on day 169 and thereafter due to disease progression, mixed response, or unchanged response, due to toxicity to BAT, or due to chronic GvHD flare.

Efficacy in patients that transition from active acute GvHD to chronic GvHD without tapering off corticosteroids and any systemic treatment is unknown. Efficacy in acute or chronic GvHD after donor lymphocyte infusion (DLI) and in patients who did not tolerate steroid treatment is unknown.

Tapering of Jakavi was allowed after the day 169 visit.

Baseline demographics and disease characteristics were balanced between the two treatment arms. The median age was 49 years (range 12 to 76 years). The study included 3.6% adolescent, 61.1% male and 75.4% white patients. The majority of enrolled patients had malignant underlying disease.

The severity at diagnosis of corticosteroid-refractory chronic GvHD was balanced between the two treatment arms, with 41% and 45% moderate, and 59% and 55% severe, in the Jakavi and the BAT arms, respectively.

Patients’ insufficient response to corticosteroids in the Jakavi and BAT arm were characterised by i) a lack of response or disease progression after corticosteroid treatment for at least 7 days at 1 mg/kg/day of prednisone equivalents (37.6% and 44.5%, respectively), ii) disease persistence after 4 weeks at 0.5 mg/kg/day (35.2% and 25.6%), or iii) corticosteroid dependency (27.3% and 29.9%, respectively).

Among all patients, 73% and 45% had skin and lung involvement in the Jakavi arm, compared to 69% and 41% in the BAT arm.

The most frequently used prior systemic chronic GvHD therapies were corticosteroids only (43% in the Jakavi arm and 49% in the BAT arm) and corticosteroids+CNIs (41% patients in the Jakavi arm and 42% in the BAT arm).

The primary endpoint was the ORR on day 169, defined as the proportion of patients in each arm with a CR or a PR without the requirement of additional systemic therapies for an earlier progression, mixed response or non-response based on investigator assessment per National Institutes of Health (NIH) criteria.

A key secondary endpoint was failure free survival (FFS), a composite time to event endpoint, incorporating the earliest of the following events: i) relapse or recurrence of underlying disease or death due to underlying disease, ii) non-relapse mortality, or iii) addition or initiation of another systemic therapy for chronic GvHD.

REACH3 met its primary objective. At the time of primary analysis (data cut-off date: 08-May-2020), the ORR at week 24 was higher in the Jakavi arm (49.7%) compared to the BAT arm (25.6%). There was a statistically significant difference between the treatment arms (stratified Cochrane-Mantel-Haenszel test p<0.0001, two-sided, OR: 2.99; 95% CI: 1.86, 4.80). Results are presented in Table 12.

Among the non-responders at day 169 in the Jakavi and BAT arms, 2.4% and 12.8% had disease progression, respectively.

**Table 12** **Overall response rate at day 169 in REACH3**

|  | **Jakavi****N=165** | **BAT****N=164** |
| --- | --- | --- |
|  | **n (%)** | **95% CI** | **n (%)** | **95% CI** |
| Overall response | 82 (49.7) | 41.8, 57.6 | 42 (25.6) | 19.1, 33.0 |
| OR (95% CI) | 2.99 (1.86, 4.80) |
| p-value (2-sided) | p<0.0001 |
| Complete response | 11 (6.7) | 5 (3.0) |
| Partial response | 71 (43.0) | 37 (22.6) |

The key secondary endpoint, FFS, demonstrated a statistically significant 63% risk reduction of Jakavi versus BAT (HR: 0.370; 95% CI: 0.268, 0.510*,* p<0.0001). At 6-months, the majority of FFS events were “addition or initiation of another systemic therapy for cGvHD” (probability of that event was 13.4% vs 48.5% for the Jakavi and the BAT arms, respectively). Results for “relapse of underlying disease” and non-relapse mortality (NRM) were 2.46% vs 2.57% and 9.19% vs 4.46%, in the Jakavi and the BAT arms, respectively. No difference of cumulative incidences between treatment arms was observed when focusing on NRM only.

Paediatric population

The European Medicines Agency has waived the obligation to submit the results of studies with Jakavi in all subsets of the paediatric population for the treatment of MF and PV. In GvHD paediatric patients above 2 years of age, the safety and efficacy of Jakavi are supported by evidence from the randomised phase 3 studies REACH2 and REACH3 and from the open-label, single-arm phase 2 studies REACH4 and REACH5 (see section 4.2 for information on paediatric use). The single-arm design does not isolate the contribution of ruxolitinib to overall efficacy.

*Acute graft versus host disease*

In REACH4, 45 paediatric patients with grade II to IV acute GvHD were treated with Jakavi and corticosteroids +/- CNIs to assess the safety, efficacy and pharmacokinetics of Jakavi. Patients were enrolled into 4 groups based on age (Group 1 [≥12 years to <18 years, N=18], Group 2 [≥6 years to <12 years, N=12], Group 3 [≥2 years to <6 years, N=15] and Group 4 [≥28 days to <2 years, N=0]). The doses tested were 10 mg twice daily for Group 1, 5 mg twice daily for Group 2 and 4 mg/m2 twice daily for Group 3 and patients were treated for 24 weeks or until discontinuation. Jakavi was administered as either a 5 mg tablet or a capsule/oral solution for paediatric patients <12 years.

Patients were enrolled with either steroid-refractory or treatment-naïve disease status. Patients were considered steroid refractory as per institutional criteria or per physician decision in case institutional criteria were not available and were permitted to have received no more than one additional prior systemic treatment for acute GvHD in addition to corticosteroids. Patients were considered treatment naïve if they had not received any prior systemic treatment for acute GvHD (except for a maximum 72 hours prior systemic corticosteroid therapy of methylprednisolone or equivalent after the onset of acute GvHD). In addition to Jakavi, patients were treated with systemic corticosteroids and/or CNI (cyclosporine or tacrolimus) and topical corticosteroid therapies were also allowed per institutional guidelines. In REACH4, 40 patients (88.9%) received concomitant CNIs. Patients could also have received standard allogeneic stem cell transplantation supportive care including anti-infective medicinal products and transfusion support. Jakavi was to be discontinued in case of lack of response to acute GvHD treatment at day 28.

Tapering of Jakavi was allowed after the day 56 visit.

Male and female patients accounted for 62.2% (n=28) and for 37.8% (n=17) of patients, respectively. Overall, 27 patients (60.0%) had underlying malignancy, most frequently leukaemia (26 patients, 57.8%). Among the 45 paediatric patients enrolled in REACH4, 13 (28.9%) had treatment-naïve acute GvHD and 32 (71.1%) had steroid-refractory acute GvHD. At baseline 64.4% of patients had grade II, 26.7% had grade III and 8.9% had grade IV acute GvHD.

The overall response rate (ORR) at day 28 (primary efficacy endpoint) in REACH4 was 84.4% (90% CI: 72.8, 92.5) in all patients, with CR in 48.9% of patients and PR in 35.6% of patients. In terms of pre-treatment status, the ORR at day 28 was 90.6% in steroid refractory (SR) patients.

Rate of durable ORR at day 56 (key secondary endpoint) measured by the proportion of patients who achieved a CR or PR at day 28 and maintained a CR or PR at day 56 was 66.7% in all REACH4 patients, and 68.8% in SR patients.

*Chronic graft versus host disease*

In REACH5, 45 paediatric patients with moderate or severe chronic GvHD were treated with Jakavi and corticosteroids +/- CNIs to assess safety, efficacy and pharmacokinetics of Jakavi treatment. Patients were enrolled into 4 groups based on age (Group 1 [≥12 years to <18 years, N=22], Group 2 [≥6 years to <12 years, N=16], Group 3 [≥2 years to <6 years, N=7] and Group 4 [≥28 days to <2 years, N=0]). The doses tested were 10 mg twice daily for Group 1, 5 mg twice daily for Group 2 and 4 mg/m2 twice daily for Group 3 and patients were treated for 39 cycles/156 weeks or until discontinuation. Jakavi was administered as either a 5 mg tablet or an oral solution for paediatric patients <12 years.

Patients were enrolled with either steroid-refractory or treatment-naïve disease status. Patients were considered steroid refractory as per institutional criteria or per physician decision in case institutional criteria were not available and were permitted to have received additional prior systemic treatment for chronic GvHD in addition to corticosteroids. Patients were considered treatment naïve if they had not received any prior systemic treatment for chronic GvHD (except for a maximum 72 hours prior systemic corticosteroid therapy of methylprednisolone or equivalent after the onset of chronic GvHD). In addition to Jakavi, patients continued use of systemic corticosteroids and/or CNI (cyclosporine or tacrolimus) and topical corticosteroid therapies were also allowed per institutional guidelines. In REACH5, 23 patients (51.1%) received concomitant CNIs. Patients could also have received standard allogeneic stem cell transplantation supportive care including anti-infective medicinal products and transfusion support. Jakavi was to be discontinued in case of lack of response to chronic GvHD treatment day 169.

Tapering of Jakavi was allowed after the day 169 visit.

Male and female patients accounted for 64.4% (n=29) and for 35.6% (n=16) of patients, respectively, with 30 patients (66.7%) with pre-transplant disease history of underlying malignancy, most frequently leukaemia (27 patients, 60%).

Among the 45 paediatric patients enrolled in REACH5, 17 (37.8%) were treatment-naïve chronic GvHD patients and 28 (62.2%) were SR chronic GvHD patients. The disease was severe in 62.2% of patients and moderate in 37.8% of patients. Thirty-one (68.9%) patients had skin involvement, eighteen (40%) had mouth involvement, and fourteen (31.1%) had lung involvement.

The ORR at day 169 (primary efficacy endpoint) was 40% (90% CI: 27.7, 53.3) in all REACH5 paediatric patients, and 39.3% in SR patients.

**5.2 Pharmacokinetic properties**

Absorption

Ruxolitinib is a Biopharmaceutical Classification System (BCS) class 1 compound, with high permeability, high solubility and rapid dissolution characteristics. In clinical studies, ruxolitinib is rapidly absorbed after oral administration with maximal plasma concentration (Cmax) achieved approximately 1 hour post-dose. Based on a human mass balance study, oral absorption of ruxolitinib, as ruxolitinib or metabolites formed under first-pass, is 95% or greater. Mean ruxolitinib Cmax and total exposure (AUC) increased proportionally over a single dose range of 5 to 200 mg. There was no clinically relevant change in the pharmacokinetics of ruxolitinib upon administration with a high-fat meal. The mean Cmax was moderately decreased (24%) while the mean AUC was nearly unchanged (4% increase) on dosing with a high-fat meal.

Distribution

The mean volume of distribution at steady state is approximately 75 litres in MF and PV patients, 67.5 litres in adolescent and adult acute GvHD patients and 60.9 litres in adolescent and adult chronic GvHD patients. The mean volume of distribution at steady state is approximately 30 litres in paediatric patients with acute or chronic GvHD and with a body surface area (BSA) below 1 m2. At clinically relevant concentrations of ruxolitinib, binding to plasma proteins *in vitro* is approximately 97%, mostly to albumin. A whole body autoradiography study in rats has shown that ruxolitinib does not penetrate the blood-brain barrier.

Biotransformation

Ruxolitinib is mainly metabolised by CYP3A4 (>50%), with additional contribution from CYP2C9. Parent compound is the predominant entity in human plasma, representing approximately 60% of the drug-related material in circulation. Two major and active metabolites are present in plasma representing 25% and 11% of parent AUC. These metabolites have one half to one fifth of the parent JAK-related pharmacological activity. The sum total of all active metabolites contributes to 18% of the overall pharmacodynamics of ruxolitinib. At clinically relevant concentrations, ruxolitinib does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A4 and is not a potent inducer of CYP1A2, CYP2B6 or CYP3A4 based on *in vitro* studies. *In vitro* data indicate that ruxolitinib may inhibit P-gp and BCRP.

Elimination

Ruxolitinib is mainly eliminated through metabolism. The mean elimination half-life of ruxolitinib is approximately 3 hours. Following a single oral dose of [14C]-labelled ruxolitinib in healthy adult subjects, elimination was predominately through metabolism, with 74% of radioactivity excreted in urine and 22% via faeces. Unchanged parent substance accounted for less than 1% of the excreted total radioactivity.

Linearity/non-linearity

Dose proportionality was demonstrated in the single and multiple dose studies.

Special populations

*Effects of age, gender or race*

Based on studies in healthy subjects, no relevant differences in ruxolitinib pharmacokinetics were observed with regard to gender and race.

*Population pharmacokinetics*

In a population pharmacokinetic evaluation in MF patients, no relationship was apparent between oral clearance and patient age or race. The predicted oral clearance was 17.7 l/h in women and 22.1 l/h in men, with 39% inter-subject variability in MF patients. Clearance was 12.7 l/h in PV patients, with a 42% inter-subject variability and no relationship was apparent between oral clearance and gender, patient age or race, based on a population pharmacokinetic evaluation in PV patients. Clearance was 10.4 l/h in adolescent and adult patients with acute GvHD and 7.8 l/h in adolescent and adult patients with chronic GvHD, with a 49% inter-subject variability. In paediatric patients with acute or chronic GvHD and with a BSA below 1 m2, clearance was between 6.5 and 7 l/h. No relationship was apparent between oral clearance and gender, patient age or race, based on a population pharmacokinetic evaluation in GvHD patients. At a dose of 10 mg twice daily, exposure was increased in GvHD patients with a low BSA. In subjects with a BSA of 1 m2, 1.25 m2 and 1.5 m2, the predicted mean exposure (AUC) was respectively 31%, 22% and 12% higher than the typical adult (1.79 m2).

*Paediatric population*

The pharmacokinetics of Jakavi in paediatric patients <18 years old with MF and PV have not been established.

As in adult patients with GvHD, ruxolitinib was rapidly absorbed after oral administration in paediatric patients with GvHD. Dosing in children between 6 and 11 years old at 5 mg twice daily achieved comparable exposure to a dose of 10 mg twice daily in adolescents and adults with acute and chronic GvHD, confirming the exposure matching approach implemented as part of the extrapolation assumption. In children between 2 and 5 years old with acute and chronic GvHD, the exposure matching approach suggested a dose of 8 mg/m2 twice daily.

Ruxolitinib has not been evaluated in paediatric patients with acute or chronic GvHD below the age of 2 years, therefore modelling which accounts for age-related aspects in younger patients has been used to predict the exposure in these patients, based on the data from adult patients.

Based on a pooled population pharmacokinetic analysis in paediatric patients with acute or chronic GvHD, clearance of ruxolitinib decreased with decreasing BSA. After correcting for the BSA effect, other demographic factors such as age, body weight and body mass index did not have clinically significant effects on the exposure of ruxolitinib.

*Renal impairment*

Renal function was determined using both Modification of Diet in Renal Disease (MDRD) and urinary creatinine. Following a single ruxolitinib dose of 25 mg, the exposure of ruxolitinib was similar in subjects with various degrees of renal impairment and in those with normal renal function. However, plasma AUC values of ruxolitinib metabolites tended to increase with increasing severity of renal impairment, and were most markedly increased in the subjects with severe renal impairment. It is unknown whether the increased metabolite exposure is of safety concern. A dose modification is recommended in patients with severe renal impairment and end-stage renal disease (see section 4.2). Dosing only on dialysis days reduces the metabolite exposure, but also the pharmacodynamic effect, especially on the days between dialysis.

*Hepatic impairment*

Following a single ruxolitinib dose of 25 mg in patients with varying degrees of hepatic impairment, the mean AUC for ruxolitinib was increased in patients with mild, moderate and severe hepatic impairment by 87%, 28% and 65%, respectively, compared to patients with normal hepatic function. There was no clear relationship between AUC and the degree of hepatic impairment based on Child-Pugh scores. The terminal elimination half-life was prolonged in patients with hepatic impairment compared to healthy controls (4.1 to 5.0 hours versus 2.8 hours). A dose reduction of approximately 50% is recommended for MF and PV patients with hepatic impairment (see section 4.2).

In GvHD patients with hepatic impairment not related to GvHD, the starting dose of ruxolitinib should be reduced by 50%.

**5.3 Preclinical safety data**

Ruxolitinib has been evaluated in safety pharmacology, repeated dose toxicity, genotoxicity and reproductive toxicity studies and in a carcinogenicity study. Target organs associated with the pharmacological action of ruxolitinib in repeated dose studies include bone marrow, peripheral blood and lymphoid tissues. Infections generally associated with immunosuppression were noted in dogs. Adverse decreases in blood pressure along with increases in heart rate were noted in a dog telemetry study, and an adverse decrease in minute volume was noted in a respiratory study in rats. The margins (based on unbound Cmax) at the non-adverse level in the dog and rat studies were 15.7-fold and 10.4-fold greater, respectively, than the maximum human recommended dose of 25 mg twice daily. No effects were noted in an evaluation of the neuropharmacological effects of ruxolitinib.

In juvenile rat studies, administration of ruxolitinib resulted in effects on growth and bone measures. Reduced bone growth was observed at doses ≥5 mg/kg/day when treatment started on postnatal day 7 (comparable to human newborn) and at ≥15 mg/kg/day when treatment started on postnatal days 14 or 21 (comparable to human infant, 1–3 years). Fractures and early termination of rats were observed at doses ≥30 mg/kg/day when treatment was started on postnatal day 7. Based on unbound AUC, the exposure at the NOAEL (no observed adverse effect level) in juvenile rats treated as early as postnatal day 7 was 0.3-fold that of adult patients at 25 mg twice daily, while reduced bone growth and fractures occurred at exposures that were 1.5- and 13-fold that of adult patients at 25 mg twice daily, respectively. The effects were generally more severe when administration was initiated earlier in the postnatal period. Other than bone development, the effects of ruxolitinib in juvenile rats were similar to those in adult rats. Juvenile rats are more sensitive than adult rats to ruxolitinib toxicity.

Ruxolitinib decreased foetal weight and increased post-implantation loss in animal studies. There was no evidence of a teratogenic effect in rats and rabbits. However, the exposure margins compared to the highest clinical dose were low and the results are therefore of limited relevance for humans. No effects were noted on fertility. In a pre- and post-natal development study, a slightly prolonged gestation period, reduced number of implantation sites, and reduced number of pups delivered were observed. In the pups, decreased mean initial body weights and short period of decreased mean body weight gain were observed. In lactating rats, ruxolitinib and/or its metabolites were excreted into the milk with a concentration that was 13-fold higher than the maternal plasma concentration. Ruxolitinib was not mutagenic or clastogenic. Ruxolitinib was not carcinogenic in the Tg.rasH2 transgenic mouse model.

**6. PHARMACEUTICAL PARTICULARS**

**6.1 List of excipients**

Cellulose, microcrystalline

Magnesium stearate

Silica, colloidal anhydrous

Sodium starch glycolate (Type A)

Povidone K30

Hydroxypropylcellulose 300 to 600 cps

Lactose monohydrate

**6.2 Incompatibilities**

Not applicable.

**6.3 Shelf life**

3 years

**6.4 Special precautions for storage**

Do not store above 30°C.

**6.5 Nature and contents of container**

PVC/PE/PVDC/aluminium blister packs containing 14 or 56 tablets or multipacks containing 168 (3 packs of 56) tablets.

Not all pack sizes or types may be marketed.

**6.6 Special precautions for disposal**

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

**7. MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited

Vista Building

Elm Park, Merrion Road

Dublin 4

Ireland

**8. MARKETING AUTHORISATION NUMBER(S)**

Jakavi 5 mg tablets

EU/1/12/773/004-006

Jakavi 10 mg tablets

EU/1/12/773/014-016

Jakavi 15 mg tablets

EU/1/12/773/007-009

Jakavi 20 mg tablets

EU/1/12/773/010-012

**9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 23 August 2012

Date of latest renewal: 24 April 2017

**10. DATE OF REVISION OF THE TEXT**

Detailed information on this medicinal product is available on the website of the European Medicines Agency <https://www.ema.europa.eu>

**1. NAME OF THE MEDICINAL PRODUCT**

Jakavi 5 mg/ml oral solution

**2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

1 ml oral solution contains 5 mg ruxolitinib (as phosphate).

60 ml oral solution in bottle contains 300 mg ruxolitinib (as phosphate).

Excipients with known effect

Each ml of the oral solution contains 150 mg propylene glycol, 1.2 mg methyl parahydroxybenzoate and 0.4 mg propyl parahydroxybenzoate (see section 4.4).

For the full list of excipients, see section 6.1.

**3. PHARMACEUTICAL FORM**

Oral solution.

Clear, colourless to light yellow solution, which may have some small colourless particles or a small amount of sediment in it.

**4. CLINICAL PARTICULARS**

**4.1 Therapeutic indications**

Graft versus host disease (GvHD)

*Acute GvHD*

Jakavi is indicated for the treatment of adults and paediatric patients aged 28 days and older with acute graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.1).

*Chronic GvHD*

Jakavi is indicated for the treatment of adults and paediatric patients aged 6 months and older with chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.1).

**4.2 Posology and method of administration**

Jakavi treatment should only be initiated by a physician experienced in the administration of anti-cancer medicinal products.

A complete blood cell count, including a white blood cell count differential, must be performed before initiating therapy with Jakavi.

Complete blood count, including a white blood cell count differential, should be monitored every 2 to 4 weeks until Jakavi doses are stabilised, and then as clinically indicated (see section 4.4).

Posology

*Starting dose*

The recommended starting dose of Jakavi in acute and chronic GvHD is based on age (see Tables 1 and 2):

**Table 1** **Starting doses in acute graft versus host disease**

|  |  |
| --- | --- |
| **Age group** | **Starting dose** |
| 12 years old and above | 10 mg / 2 ml twice daily |
| 6 years to less than 12 years old | 5 mg / 1 ml twice daily |
| 28 days to less than 6 years old | 8 mg/m2 twice daily (see Table 3) |

**Table 2** **Starting doses in chronic graft versus host disease**

|  |  |
| --- | --- |
| **Age group** | **Starting dose** |
| 12 years old and above | 10 mg / 2 ml twice daily |
| 6 years to less than 12 years old | 5 mg / 1 ml twice daily |
| 6 months to less than 6 years old | 8 mg/m2 twice daily (see Table 3) |

These starting doses in GvHD can be administered using either the tablet for patients who can swallow tablets whole or the oral solution.

The volume of Jakavi to be administered twice daily when using a starting dose of 8 mg/m2 in patients less than 6 years old is presented in Table 3.

**Table 3** **Volume of Jakavi oral solution (5 mg/ml) to be administered twice daily** **when using a starting dose of 8 mg/m2 in patients less than 6 years old**

|  |  |
| --- | --- |
| Body surface area (BSA) (m2) | Volume (ml) |
| Min | Max |  |
| 0.16 | 0.21 | 0.3 |
| 0.22 | 0.28 | 0.4 |
| 0.29 | 0.34 | 0.5 |
| 0.35 | 0.40 | 0.6 |
| 0.41 | 0.46 | 0.7 |
| 0.47 | 0.53 | 0.8 |
| 0.54 | 0.59 | 0.9 |
| 0.60 | 0.65 | 1.0 |
| 0.66 | 0.71 | 1.1 |
| 0.72 | 0.78 | 1.2 |
| 0.79 | 0.84 | 1.3 |
| 0.85 | 0.90 | 1.4 |
| 0.91 | 0.96 | 1.5 |
| 0.97 | 1.03 | 1.6 |
| 1.04 | 1.09 | 1.7 |
| 1.10 | 1.15 | 1.8 |

Jakavi can be added to corticosteroids and/or calcineurin inhibitors (CNIs).

*Dose modifications*

Doses may be titrated based on efficacy and safety.

Dose reductions and temporary interruptions of treatment may be needed in GvHD-patients with thrombocytopenia, neutropenia, or elevated total bilirubin after standard supportive therapy including growth-factors, anti-infective therapies and transfusions. The recommended starting dose for GvHD patients should be reduced by approximately 50% to be administered twice daily. In patients who are unable to tolerate Jakavi at the reduced dose level, treatment should be interrupted. Detailed dosing recommendations are provided in Table 4.

**Table 4 Dosing recommendations during ruxolitinib therapy for GvHD patients with thrombocytopenia, neutropenia or elevated total bilirubin**

|  |  |
| --- | --- |
| **Laboratory parameter** | **Dosing recommendation** |
| Platelet count <20 000/mm3 | Reduce Jakavi by one dose level. If platelet count ≥20 000/mm3 within seven days, dose may be increased to initial dose level, otherwise maintain reduced dose. |
| Platelet count <15 000/mm3 | Hold Jakavi until platelet count ≥20 000/mm3, then resume at one lower dose level. |
| Absolute neutrophil count (ANC) ≥500/mm3 to <750/mm3 | Reduce Jakavi by one dose level. Resume at initial dose level if ANC >1 000/mm3. |
| Absolute neutrophil count <500/mm3 | Hold Jakavi until ANC >500/mm3, then resume at one lower dose level. If ANC >1 000/mm3,dosing may resume at initial dose level. |
| Total bilirubin elevation not caused by GvHD (no liver GvHD) | >3.0 to 5.0 x upper limit of normal (ULN): Continue Jakavi at one lower dose level until ≤3.0 x ULN. |
| >5.0 to 10.0 x ULN: Hold Jakavi up to 14 days until total bilirubin ≤3.0 x ULN. If total bilirubin ≤3.0 x ULN dosing may resume at current dose. If not ≤3.0 x ULN after 14 days, resume at one lower dose level. |
| >10.0 x ULN: Hold Jakavi until total bilirubin ≤3.0 x ULN, then resume at one lower dose level. |
| Total bilirubin elevation caused by GvHD (liver GvHD) | >3.0 x ULN: Continue Jakavi at one lower dose level until total bilirubin ≤3.0 x ULN. |

*Dose adjustment with concomitant strong CYP3A4 inhibitors or dual CYP2C9/3A4 inhibitors*

When ruxolitinib is administered with strong CYP3A4 inhibitors or dual inhibitors of CYP2C9 and CYP3A4 enzymes (e.g. fluconazole) the unit dose of ruxolitinib should be reduced by approximately 50%, to be administered twice daily (see sections 4.4 and 4.5). The concomitant use of ruxolitinib with fluconazole doses greater than 200 mg daily should be avoided.

*Special populations*

*Renal impairment*

No specific dose adjustment is needed in patients with mild or moderate renal impairment.

The recommended starting dose for GvHD patients with severe renal impairment (creatinine clearance less than 30 ml/min) should be reduced by approximately 50% to be administered twice daily. Patients should be carefully monitored with regard to safety and efficacy during ruxolitinib treatment (see section 4.4).

There are no data for GvHD patients with end-stage renal disease (ESRD).

*Hepatic impairment*

Ruxolitinib dose can be titrated to reduce the risk of cytopenia.

In patients with mild, moderate or severe hepatic impairment not related to GvHD, the starting dose of ruxolitinib should be reduced by 50% (see section 5.2).

In patients with GvHD liver involvement and an increase of total bilirubin to >3 x ULN, blood counts should be monitored more frequently for toxicity and a dose reduction by one dose level is recommended (see section 4.4).

*Elderly patients (≥65 years)*

No additional dose adjustments are recommended for elderly patients.

*Treatment discontinuation*

Tapering of Jakavi may be considered in patients with a response and after having discontinued corticosteroids. A 50% dose reduction of Jakavi every two months is recommended. If signs or symptoms of GvHD reoccur during or after the taper of Jakavi, re-escalation of treatment should be considered.

Method of administration

Jakavi is to be taken orally, with or without food.

It is recommended that a healthcare professional discusses how to administer the prescribed daily dose of the oral solution with the caregiver prior to administration of the first dose.

It is recommended that the dose of Jakavi is taken at a similar time every day, using the re-usable oral syringe provided.

If a dose is missed, the patient should not take an additional dose, but should take the next usual prescribed dose.

The patient can drink water after taking the oral solution to ensure the medicinal product has been completely swallowed. If the patient is unable to swallow and has a nasogastric or gastric tube *in situ*, the Jakavi oral solution can be administered via a nasogastric or gastric feeding tube of size French 4 (or greater) and not exceeding 125 cm in length. The tube must be flushed with water immediately after delivering the oral solution.

Instructions for preparation are provided in the instructions for use at the end of the leaflet.

**4.3 Contraindications**

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Pregnancy and lactation.

**4.4 Special warnings and precautions for use**

Myelosuppression

Treatment with Jakavi can cause haematological adverse drug reactions, including thrombocytopenia, anaemia and neutropenia. A complete blood count, including a white blood cell count differential, must be performed before initiating therapy with Jakavi.

Thrombocytopenia is generally reversible and is usually managed by reducing the dose or temporarily withholding Jakavi (see sections 4.2 and 4.8). However, platelet transfusions may be required as clinically indicated.

Patients developing anaemia may require blood transfusions. Dose modifications or interruption for patients developing anaemia may also need to be considered.

Patients with a haemoglobin level below 10.0 g/dl at the beginning of the treatment have a higher risk of developing a haemoglobin level below 8.0 g/dl during treatment compared to patients with a higher baseline haemoglobin level (79.3% versus 30.1%). More frequent monitoring of haematology parameters and of clinical signs and symptoms of Jakavi-related adverse drug reactions is recommended for patients with baseline haemoglobin below 10.0 g/dl.

Neutropenia (absolute neutrophil count <500) was generally reversible and was managed by temporarily withholding Jakavi (see sections 4.2 and 4.8).

Complete blood counts should be monitored as clinically indicated and dose adjusted as required (see sections 4.2 and 4.8).

Infections

Serious bacterial, mycobacterial, fungal, viral and other opportunistic infections have occurred in patients treated with Jakavi. Patients should be assessed for the risk of developing serious infections. Physicians should carefully observe patients receiving Jakavi for signs and symptoms of infections and initiate appropriate treatment promptly. Treatment with Jakavi should not be started until active serious infections have resolved.

Tuberculosis has been reported in patients receiving Jakavi. Before starting treatment, patients should be evaluated for active and inactive (“latent”) tuberculosis, as per local recommendations. This can include medical history, possible previous contact with tuberculosis, and/or appropriate screening such as lung x-ray, tuberculin test and/or interferon-gamma release assay, as applicable. Prescribers are reminded of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or immunocompromised.

Hepatitis B viral load (HBV-DNA titre) increases, with and without associated elevations in alanine aminotransferaseand aspartate aminotransferase, have been reported in patients with chronic HBV infections taking Jakavi. It is recommended to screen for HBV prior to commencing treatment with Jakavi. Patients with chronic HBV infection should be treated and monitored according to clinical guidelines.

Herpes zoster

Physicians should educate patients about early signs and symptoms of herpes zoster, advising that treatment should be sought as early as possible.

Progressive multifocal leukoencephalopathy

Progressive multifocal leukoencephalopathy (PML) has been reported with Jakavi treatment. Physicians should be particularly alert to symptoms suggestive of PML that patients may not notice (e.g., cognitive, neurological or psychiatric symptoms or signs). Patients should be monitored for any of these new or worsening symptoms or signs, and if such symptoms/signs occur, referral to a neurologist and appropriate diagnostic measures for PML should be considered. If PML is suspected, further dosing must be suspended until PML has been excluded.

Lipid abnormalities/elevations

Treatment with Jakavi has been associated with increases in lipid parameters including total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides. Lipid monitoring and treatment of dyslipidaemia according to clinical guidelines is recommended.

Major adverse cardiac events (MACE)

In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in rheumatoid arthritis patients 50 years of age and older with at least one additional cardiovascular risk factor, a higher rate of MACE, defined as cardiovascular death, non-fatal myocardial infarction (MI) and non-fatal stroke, was observed with tofacitinib compared to tumour necrosis factor (TNF) inhibitors.

MACE have been reported in patients receiving Jakavi. Prior to initiating or continuing therapy with Jakavi, the benefits and risks for the individual patient should be considered particularly in patients 65 years of age and older, patients who are current or past long-time smokers, and patients with a history of atherosclerotic cardiovascular disease or other cardiovascular risk factors.

Thrombosis

In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in rheumatoid arthritis patients 50 years of age and older with at least one additional cardiovascular risk factor, a dose dependent higher rate of venous thromboembolic events (VTE) including deep venous thrombosis (DVT) and pulmonary embolism (PE) was observed with tofacitinib compared to TNF inhibitors.

Events of deep venous thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients receiving Jakavi. In patients with MF and PV treated with Jakavi in clinical studies, the rates of thromboembolic events were similar in Jakavi and control-treated patients.

Prior to initiating or continuing therapy with Jakavi, the benefits and risks for the individual patient should be considered, particularly in patients with cardiovascular risk factors (see also section 4.4 “Major adverse cardiovascular events (MACE)”).

Patients with symptoms of thrombosis should be promptly evaluated and treated appropriately.

Second primary malignancies

In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in rheumatoid arthritis patients 50 years of age and older with at least one additional cardiovascular risk factor, a higher rate of malignancies, particularly lung cancer, lymphoma, and non-melanoma skin cancer (NMSC) was observed with tofacitinib compared to TNF inhibitors.

Lymphoma and other malignancies have been reported in patients receiving JAK inhibitors, including Jakavi.

Non-melanoma skin cancers (NMSCs), including basal cell, squamous cell, and Merkel cell carcinoma, have been reported in patients treated with ruxolitinib. Periodic skin examination is recommended for patients who are at increased risk for skin cancer.

Special populations

*Renal impairment*

In GvHD patients with severe renal impairment, the starting dose of Jakavi should be reduced by approximately 50% (see sections 4.2 and 5.2).

*Hepatic impairment*

In GvHD patients with hepatic impairment not related to GvHD, the starting dose of Jakavi should be reduced by approximately 50% (see sections 4.2 and 5.2).

Patients diagnosed with hepatic impairment while receiving ruxolitinib should have complete blood counts, including a white blood cell count differential, monitored at least every one to two weeks for the first 6 weeks after initiation of therapy with ruxolitinib and as clinically indicated thereafter once their liver function and blood counts have been stabilised.

Interactions

If Jakavi is to be co-administered with strong CYP3A4 inhibitors or dual inhibitors of CYP3A4 and CYP2C9 enzymes (e.g. fluconazole), the unit dose of Jakavi should be reduced by approximately 50%, to be administered twice daily (see sections 4.2 and 4.5).

More frequent monitoring (e.g. twice a week) of haematology parameters and of clinical signs and symptoms of ruxolitinib-related adverse drug reactions is recommended while on strong CYP3A4 inhibitors or dual inhibitors of CYP2C9 and CYP3A4 enzymes.

The concomitant use of cytoreductive therapies with Jakavi was associated with manageable cytopenias (see section 4.2 for dose modifications during cytopenias).

Excipients with known effect

*Propylene glycol*

This medicinal product contains 150 mg propylene glycol in each ml of oral solution.

Co-administration with any substrate for alcohol dehydrogenase such as ethanol may induce adverse effects in children less than 5 years old.

*Parahydroxybenzoate*

This medicinal product contains methyl and propyl parahydroxybenzoate, which may cause allergic reactions (possibly delayed).

**4.5 Interaction with other medicinal products and other forms of interaction**

Interaction studies have only been performed in adults.

Ruxolitinib is eliminated through metabolism catalysed by CYP3A4 and CYP2C9. Thus, medicinal products inhibiting these enzymes can give rise to increased ruxolitinib exposure.

Interactions resulting in dose reduction of ruxolitinib

*CYP3A4 inhibitors*

*Strong CYP3A4 inhibitors (such as, but not limited to, boceprevir, clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, saquinavir, telaprevir, telithromycin, voriconazole)*

In healthy subjects co-administration of ruxolitinib (10 mg single dose) with a strong CYP3A4 inhibitor, ketoconazole, resulted in ruxolitinib Cmax and AUC that were higher by 33% and 91%, respectively, than with ruxolitinib alone. The half-life was prolonged from 3.7 to 6.0 hours with concurrent ketoconazole administration.

When administering ruxolitinib with strong CYP3A4 inhibitors the unit dose of ruxolitinib should be reduced by approximately 50%, to be administered twice daily.

Patients should be closely monitored (e.g. twice weekly) for cytopenias and dose titrated based on safety and efficacy (see section 4.2).

*Dual CYP2C9 and CYP3A4 inhibitors*

In healthy subjects co-administration of ruxolitinib (10 mg single dose) with a dual CYP2C9 and CYP3A4 inhibitor, fluconazole, resulted in ruxolitinib Cmax and AUC that were higher by 47% and 232%, respectively, than with ruxolitinib alone.

50% dose reduction should be considered when using medicinal products which are dual inhibitors of CYP2C9 and CYP3A4 enzymes (e.g. fluconazole). Avoid the concomitant use of ruxolitinib with fluconazole doses greater than 200 mg daily.

Enzyme inducers

*CYP3A4 inducers (such as, but not limited to, avasimibe, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin (rifampicin), St.John’s wort (Hypericum perforatum))*

Patients should be closely monitored and the dose titrated based on safety and efficacy (see section 4.2).

In healthy subjects given ruxolitinib (50 mg single dose) following the potent CYP3A4 inducer rifampicin (600 mg daily dose for 10 days), ruxolitinib AUC was 70% lower than after administration of ruxolitinib alone. The exposure of ruxolitinib active metabolites was unchanged. Overall, the ruxolitinib pharmacodynamic activity was similar, suggesting the CYP3A4 induction resulted in minimal effect on the pharmacodynamics. However, this could be related to the high ruxolitinib dose resulting in pharmacodynamic effects near Emax. It is possible that in the individual patient, an increase of the ruxolitinib dose is needed when initiating treatment with a strong enzyme inducer.

Other interactions to be considered affecting ruxolitinib

*Mild or moderate CYP3A4 inhibitors (such as, but not limited to, ciprofloxacin, erythromycin, amprenavir, atazanavir, diltiazem, cimetidine)*

In healthy subjects co-administration of ruxolitinib (10 mg single dose) with erythromycin 500 mg twice daily for four days resulted in ruxolitinib Cmax and AUC that were higher by 8% and 27%, respectively, than with ruxolitinib alone.

No dose adjustment is recommended when ruxolitinib is co-administered with mild or moderate CYP3A4 inhibitors (e.g. erythromycin). However, patients should be closely monitored for cytopenias when initiating therapy with a moderate CYP3A4 inhibitor.

Effects of ruxolitinib on other medicinal products

*Substances transported by P-glycoprotein or other transporters*

Ruxolitinib may inhibit P-glycoprotein and breast cancer resistance protein (BCRP) in the intestine. This may result in increased sytemic exposure of substrates of these transporters, such as dabigatran etexilate, ciclosporin, rosuvastatin and potentially digoxin. Therapeutic drug monitoring (TDM) or clinical monitoring of the affected substance is advised.

It is possible that the potential inhibition of P-gp and BCRP in the intestine can be minimised if the time between administrations is kept apart as long as possible.

A study in healthy subjects indicated that ruxolitinib did not inhibit the metabolism of the oral CYP3A4 substrate midazolam. Therefore, no increase in exposure of CYP3A4 substrates is anticipated when combining them with ruxolitinib. Another study in healthy subjects indicated that ruxolitinib does not affect the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel. Therefore, it is not anticipated that the contraceptive efficacy of this combination will be compromised by co-administration of ruxolitinib.

**4.6 Fertility, pregnancy and lactation**

Pregnancy

There are no data from the use of Jakavi in pregnant women.

Animal studies have shown that ruxolitinib is embryotoxic and foetotoxic. Teratogenicity was not observed in rats or rabbits. However, the exposure margins compared to the highest clinical dose were low and the results are therefore of limited relevance for humans (see section 5.3). The potential risk for humans is unknown. As a precautionary measure, the use of Jakavi during pregnancy is contraindicated (see section 4.3).

Women of childbearing potential/Contraception

Women of child-bearing potential should use effective contraception during the treatment with Jakavi. In case pregnancy should occur during treatment with Jakavi, a risk/benefit evaluation must be carried out on an individual basis with careful counselling regarding potential risks to the foetus (see section 5.3).

Breast-feeding

Jakavi must not be used during breast-feeding (see section 4.3) and breast-feeding should therefore be discontinued when treatment is started. It is unknown whether ruxolitinib and/or its metabolites are excreted in human milk. A risk to the breast-fed child cannot be excluded. Available pharmacodynamic/toxicological data in animals have shown excretion of ruxolitinib and its metabolites in milk (see section 5.3).

Fertility

There are no human data on the effect of ruxolitinib on fertility. In animal studies, no effect on fertility was observed.

**4.7 Effects on ability to drive and use machines**

Jakavi has no or negligible sedating effect. However, patients who experience dizziness after the intake of Jakavi should refrain from driving or using machines.

**4.8 Undesirable effects**

Summary of the safety profile

*Acute GvHD*

The most frequently reported adverse drug reactions in REACH2 (adult and adolescent patients) were thrombocytopenia, anaemia, neutropenia, increased alanine aminotransferase and increased aspartate aminotransferase. The most frequently reported adverse drug reactions in the pool of paediatric patients (adolescents from REACH2 and paediatric patients from REACH4) were anaemia, neutropenia, increased alanine aminotransferase, hypercholesterolaemia and thrombocytopenia.

Haematological laboratory abnormalities identified as adverse drug reactions in REACH2 (adult and adolescent patients) and in the pool of paediatric patients (REACH2 and REACH4) included thrombocytopenia (85.2% and 55.1%), anaemia (75.0% and 70.8%) and neutropenia (65.1% and 70.0%), respectively. Grade 3 anaemia was reported in 47.7% of patients in REACH2 and in 45.8% of patients in the paediatric pool. Grade 3 and 4 thrombocytopenia were reported in 31.3% and 47.7% of patients in REACH2 and in 14.6% and 22.4% of patients in the paediatric pool, respectively. Grade 3 and 4 neutropenia were reported in 17.9% and 20.6% of patients in REACH2 and in 32.0% and 22.0% of patients in the paediatric pool, respectively.

The most frequent non-haematological adverse drug reactions in REACH2 (adult and adolescent patients) and in the pool of paediatric patients (REACH2 and REACH4) were cytomegalovirus (CMV) infection (32.3% and 31.4%), sepsis (25.4% and 9.8%), urinary tract infections (17.9% and 9.8%), hypertension (13.4% and 17.6%) and nausea (16.4% and 3.9%), respectively.

The most frequent non-haematological laboratory abnormalities identified as adverse drug reactions in REACH2 (adult and adolescent patients) and in the pool of paediatric patients (REACH2 and REACH4) were increased alanine aminotransferase (54.9% and 63.3%), increased aspartate aminotransferase (52.3% and 50.0%) and hypercholesterolaemia (49.2% and 61.2%), respectively. The majority were of grade 1 and 2, however grade 3 increased alanine aminotransferase was reported in 17.6% of patients in REACH2 and 27.3% of patients in the paediatric pool.

Discontinuation due to adverse events, regardless of causality, was observed in 29.4% of patients in REACH2 and in 21.6% of patients in the paediatric pool.

*Chronic GvHD*

The most frequently reported adverse drug reactions in REACH3 (adult and adolescent patients) were anaemia, hypercholesterolemia and increased aspartate aminotransferase. The most frequently reported adverse drug reactions in the pool of paediatric patients (adolescents from REACH3 and paediatric patients from REACH5) were neutropenia, hypercholesterolaemia and increased alanine aminotransferase.

Haematological laboratory abnormalities identified as adverse drug reactions in REACH3 (adult and adolescent patients) and in the pool of paediatric patients (REACH3 and REACH5) included anaemia (68.6% and 49.1%), neutropenia (36.2% and 59.3%), and thrombocytopenia (34.4% and 35.2%), respectively. Grade 3 anaemia was reported in 14.8% of patients in REACH3 and in 17.0% of patients in the paediatric pool. Grade 3 and 4 neutropenia were reported in 9.5% and 6.7% of patients in REACH3 and in 17.3% and 11.1% of patients in the paediatric pool, respectively. Grade 3 and 4 thrombocytopenia were reported in 5.9% and 10.7% of adult and adolescent patients in REACH3 and in 7.7% and 11.1% of patients in the paediatric pool, respectively.

The most frequent non-haematological adverse drug reactions in REACH3 (adult and adolescent patients) and in the pool of paediatric patients (REACH3 and REACH5) were hypertension (15.0% and 14.5%) and headache (10.2% and 18.2%), respectively.

The most frequent non-haematological laboratory abnormalities identified as adverse drug reactions in REACH3 (adult and adolescent patients) and in the pool of paediatric patients (REACH3 and REACH5) were hypercholesterolaemia (52.3% and 54.9%), increased aspartate aminotransferase (52.2% and 45.5%) and increased alanine aminotransferase (43.1% and 50.9%). The majority were grade 1 and 2, however grade 3 laboratory abnormalities reported in the pool of paediatric patients included increased alanine aminotransferase (14.9%) and increased aspartate aminotransferase (11.5%).

Discontinuation due to adverse events, regardless of causality, was observed in 18.1% of patients in REACH3 and in 14.5% of patients in the paediatric pool.

Tabulated list of adverse reactions

The safety of Jakavi in acute GvHD patients was evaluated in the phase 3 study REACH2 and in the phase 2 study REACH4. REACH2 included data from 201 patients ≥12 years of age initially randomised to Jakavi (n=152) and patients who received Jakavi after crossing over from the best available therapy (BAT) arm (n=49). The median exposure upon which the adverse drug reaction frequency categories were based was 8.9 weeks (range 0.3 to 66.1 weeks). In the pool of paediatric patients ≥2 years of age (6 patients in REACH2 and 45 patients in REACH4), the median exposure was 16.7 weeks (range 1.1 to 48.9 weeks).

The safety of Jakavi in chronic GvHD patients was evaluated in the phase 3 study REACH3 and in the phase 2 study REACH5. REACH3 included data from 226 patients ≥12 years of age initially randomised to Jakavi (n=165) and patients who received Jakavi after crossing over from BAT (n=61). The median exposure upon which the adverse drug reaction frequency categories were based was 41.4 weeks (range 0.7 to 127.3 weeks). In the pool of paediatric patients ≥2 years of age (10 patients in REACH3 and 45 patients in REACH5), the median exposure was 57.1 weeks (range 2.1 to 155.4 weeks).

In the clinical study programme the severity of adverse drug reactions was assessed based on the CTCAE, defining grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening or disabling, grade 5=death.

Adverse drug reactions from clinical studies in acute and chronic GvHD (Table 5) are listed by MedDRA system organ class. Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first. In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1 000 to <1/100); rare (≥1/10 000 to <1/1 000); very rare (<1/10 000); not known (cannot be estimated from the available data).

**Table 5 Frequency category of adverse drug reactions reported in clinical studies in GvHD**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Acute GvHD (REACH2)** | **Acute GvHD (Paediatric pool)** | **Chronic GvHD (REACH3)** | **Chronic GvHD (Paediatric pool)** |
| **Adverse drug reaction** | **Frequency category** | **Frequency category** | **Frequency category** | **Frequency category** |
| **Infections and infestations** |
| CMV infections | Very common | Very common | Common | Common |
|  CTCAE3 grade ≥3 | Very common | Common | Common | N/A5 |
| Sepsis | Very common | Common | -6 | -6 |
|  CTCAE grade ≥34 | Very common | Common | -6 | -6 |
| Urinary tract infections | Very common | Common | Common | Common |
|  CTCAE grade ≥3 | Common | Common | Common | Common |
| BK virus infections | -6 | -6 | Common | Common |
|  CTCAE grade ≥3 | -6 | -6 | Uncommon | N/A5 |
| **Blood and lymphatic system disorders** |
| Thrombocytopenia1 | Very common | Very common | Very common | Very common |
|  CTCAE grade 3 | Very common | Very common | Common | Common |
|  CTCAE grade 4 | Very common | Very common | Very common | Very common |
| Anaemia1 | Very common | Very common | Very common | Very common |
|  CTCAE grade 3 | Very common | Very common | Very common | Very common |
| Neutropenia1 | Very common | Very common | Very common | Very common |
|  CTCAE grade 3 | Very common | Very common | Common | Very common |
|  CTCAE grade 4 | Very common | Very common | Common | Very common |
| Pancytopenia1,2 | Very common | Very common | -6 | -6 |
| **Metabolism and nutrition disorders** |
| Hypercholesterolaemia1 | Very common | Very common | Very common | Very common |
|  CTCAE grade 3 | Common | N/A5 | Common | Common |
|  CTCAE grade 4 | Common | N/A5 | Uncommon | Common |
| Weight gain | -6 | -6 | Common | Common |
|  CTCAE grade ≥3 | -6 | -6 | N/A5 | Common |
| **Nervous system disorders** |
| Headache | Common | Common | Very common | Very common |
|  CTCAE grade ≥3 | Uncommon | N/A5 | Common | Common |
| **Vascular disorders** |
| Hypertension | Very common | Very common | Very common | Very common |
|  CTCAE grade ≥3 | Common | Very common | Common | Common |
| **Gastrointestinal disorders** |
| Increased lipase1 | -6 | -6 | Very common | Very common |
|  CTCAE grade 3 | -6 | -6 | Common | Common |
|  CTCAE grade 4 | -6 | -6 | Uncommon | Common |
| Increased amylase1 | -6 | -6 | Very common | Very common |
|  CTCAE grade 3 | -6 | -6 | Common | Common |
|  CTCAE grade 4 | -6 | -6 | Common | N/A5 |
| Nausea | Very common | Common | -6 | -6 |
|  CTCAE grade ≥3 | Uncommon | N/A5 | -6 | -6 |
| Constipation | -6 | -6 | Common | Common |
|  CTCAE grade ≥3 | -6 | -6 | N/A5 | N/A5 |
| **Hepatobiliary disorders** |
| Increased alanine aminotransferase1 | Very common | Very common | Very common | Very common |
|  CTCAE grade 3 | Very common | Very common | Common | Very common |
|  CTCAE grade 4 | Common | N/A5 | Uncommon | Common |
| Increased aspartate aminotransferase1 | Very common | Very common | Very common | Very common |
|  CTCAE grade 3 | Common | Common | Common | Very common |
|  CTCAE grade 4 | N/A5 | N/A5 | Uncommon | N/A5 |
| **Musculoskeletal and connective tissue disorders** |
| Increased blood creatine phosphokinase1 | -6 | -6 | Very common | Very common |
|  CTCAE grade 3 | -6 | -6 | Common | N/A5 |
|  CTCAE grade 4 | -6 | -6 | Common | N/A5 |
| **Renal and urinary disorders** |
| Increased blood creatinine1 | -6 | -6 | Very common | Common |
|  CTCAE grade 3 | -6 | -6 | Common | N/A5 |
|  CTCAE grade 4 | -6 | -6 | N/A5 | N/A5 |
| 1 Frequency is based on new or worsened laboratory abnormalities compared to baseline.2 Pancytopenia is defined as haemoglobin level <100 g/l, platelet count <100 x 109/l, and neutrophil count <1.5 x 109/l (or low white blood cell count of grade 2 if neutrophil count is missing), simultaneously in the same laboratory assessment.3 CTCAE Version 4.03.4 Grade ≥3 sepsis includes 20 (10%) grade 5 events in REACH2. There were no grade 5 events in the paediatric pool.5 Not applicable: no cases reported6 “-”: not an identified adverse drug reaction in this indication |

Description of selected adverse drug reactions

*Anaemia*

In the phase 3 acute (REACH2) and chronic (REACH3) GvHD studies, anaemia (all grades) was reported in 75.0% and 68.6% of patients, CTCAE grade 3 was reported in 47.7% and 14.8% of patients, respectively. In paediatric patients with acute and chronic GvHD, anaemia (all grades) was reported in 70.8% and 49.1% of patients, CTCAE grade 3 was reported in 45.8% and 17.0% of patients, respectively.

*Thrombocytopenia*

In the phase 3 acute GvHD study (REACH2), grade 3 and 4 thrombocytopenia was observed in 31.3% and 47.7% of patients, respectively. In the phase 3 chronic GvHD study (REACH3), grade 3 and 4 thrombocytopenia was lower (5.9% and 10.7%) than in acute GvHD. The frequency of grade 3 (14.6%) and 4 (22.4%) thrombocytopenia in paediatric patients with acute GvHD was lower than in REACH2. In paediatric patients with chronic GvHD, grade 3 and 4 thrombocytopenia was lower (7.7% and 11.1%) than in paediatric patients with acute GvHD.

*Neutropenia*

In the phase 3 acute GvHD study (REACH2), grade 3 and 4 neutropenia was observed in 17.9% and 20.6% of patients, respectively. In the phase 3 chronic GvHD study (REACH3), grade 3 and 4 neutropenia was lower (9.5% and 6.7%) than in acute GvHD. In paediatric patients, the frequency of grade 3 and 4 neutropenia was 32.0% and 22.0%, respectively, in acute GvHD and 17.3% and 11.1%, respectively, in chronic GvHD.

*Bleeding*

In the comparative period of the phase 3 acute GvHD study (REACH2), bleeding events were reported in 25.0% and 22.0% of patients in the ruxolitinib and BAT arms respectively. The sub-groups of bleeding events were generally similar between treatment arms: bruising events (5.9% in ruxolitinib vs. 6.7% in BAT arm), gastrointestinal events (9.2% vs. 6.7%) and other haemorrhage events (13.2% vs. 10.7%). Intracranial bleeding events were reported in 0.7% of patients in the BAT arm and in no patients in the ruxolitinib arm. In paediatric patients, the frequency of bleeding events was 23.5%. Events reported in ≥5% of patients were cystitis haemorrhagic and epistaxis (5.9% each). No intracranial bleeding events were reported in paediatric patients.

In the comparative period of the phase 3 chronic GvHD study (REACH3), bleeding events were reported in 11.5% and 14.6% of patients in the ruxolitinib and BAT arms respectively. The sub-groups of bleeding events were generally similar between treatment arms: bruising events (4.2% in ruxolitinib vs. 2.5% in BAT arm), gastrointestinal events (1.2% vs. 3.2%) and other haemorrhage events (6.7% vs. 10.1%). In paediatric patients, the frequency of bleeding events was 9.1%. The reported events were epistaxis, haematochezia, haematoma, post-procedural haemorrhage, and skin haemorrhage (1.8% each). No intracranial bleeding events were reported in patients with chronic GvHD.

*Infections*

In the phase 3 acute GvHD study (REACH2), during the *comparative period*, urinary tract infections were reported in 9.9% (grade ≥3, 3.3%) of patients in the ruxolitinib arm compared to 10.7% (grade ≥3, 6.0%) in the BAT arm. CMV infections were reported in 28.3% (grade ≥3, 9.3%) of patients in the ruxolitinib arm compared to 24.0% (grade ≥3, 10.0%) in the BAT arm. Sepsis events were reported in 12.5% (grade ≥3, 11.1%) of patients in the ruxolitinib arm compared to 8.7% (grade ≥3, 6.0%) in the BAT arm. BK virus infection was reported only in the ruxolitinib arm in 3 patients with one grade 3 event. During *extended follow-up* of patients treated with ruxolitinib, urinary tract infections were reported in 17.9% (grade ≥3, 6.5%) of patients and CMV infections were reported in 32.3% (grade ≥3, 11.4%) of patients. CMV infection with organ involvement was seen in very few patients; CMV colitis, CMV enteritis and CMV gastrointestinal infection of any grade were reported in four, two and one patients, respectively. Sepsis events, including septic shock, of any grade were reported in 25.4% (grade ≥3, 21.9%) of patients. Urinary tract infections and sepsis events were reported with lower frequency in paediatric patients with acute GvHD (9.8% each) compared to adult and adolescent patients. CMV infections were reported in 31.4% of paediatric patients (grade 3, 5.9%).

In the phase 3 chronic GvHD study (REACH3), during the *comparative period*, urinary tract infections were reported in 8.5% (grade ≥3, 1.2%) of patients in the ruxolitinib arm compared to 6.3% (grade ≥3, 1.3%) in the BAT arm. BK virus infection was reported in 5.5% (grade ≥3, 0.6%) of patients in the ruxolitinib arm compared to 1.3% in the BAT arm. CMV infections were reported in 9.1% (grade ≥3, 1.8%) of patients in the ruxolitinib arm compared to 10.8% (grade ≥3, 1.9%) in the BAT arm. Sepsis events were reported in 2.4% (grade ≥3, 2.4%) of patients in the ruxolitinib arm compared to 6.3% (grade ≥3, 5.7%) in the BAT arm. During *extended follow-up* of patients treated with ruxolitinib, urinary tract infections and BK virus infections were reported in 9.3% (grade ≥3, 1.3%) and 4.9% (grade ≥3, 0.4%) of patients, respectively. CMV infections and sepsis events were reported in 8.8% (grade ≥3, 1.3%) and 3.5% (grade ≥3, 3.5%) of patients, respectively. In paediatric patients with chronic GvHD, urinary tract infections were reported in 5.5% (grade 3, 1.8%) of patients and BK virus infection was reported in 1.8% (no grade ≥3) of patients. CMV infections occurred in 7.3% (no grade ≥3) of patients.

*Elevated lipase*

In the *comparative period* of the phase 3 acute GvHD study (REACH2), new or worsened lipase values were reported in 19.7% of patients in the ruxolitinib arm compared to 12.5% in the BAT arm; corresponding grade 3 (3.1% vs 5.1%) and grade 4 (0% vs 0.8%) increases were similar. During *extended follow-up* of patients treated with ruxolitinib, increased lipase values were reported in 32.2% of patients; grade 3 and 4 were reported in 8.7% and 2.2% of patients respectively. Elevated lipase was reported in 20.4% of paediatric patients (grade 3 and 4: 8.5% and 4.1%, respectively).

In the *comparative period* of the phase 3 chronic GvHD study (REACH3), new or worsened lipase values were reported in 32.1% of patients in the ruxolitinib arm compared to 23.5% in the BAT arm; corresponding grade 3 (10.6% vs 6.2%) and grade 4 (0.6% vs 0%) increases were similar. During *extended follow-up* of patients treated with ruxolitinib, increased lipase values were reported in 35.9% of patients; grade 3 and 4 were observed in 9.5% and 0.4% of patients, respectively. Elevated lipase was reported with lower frequency (20.4%, grade 3 and 4: 3.8% and 1.9%, respectively) in paediatric patients.

Paediatric patients

A total of 106 patients aged 2 to <18 years with GvHD were analysed for safety: 51 patients (45 patients in REACH4 and 6 patients in REACH2) in acute GvHD studies and 55 patients (45 patients in REACH5 and 10 patients in REACH3) in the chronic GvHD studies. The safety profile observed in paediatric patients who received treatment with ruxolitinib was similar to that observed in adult patients.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in [Appendix V](https://www.ema.europa.eu/documents/template-form/qrd-appendix-v-adverse-drug-reaction-reporting-details_en.docx).

**4.9 Overdose**

There is no known antidote for overdoses with Jakavi. Single doses up to 200 mg have been given with acceptable acute tolerability. Higher than recommended repeat doses are associated with increased myelosuppression including leukopenia, anaemia and thrombocytopenia. Appropriate supportive treatment should be given.

Haemodialysis is not expected to enhance the elimination of ruxolitinib.

**5. PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitors, ATC code: L01EJ01

Mechanism of action

Ruxolitinib is a selective inhibitor of the Janus Associated Kinases (JAKs) JAK1 and JAK2 (IC50 values of 3.3 nM and 2.8 nM for JAK1 and JAK2 enzymes, respectively). These mediate the signalling of a number of cytokines and growth factors that are important for haematopoiesis and immune function.

Ruxolitinib inhibits JAK-STAT signalling and cell proliferation of cytokine-dependent cellular models of haematological malignancies, as well as of Ba/F3 cells rendered cytokine-independent by expressing the JAK2V617F mutated protein, with IC50 ranging from 80 to 320 nM.

JAK-STAT signalling pathways play a role in regulating the development, proliferation, and activation of several immune cell types important for GvHD pathogenesis.

Pharmacodynamic effects

In a thorough QT study in healthy subjects, there was no indication of a QT/QTc prolonging effect of ruxolitinib in single doses up to a supratherapeutic dose of 200 mg, indicating that ruxolitinib has no effect on cardiac repolarisation.

Clinical efficacy and safety

Two randomised phase 3, open-label, multi-centre studies investigated Jakavi in patients 12 years of age and older with acute GvHD (REACH2) and chronic GvHD (REACH3) after allogeneic haematopoietic stem cell transplantation (alloSCT) and insufficient response to corticosteroids and/or other systemic therapies. The starting dose of Jakavi was 10 mg twice daily.

*Acute graft-versus-host disease*

In REACH2, 309 patients with grade II to IV corticosteroid-refractory, acute GvHD were randomised 1:1 to Jakavi or BAT. Patients were stratified by severity of acute GvHD at the time of randomisation. Corticosteroid refractoriness was determined when patients had progression after at least 3 days, failed to achieve a response after 7 days or failed corticosteroid taper.

BAT was selected by the investigator on a patient-by-patient basis and included anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mesenchymal stromal cells (MSC), low dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, or infliximab.

In addition to Jakavi or BAT, patients could have received standard allogeneic stem cell transplantation supportive care including anti-infective medicinal products and transfusion support. Ruxolitinib was added to continued use of corticosteroids and/or calcineurin inhibitors (CNIs) such as cyclosporine or tacrolimus and/or topical or inhaled corticosteroid therapies per institutional guidelines.

Patients who received one prior systemic treatment other than corticosteroids and CNI for acute GvHD were eligible for inclusion in the study. In addition to corticosteroids and CNI, prior systemic medicinal product for acute GvHD was allowed to continue only if used for acute GvHD prophylaxis (i.e. started before the acute GvHD diagnosis) as per common medical practice.

Patients on BAT could cross over to ruxolitinib after day 28 if they met the following criteria:

* Failed to meet the primary endpoint response definition (complete response [CR] or partial response [PR]) at day 28; OR
* Lost the response thereafter and met criteria for progression, mixed response, or no response, necessitating new additional systemic immunosuppressive treatment for acute GvHD, AND
* Did not have signs/symptoms of chronic GvHD.

Tapering of Jakavi was allowed after the day 56 visit for patients with treatment response.

Baseline demographics and disease characteristics were balanced between the two treatment arms. The median age was 54 years (range 12 to 73 years). The study included 2.9% adolescent, 59.2% male and 68.9% white patients. The majority of enrolled patients had malignant underlying disease.

The severity of acute GvHD was grade II in 34% and 34%, grade III in 46% and 47%, and grade IV in 20% and 19% of the Jakavi and BAT arms, respectively.

The reasons for patients’ insufficient response to corticosteroids in the Jakavi and BAT arms were i) failure in achieving a response after 7 days of corticosteroid treatment (46.8% and 40.6%, respectively), ii) failure of corticosteroid taper (30.5% and 31.6%, respectively) or iii) disease progression after 3 days of treatment (22.7% and 27.7%, respectively).

Among all patients, the most common organs involved in acute GvHD were skin (54.0%) and lower gastrointestinal tract (68.3%). More patients in the Jakavi arm had acute GvHD involving skin (60.4%) and liver (23.4%), compared to the BAT arm (skin: 47.7% and liver: 16.1%).

The most frequently used prior systemic acute GvHD therapies were corticosteroids+CNIs (49.4% in the Jakavi arm and 49.0% in the BAT arm).

The primary endpoint was the overall response rate (ORR) on day 28, defined as the proportion of patients in each arm with a complete response (CR) or a partial response (PR) without the requirement of additional systemic therapies for an earlier progression, mixed response or non-response based on investigator assessment following the criteria by Harris et al. (2016).

The key secondary endpoint was the proportion of patients who achieved a CR or PR at day 28 and maintained a CR or PR at day 56.

REACH2 met its primary objective. ORR at day 28 of treatment was higher in the Jakavi arm (62.3%) compared to the BAT arm (39.4%). There was a statistically significant difference between the treatment arms (stratified Cochrane-Mantel-Haenszel test p<0.0001, two-sided, OR: 2.64; 95% CI: 1.65, 4.22).

There was also a higher proportion of complete responders in the Jakavi arm (34.4%) compared to BAT arm (19.4%).

Day-28 ORR was 76% for grade II GvHD, 56% for grade III GvHD, and 53% for grade IV GvHD in the Jakavi arm, and 51% for grade II GvHD, 38% for grade III GvHD, and 23% for grade IV GvHD in the BAT arm.

Among the non-responders at day 28 in the Jakavi and BAT arms, 2.6% and 8.4% had disease progression, respectively.

Overall results are presented in Table 6.

**Table 6 Overall response rate at day 28 in REACH2**

|  |  |  |
| --- | --- | --- |
|  | **Jakavi****N=154** | **BAT****N=155** |
|  | **n (%)** | **95% CI** | **n (%)** | **95% CI** |
| Overall response | 96 (62.3) | 54.2, 70.0 | 61 (39.4) | 31.6, 47.5 |
| OR (95% CI) | 2.64 (1.65, 4.22) |
| p-value (2-sided) | p <0.0001 |
| Complete response | 53 (34.4) | 30 (19.4) |
| Partial response | 43 (27.9) | 31 (20.0) |

The study met its key secondary endpoint based on the primary data analysis. Durable ORR at day 56 was 39.6% (95% CI: 31.8, 47.8) in the Jakavi arm and 21.9% (95% CI: 15.7, 29.3) in the BAT arm. There was a statistically significant difference between the two treatment arms (OR: 2.38; 95% CI: 1.43, 3.94; p=0.0007). The proportion of patients with a CR was 26.6% in the Jakavi arm versus 16.1% in the BAT arm. Overall, 49 patients (31.6%) originally randomised to the BAT arm crossed over to the Jakavi arm.

*Chronic graft-versus-host disease*

In REACH3, 329 patients with moderate or severe corticosteroid-refractory, chronic GvHD were randomised 1:1 to Jakavi or BAT. Patients were stratified by severity of chronic GvHD at the time of randomisation. Corticosteroid refractoriness was determined when patients had lack of response or disease progression after 7 days, or had disease persistence for 4 weeks or failed corticosteroid taper twice.

BAT was selected by the investigator on a patient-by-patient basis and included extracorporeal photopheresis (ECP), low dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib, or ibrutinib.

In addition to Jakavi or BAT, patients could have received standard allogeneic stem cell transplantation supportive care including anti-infective medicinal products and transfusion support. Continued use of corticosteroids and CNIs such as cyclosporine or tacrolimus and topical or inhaled corticosteroid therapies were allowed per institutional guidelines.

Patients who received one prior systemic treatment other than corticosteroids and/or CNI for chronic GvHD were eligible for inclusion in the study. In addition to corticosteroids and CNI, prior systemic medicinal product for chronic GvHD was allowed to continue only if used for chronic GvHD prophylaxis (i.e. started before the chronic GvHD diagnosis) as per common medical practice.

Patients on BAT could cross over to ruxolitinib on day 169 and thereafter due to disease progression, mixed response, or unchanged response, due to toxicity to BAT, or due to chronic GvHD flare.

Efficacy in patients that transition from active acute GvHD to chronic GvHD without tapering off corticosteroids and any systemic treatment is unknown. Efficacy in acute or chronic GvHD after donor lymphocyte infusion (DLI) and in patients who did not tolerate steroid treatment is unknown.

Tapering of Jakavi was allowed after the day 169 visit.

Baseline demographics and disease characteristics were balanced between the two treatment arms. The median age was 49 years (range 12 to 76 years). The study included 3.6% adolescent, 61.1% male and 75.4% white patients. The majority of enrolled patients had malignant underlying disease.

The severity at diagnosis of corticosteroid-refractory chronic GvHD was balanced between the two treatment arms, with 41% and 45% moderate, and 59% and 55% severe, in the Jakavi and the BAT arms, respectively.

Patients’ insufficient response to corticosteroids in the Jakavi and BAT arm were characterised by i) a lack of response or disease progression after corticosteroid treatment for at least 7 days at 1 mg/kg/day of prednisone equivalents (37.6% and 44.5%, respectively), ii) disease persistence after 4 weeks at 0.5 mg/kg/day (35.2% and 25.6%), or iii) corticosteroid dependency (27.3% and 29.9%, respectively).

Among all patients, 73% and 45% had skin and lung involvement in the Jakavi arm, compared to 69% and 41% in the BAT arm.

The most frequently used prior systemic chronic GvHD therapies were corticosteroids only (43% in the Jakavi arm and 49% in the BAT arm) and corticosteroids+CNIs (41% patients in the Jakavi arm and 42% in the BAT arm).

The primary endpoint was the ORR on day 169, defined as the proportion of patients in each arm with a CR or a PR without the requirement of additional systemic therapies for an earlier progression, mixed response or non-response based on investigator assessment per National Institutes of Health (NIH) criteria.

A key secondary endpoint was failure free survival (FFS), a composite time to event endpoint, incorporating the earliest of the following events: i) relapse or recurrence of underlying disease or death due to underlying disease, ii) non-relapse mortality, or iii) addition or initiation of another systemic therapy for chronic GvHD.

REACH3 met its primary objective. At the time of primary analysis (data cut-off date: 08-May-2020), the ORR at week 24 was higher in the Jakavi arm (49.7%) compared to the BAT arm (25.6%). There was a statistically significant difference between the treatment arms (stratified Cochrane-Mantel-Haenszel test p<0.0001, two-sided, OR: 2.99; 95% CI: 1.86, 4.80). Results are presented in Table 7.

Among the non-responders at day 169 in the Jakavi and BAT arms, 2.4% and 12.8% had disease progression, respectively.

**Table 7** **Overall response rate at day 169 in REACH3**

|  | **Jakavi****N=165** | **BAT****N=164** |
| --- | --- | --- |
|  | **n (%)** | **95% CI** | **n (%)** | **95% CI** |
| Overall response | 82 (49.7) | 41.8, 57.6 | 42 (25.6) | 19.1, 33.0 |
| OR (95% CI) | 2.99 (1.86, 4.80) |
| p-value (2-sided) | p<0.0001 |
| Complete response | 11 (6.7) | 5 (3.0) |
| Partial response | 71 (43.0) | 37 (22.6) |

The key secondary endpoint, FFS, demonstrated a statistically significant 63% risk reduction of Jakavi versus BAT (HR: 0.370; 95% CI: 0.268, 0.510*,* p<0.0001). At 6-months, the majority of FFS events were “addition or initiation of another systemic therapy for cGvHD” (probability of that event was 13.4% vs 48.5% for the Jakavi and the BAT arms, respectively). Results for “relapse of underlying disease” and non-relapse mortality (NRM) were 2.46% vs 2.57% and 9.19% vs 4.46%, in the Jakavi and the BAT arms, respectively. No difference of cumulative incidences between treatment arms was observed when focusing on NRM only.

Paediatric population

In GvHD paediatric patients above 2 years of age, the safety and efficacy of Jakavi are supported by evidence from the randomised phase 3 studies REACH2 and REACH3 and from the open-label, single-arm phase 2 studies REACH4 and REACH5 (see section 4.2 for information on paediatric use). The single-arm design does not isolate the contribution of ruxolitinib to overall efficacy.

*Acute graft versus host disease*

In REACH4, 45 paediatric patients with grade II to IV acute GvHD were treated with Jakavi and corticosteroids +/- CNIs to assess the safety, efficacy and pharmacokinetics of Jakavi. Patients were enrolled into 4 groups based on age (Group 1 [≥12 years to <18 years, N=18], Group 2 [≥6 years to <12 years, N=12], Group 3 [≥2 years to <6 years, N=15] and Group 4 [≥28 days to <2 years, N=0]). The doses tested were 10 mg twice daily for Group 1, 5 mg twice daily for Group 2 and 4 mg/m2 twice daily for Group 3 and patients were treated for 24 weeks or until discontinuation. Jakavi was administered as either a 5 mg tablet or a capsule/oral solution for paediatric patients <12 years.

Patients were enrolled with either steroid-refractory or treatment-naïve disease status. Patients were considered steroid refractory as per institutional criteria or per physician decision in case institutional criteria were not available and were permitted to have received no more than one additional prior systemic treatment for acute GvHD in addition to corticosteroids. Patients were considered treatment naïve if they had not received any prior systemic treatment for acute GvHD (except for a maximum 72 hours prior systemic corticosteroid therapy of methylprednisolone or equivalent after the onset of acute GvHD). In addition to Jakavi, patients were treated with systemic corticosteroids and/or CNI (cyclosporine or tacrolimus) and topical corticosteroid therapies were also allowed per institutional guidelines. In REACH4, 40 patients (88.9%) received concomitant CNIs. Patients could also have received standard allogeneic stem cell transplantation supportive care including anti-infective medicinal products and transfusion support. Jakavi was to be discontinued in case of lack of response to acute GvHD treatment at day 28.

Tapering of Jakavi was allowed after the day 56 visit.

Male and female patients accounted for 62.2% (n=28) and for 37.8% (n=17) of patients, respectively. Overall, 27 patients (60.0%) had underlying malignancy, most frequently leukaemia (26 patients, 57.8%). Among the 45 paediatric patients enrolled in REACH4, 13 (28.9%) had treatment-naïve acute GvHD and 32 (71.1%) had steroid-refractory acute GvHD. At baseline 64.4% of patients had grade II, 26.7% had grade III and 8.9% had grade IV acute GvHD.

The overall response rate (ORR) at day 28 (primary efficacy endpoint) in REACH4 was 84.4% (90% CI: 72.8, 92.5) in all patients, with CR in 48.9% of patients and PR in 35.6% of patients. In terms of pre-treatment status, the ORR at day 28 was 90.6% in steroid refractory (SR) patients.

Rate of durable ORR at day 56 (key secondary endpoint measured by the proportion of patients who achieved a CR or PR at day 28 and maintained a CR or PR at day 56 was 66.7% in all REACH4 patients, and 68.8% in SR patients.

*Chronic graft versus host disease*

In REACH5, 45 paediatric patients with moderate or severe chronic GvHD were treated with Jakavi and corticosteroids +/- CNIs to assess safety, efficacy and pharmacokinetics of Jakavi treatment. Patients were enrolled into 4 groups based on age (Group 1 [≥12 years to <18 years, N=22], Group 2 [≥6 years to <12 years, N=16], Group 3 [≥2 years to <6 years, N=7] and Group 4 [≥28 days to <2 years, N=0]). The doses tested were 10 mg twice daily for Group 1, 5 mg twice daily for Group 2 and 4 mg/m2 twice daily for Group 3 and patients were treated for 39 cycles/156 weeks or until discontinuation. Jakavi was administered as either a 5 mg tablet or an oral solution for paediatric patients <12 years.

Patients were enrolled with either steroid-refractory or treatment-naïve disease status. Patients were considered steroid refractory as per institutional criteria or per physician decision in case institutional criteria were not available and were permitted to have received additional prior systemic treatment for chronic GvHD in addition to corticosteroids. Patients were considered treatment naïve if they had not received any prior systemic treatment for chronic GvHD (except for a maximum 72 hours prior systemic corticosteroid therapy of methylprednisolone or equivalent after the onset of chronic GvHD). In addition to Jakavi, patients continued use of systemic corticosteroids and/or CNI (cyclosporine or tacrolimus) and topical corticosteroid therapies were also allowed per institutional guidelines. In REACH5, 23 patients (51.1%) received concomitant CNIs. Patients could also have received standard allogeneic stem cell transplantation supportive care including anti-infective medicinal products and transfusion support. Jakavi was to be discontinued in case of lack of response to chronic GvHD treatment at day 169.

Tapering of Jakavi was allowed after the day 169 visit.

Male and female patients accounted for 64.4% (n=29) and for 35.6% (n=16) of patients, respectively, with 30 patients (66.7%) with pre-transplant disease history of underlying malignancy, most frequently leukaemia (27 patients, 60%).

Among the 45 paediatric patients enrolled in REACH5, 17 (37.8%) were treatment-naïve chronic GvHD patients and 28 (62.2%) were SR chronic GvHD patients. The disease was severe in 62.2% of patients and moderate in 37.8% of patients. Thirty-one (68.9%) patients had skin involvement, eighteen (40%) had mouth involvement, and fourteen (31.1%) had lung involvement.

The ORR at day 169 (primary efficacy endpoint) was 40% (90% CI: 27.7, 53.3) in all REACH5 paediatric patients, and 39.3% in SR patients.

**5.2 Pharmacokinetic properties**

Absorption

Ruxolitinib is a Biopharmaceutical Classification System (BCS) class 1 compound, with high permeability, high solubility and rapid dissolution characteristics. In clinical studies, ruxolitinib is rapidly absorbed after oral administration with maximal plasma concentration (Cmax) achieved approximately 1 hour post-dose. Based on a human mass balance study, oral absorption of ruxolitinib, as ruxolitinib or metabolites formed under first-pass, is 95% or greater. Mean ruxolitinib Cmax and total exposure (AUC) increased proportionally over a single dose range of 5 to 200 mg. There was no clinically relevant change in the pharmacokinetics of ruxolitinib upon administration with a high-fat meal. The mean Cmax was moderately decreased (24%) while the mean AUC was nearly unchanged (4% increase) on dosing with a high-fat meal.

Distribution

The mean volume of distribution at steady state is approximately 67.5 litres in adolescent and adult acute GvHD patients and 60.9 litres in adolescent and adult chronic GvHD patients. The mean volume of distribution at steady state is approximately 30 litres in paediatric patients with acute or chronic GvHD and with a body surface area (BSA) below 1 m2. At clinically relevant concentrations of ruxolitinib, binding to plasma proteins *in vitro* is approximately 97%, mostly to albumin. A whole body autoradiography study in rats has shown that ruxolitinib does not penetrate the blood-brain barrier.

Biotransformation

Ruxolitinib is mainly metabolised by CYP3A4 (>50%), with additional contribution from CYP2C9. Parent compound is the predominant entity in human plasma, representing approximately 60% of the drug-related material in circulation. Two major and active metabolites are present in plasma representing 25% and 11% of parent AUC. These metabolites have one half to one fifth of the parent JAK-related pharmacological activity. The sum total of all active metabolites contributes to 18% of the overall pharmacodynamics of ruxolitinib. At clinically relevant concentrations, ruxolitinib does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A4 and is not a potent inducer of CYP1A2, CYP2B6 or CYP3A4 based on *in vitro* studies. *In vitro* data indicate that ruxolitinib may inhibit P-gp and BCRP.

Elimination

Ruxolitinib is mainly eliminated through metabolism. The mean elimination half-life of ruxolitinib is approximately 3 hours. Following a single oral dose of [14C]-labelled ruxolitinib in healthy adult subjects, elimination was predominately through metabolism, with 74% of radioactivity excreted in urine and 22% via faeces. Unchanged parent substance accounted for less than 1% of the excreted total radioactivity.

Linearity/non-linearity

Dose proportionality was demonstrated in the single and multiple dose studies.

Special populations

*Effects of age, gender or race*

Based on studies in healthy subjects, no relevant differences in ruxolitinib pharmacokinetics were observed with regard to gender and race.

No relationship was apparent between oral clearance and gender, patient age or race, based on a population pharmacokinetic evaluation in GvHD patients.

*Paediatric population*

As in adult patients with GvHD, ruxolitinib was rapidly absorbed after oral administration in paediatric patients with GvHD. Dosing in children between 6 and 11 years old at 5 mg twice daily achieved comparable exposure to a dose of 10 mg twice daily in adolescents and adults with acute and chronic GvHD, confirming the exposure matching approach implemented as part of the extrapolation assumption. In children between 2 and 5 years old with acute and chronic GvHD, the exposure matching approach suggested a dose of 8 mg/m2 twice daily.

Ruxolitinib has not been evaluated in paediatric patients with acute or chronic GvHD below the age of 2 years, therefore modelling which accounts for age-related aspects in younger patients has been used to predict the exposure in these patients, based on the data from adult patients.

Based on a pooled population pharmacokinetic analysis in paediatric patients with acute or chronic GvHD, clearance of ruxolitinib decreased with decreasing BSA. Clearance was 10.4 l/h in adolescent and adult patients with acute GvHD and 7.8 l/h in adolescent and adult patients with chronic GvHD, with a 49% intersubject variability. In paediatric patients with acute or chronic GvHD and with a BSA below 1 m2, clearance was between 6.5 and 7 l/h. After correcting for the BSA effect, other demographic factors such as age, body weight and body mass index did not have clinically significant effects on the exposure of ruxolitinib.

*Renal impairment*

Renal function was determined using both Modification of Diet in Renal Disease (MDRD) and urinary creatinine. Following a single ruxolitinib dose of 25 mg, the exposure of ruxolitinib was similar in subjects with various degrees of renal impairment and in those with normal renal function. However, plasma AUC values of ruxolitinib metabolites tended to increase with increasing severity of renal impairment, and were most markedly increased in the subjects with severe renal impairment. It is unknown whether the increased metabolite exposure is of safety concern. A dose modification is recommended in patients with severe renal impairment.

*Hepatic impairment*

Following a single ruxolitinib dose of 25 mg in patients with varying degrees of hepatic impairment, the mean AUC for ruxolitinib was increased in patients with mild, moderate and severe hepatic impairment by 87%, 28% and 65%, respectively, compared to patients with normal hepatic function. There was no clear relationship between AUC and the degree of hepatic impairment based on Child-Pugh scores. The terminal elimination half-life was prolonged in patients with hepatic impairment compared to healthy controls (4.1 to 5.0 hours versus 2.8 hours). A dose reduction of approximately 50% is recommended for MF and PV patients with hepatic impairment (see section 4.2).

In GvHD patients with hepatic impairment not related to GvHD, the starting dose of ruxolitinib should be reduced by 50%.

**5.3 Preclinical safety data**

Ruxolitinib has been evaluated in safety pharmacology, repeated dose toxicity, genotoxicity and reproductive toxicity studies and in a carcinogenicity study. Target organs associated with the pharmacological action of ruxolitinib in repeated dose studies include bone marrow, peripheral blood and lymphoid tissues. Infections generally associated with immunosuppression were noted in dogs. Adverse decreases in blood pressure along with increases in heart rate were noted in a dog telemetry study, and an adverse decrease in minute volume was noted in a respiratory study in rats. The margins (based on unbound Cmax) at the non-adverse level in the dog and rat studies were 15.7-fold and 10.4-fold greater, respectively, than the maximum human recommended dose of 25 mg twice daily. No effects were noted in an evaluation of the neuropharmacological effects of ruxolitinib.

In juvenile rat studies, administration of ruxolitinib resulted in effects on growth and bone measures. Reduced bone growth was observed at doses ≥5 mg/kg/day when treatment started on postnatal day 7 (comparable to human newborn) and at ≥15 mg/kg/day when treatment started on postnatal days 14 or 21 (comparable to human infant, 1–3 years). Fractures and early termination of rats were observed at doses ≥30 mg/kg/day when treatment was started on postnatal day 7. Based on unbound AUC, the exposure at the NOAEL (no observed adverse effect level) in juvenile rats treated as early as postnatal day 7 was 0.3-fold that of adult patients at 25 mg twice daily, while reduced bone growth and fractures occurred at exposures that were 1.5- and 13-fold that of adult patients at 25 mg twice daily, respectively. The effects were generally more severe when administration was initiated earlier in the postnatal period. Other than bone development, the effects of ruxolitinib in juvenile rats were similar to those in adult rats. Juvenile rats are more sensitive than adult rats to ruxolitinib toxicity.

Ruxolitinib decreased foetal weight and increased post-implantation loss in animal studies. There was no evidence of a teratogenic effect in rats and rabbits. However, the exposure margins compared to the highest clinical dose were low and the results are therefore of limited relevance for humans. No effects were noted on fertility. In a pre- and post-natal development study, a slightly prolonged gestation period, reduced number of implantation sites, and reduced number of pups delivered were observed. In the pups, decreased mean initial body weights and short period of decreased mean body weight gain were observed. In lactating rats, ruxolitinib and/or its metabolites were excreted into the milk with a concentration that was 13-fold higher than the maternal plasma concentration. Ruxolitinib was not mutagenic or clastogenic. Ruxolitinib was not carcinogenic in the Tg.rasH2 transgenic mouse model.

**6. PHARMACEUTICAL PARTICULARS**

**6.1 List of excipients**

Propylene glycol (E 1520)

Citric acid anhydrous

Methyl parahydroxybenzoate (E 218)

Propyl parahydroxybenzoate (E 216)

Sucralose (E 955)

Strawberry dry flavour

Purified water

**6.2 Incompatibilities**

Not applicable.

**6.3 Shelf life**

2 years

After opening use within 60 days.

**6.4 Special precautions for storage**

Do not store above 30°C.

**6.5 Nature and contents of container**

Jakavi oral solution is available in 70 ml amber glass bottles with a white polypropylene child-resistant screw cap closure. Packs containing one bottle of 60 ml oral solution, two 1 ml polypropylene oral syringes and one low density polypropylene press-in bottle adapter. The oral syringes are equipped with plunger O-rings and printed with 0.1 ml graduation marks.

**6.6 Special precautions for disposal**

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

**7. MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited

Vista Building

Elm Park, Merrion Road

Dublin 4

Ireland

**8. MARKETING AUTHORISATION NUMBER(S)**

EU/1/12/773/017

**9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 23 August 2012

Date of latest renewal: 24 April 2017

**10. DATE OF REVISION OF THE TEXT**

Detailed information on this medicinal product is available on the website of the European Medicines Agency <https://www.ema.europa.eu>

Annex II

**A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**

**B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**

**C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

**D. conditions or restrictions with regard to the safe and effective use of the medicinal product**

**A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**

Name and address of the manufacturer responsible for batch release

Tablet

Novartis Farmacéutica S.A.

Gran Via de les Corts Catalanes, 764

08013 Barcelona

Spain

Novartis Pharmaceutical Manufacturing LLC

Verovškova ulica 57

1000 Ljubljana

Slovenia

Novartis Pharma GmbH

Roonstrasse 25

90429 Nuremberg

Germany

Novartis Pharma GmbH

Sophie-Germain-Strasse 10

90443 Nuremberg

Germany

Oral solution

Novartis Farmacéutica S.A.

Gran Via de les Corts Catalanes, 764

08013 Barcelona

Spain

Novartis Pharma GmbH

Roonstrasse 25

90429 Nuremberg

Germany

Novartis Pharma GmbH

Sophie-Germain-Strasse 10

90443 Nuremberg

Germany

The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.

**B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

**C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

* **Periodic safety update reports (PSURs)**

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

**D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT**

* **Risk management plan (RMP)**

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

* At the request of the European Medicines Agency;
* Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

**ANNEX III**

**LABELLING AND PACKAGE LEAFLET**

**A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**CARTON OF UNIT PACK**

**1. NAME OF THE MEDICINAL PRODUCT**

Jakavi 5 mg tablets

ruxolitinib

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each tablet contains 5 mg ruxolitinib (as phosphate).

**3. LIST OF EXCIPIENTS**

Contains lactose.

**4. PHARMACEUTICAL FORM AND CONTENTS**

Tablets

14 tablets

56 tablets

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Oral use.

Read the package leaflet before use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Do not store above 30°C.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited

Vista Building

Elm Park, Merrion Road

Dublin 4

Ireland

**12. MARKETING AUTHORISATION NUMBER(S)**

|  |  |
| --- | --- |
| EU/1/12/773/004 | 14 tablets |
| EU/1/12/773/005 | 56 tablets |

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

Jakavi 5 mg

**17. UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC

SN

NN

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**OUTER CARTON OF MULTIPACK**

**1. NAME OF THE MEDICINAL PRODUCT**

Jakavi 5 mg tablets

ruxolitinib

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each tablet contains 5 mg ruxolitinib (as phosphate).

**3. LIST OF EXCIPIENTS**

Contains lactose.

**4. PHARMACEUTICAL FORM AND CONTENTS**

Tablets

Multipack: 168 (3 packs of 56) tablets.

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Oral use

Read the package leaflet before use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Do not store above 30°C.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited

Vista Building

Elm Park, Merrion Road

Dublin 4

Ireland

**12. MARKETING AUTHORISATION NUMBER(S)**

|  |  |
| --- | --- |
| EU/1/12/773/006 | 168 tablets (3x56) |

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

Jakavi 5 mg

**17. UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC

SN

NN

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**INTERMEDIATE CARTON OF MULTIPACK**

**1. NAME OF THE MEDICINAL PRODUCT**

Jakavi 5 mg tablets

ruxolitinib

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each tablet contains 5 mg ruxolitinib (as phosphate).

**3. LIST OF EXCIPIENTS**

Contains lactose.

**4. PHARMACEUTICAL FORM AND CONTENTS**

Tablets

56 tablets. Component of a multipack. Not to be sold separately.

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Oral use.

Read the package leaflet before use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Do not store above 30°C.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited

Vista Building

Elm Park, Merrion Road

Dublin 4

Ireland

**12. MARKETING AUTHORISATION NUMBER(S)**

|  |  |
| --- | --- |
| EU/1/12/773/006 | 168 tablets (3x56) |

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

Jakavi 5 mg

**17. UNIQUE IDENTIFIER – 2D BARCODE**

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

**MINIMUM PARTICULARS TO APPEAR ON BLISTER OR STRIPS**

**BLISTERS**

**1. NAME OF THE MEDICINAL PRODUCT**

Jakavi 5 mg tablets

ruxolitinib

**2. NAME OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited

**3. EXPIRY DATE**

EXP

**4. BATCH NUMBER**

Lot

**5. OTHER**

Monday

Tuesday

Wednesday

Thursday

Friday

Saturday

Sunday





**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**CARTON OF UNIT PACK**

**1. NAME OF THE MEDICINAL PRODUCT**

Jakavi 10 mg tablets

ruxolitinib

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each tablet contains 10 mg ruxolitinib (as phosphate).

**3. LIST OF EXCIPIENTS**

Contains lactose.

**4. PHARMACEUTICAL FORM AND CONTENTS**

Tablets

14 tablets

56 tablets

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Oral use.

Read the package leaflet before use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Do not store above 30°C.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited

Vista Building

Elm Park, Merrion Road

Dublin 4

Ireland

**12. MARKETING AUTHORISATION NUMBER(S)**

|  |  |
| --- | --- |
| EU/1/12/773/014 | 14 tablets |
| EU/1/12/773/015 | 56 tablets |

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

Jakavi 10 mg

**17. UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC

SN

NN

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**OUTER CARTON OF MULTIPACK**

**1. NAME OF THE MEDICINAL PRODUCT**

Jakavi 10 mg tablets

ruxolitinib

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each tablet contains 10 mg ruxolitinib (as phosphate).

**3. LIST OF EXCIPIENTS**

Contains lactose.

**4. PHARMACEUTICAL FORM AND CONTENTS**

Tablets

Multipack: 168 (3 packs of 56) tablets.

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Oral use

Read the package leaflet before use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Do not store above 30°C.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited

Vista Building

Elm Park, Merrion Road

Dublin 4

Ireland

**12. MARKETING AUTHORISATION NUMBER(S)**

|  |  |
| --- | --- |
| EU/1/12/773/016 | 168 tablets (3x56) |

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

Jakavi 10 mg

**17. UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC

SN

NN

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**INTERMEDIATE CARTON OF MULTIPACK**

**1. NAME OF THE MEDICINAL PRODUCT**

Jakavi 10 mg tablets

ruxolitinib

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each tablet contains 10 mg ruxolitinib (as phosphate).

**3. LIST OF EXCIPIENTS**

Contains lactose.

**4. PHARMACEUTICAL FORM AND CONTENTS**

Tablets

56 tablets. Component of a multipack. Not to be sold separately.

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Oral use.

Read the package leaflet before use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Do not store above 30°C.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited

Vista Building

Elm Park, Merrion Road

Dublin 4

Ireland

**12. MARKETING AUTHORISATION NUMBER(S)**

|  |  |
| --- | --- |
| EU/1/12/773/016 | 168 tablets (3x56) |

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

Jakavi 10 mg

**17. UNIQUE IDENTIFIER – 2D BARCODE**

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

**MINIMUM PARTICULARS TO APPEAR ON BLISTER OR STRIPS**

**BLISTERS**

**1. NAME OF THE MEDICINAL PRODUCT**

Jakavi 10 mg tablets

ruxolitinib

**2. NAME OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited

**3. EXPIRY DATE**

EXP

**4. BATCH NUMBER**

Lot

**5. OTHER**

Monday

Tuesday

Wednesday

Thursday

Friday

Saturday

Sunday





**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**CARTON OF UNIT PACK**

**1. NAME OF THE MEDICINAL PRODUCT**

Jakavi 15 mg tablets

ruxolitinib

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each tablet contains 15 mg ruxolitinib (as phosphate).

**3. LIST OF EXCIPIENTS**

Contains lactose.

**4. PHARMACEUTICAL FORM AND CONTENTS**

Tablets

14 tablets

56 tablets

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Oral use.

Read the package leaflet before use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Do not store above 30°C.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited

Vista Building

Elm Park, Merrion Road

Dublin 4

Ireland

**12. MARKETING AUTHORISATION NUMBER(S)**

|  |  |
| --- | --- |
| EU/1/12/773/007 | 14 tablets |
| EU/1/12/773/008 | 56 tablets |

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

Jakavi 15 mg

**17. UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC

SN

NN

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**OUTER CARTON OF MULTIPACK**

**1. NAME OF THE MEDICINAL PRODUCT**

Jakavi 15 mg tablets

ruxolitinib

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each tablet contains 15 mg ruxolitinib (as phosphate).

**3. LIST OF EXCIPIENTS**

Contains lactose.

**4. PHARMACEUTICAL FORM AND CONTENTS**

Tablets

Multipack: 168 (3 packs of 56) tablets.

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Oral use

Read the package leaflet before use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Do not store above 30°C.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited

Vista Building

Elm Park, Merrion Road

Dublin 4

Ireland

**12. MARKETING AUTHORISATION NUMBER(S)**

|  |  |
| --- | --- |
| EU/1/12/773/009 | 168 tablets (3x56) |

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

Jakavi 15 mg

**17. UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC

SN

NN

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**INTERMEDIATE CARTON OF MULTIPACK**

**1. NAME OF THE MEDICINAL PRODUCT**

Jakavi 15 mg tablets

ruxolitinib

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each tablet contains 15 mg ruxolitinib (as phosphate).

**3. LIST OF EXCIPIENTS**

Contains lactose.

**4. PHARMACEUTICAL FORM AND CONTENTS**

Tablets

56 tablets. Component of a multipack. Not to be sold separately.

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Oral use.

Read the package leaflet before use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Do not store above 30°C.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited

Vista Building

Elm Park, Merrion Road

Dublin 4

Ireland

**12. MARKETING AUTHORISATION NUMBER(S)**

|  |  |
| --- | --- |
| EU/1/12/773/009 | 168 tablets (3x56) |

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

Jakavi 15 mg

**17. UNIQUE IDENTIFIER – 2D BARCODE**

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

**MINIMUM PARTICULARS TO APPEAR ON BLISTER OR STRIPS**

**BLISTERS**

**1. NAME OF THE MEDICINAL PRODUCT**

Jakavi 15 mg tablets

ruxolitinib

**2. NAME OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited

**3. EXPIRY DATE**

EXP

**4. BATCH NUMBER**

Lot

**5. OTHER**

Monday

Tuesday

Wednesday

Thursday

Friday

Saturday

Sunday





**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**CARTON OF UNIT PACK**

**1. NAME OF THE MEDICINAL PRODUCT**

Jakavi 20 mg tablets

ruxolitinib

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each tablet contains 20 mg ruxolitinib (as phosphate).

**3. LIST OF EXCIPIENTS**

Contains lactose.

**4. PHARMACEUTICAL FORM AND CONTENTS**

Tablets

14 tablets

56 tablets

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Oral use.

Read the package leaflet before use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Do not store above 30°C.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited

Vista Building

Elm Park, Merrion Road

Dublin 4

Ireland

**12. MARKETING AUTHORISATION NUMBER(S)**

|  |  |
| --- | --- |
| EU/1/12/773/010 | 14 tablets |
| EU/1/12/773/011 | 56 tablets |

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

Jakavi 20 mg

**17. UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC

SN

NN

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**OUTER CARTON OF MULTIPACK**

**1. NAME OF THE MEDICINAL PRODUCT**

Jakavi 20 mg tablets

ruxolitinib

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each tablet contains 20 mg ruxolitinib (as phosphate).

**3. LIST OF EXCIPIENTS**

Contains lactose.

**4. PHARMACEUTICAL FORM AND CONTENTS**

Tablets

Multipack: 168 (3 packs of 56) tablets.

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Oral use

Read the package leaflet before use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Do not store above 30°C.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited

Vista Building

Elm Park, Merrion Road

Dublin 4

Ireland

**12. MARKETING AUTHORISATION NUMBER(S)**

|  |  |
| --- | --- |
| EU/1/12/773/012 | 168 tablets (3x56) |

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

Jakavi 20 mg

**17. UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC

SN

NN

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**INTERMEDIATE CARTON OF MULTIPACK**

**1. NAME OF THE MEDICINAL PRODUCT**

Jakavi 20 mg tablets

ruxolitinib

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each tablet contains 20 mg ruxolitinib (as phosphate).

**3. LIST OF EXCIPIENTS**

Contains lactose.

**4. PHARMACEUTICAL FORM AND CONTENTS**

Tablets

56 tablets. Component of a multipack. Not to be sold separately.

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Oral use.

Read the package leaflet before use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Do not store above 30°C.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited

Vista Building

Elm Park, Merrion Road

Dublin 4

Ireland

**12. MARKETING AUTHORISATION NUMBER(S)**

|  |  |
| --- | --- |
| EU/1/12/773/012 | 168 tablets (3x56) |

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

Jakavi 20 mg

**17. UNIQUE IDENTIFIER – 2D BARCODE**

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

**MINIMUM PARTICULARS TO APPEAR ON BLISTER OR STRIPS**

**BLISTERS**

**1. NAME OF THE MEDICINAL PRODUCT**

Jakavi 20 mg tablets

ruxolitinib

**2. NAME OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited

**3. EXPIRY DATE**

EXP

**4. BATCH NUMBER**

Lot

**5. OTHER**

Monday

Tuesday

Wednesday

Thursday

Friday

Saturday

Sunday





**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**CARTON**

**1. NAME OF THE MEDICINAL PRODUCT**

Jakavi 5 mg/ml oral solution

ruxolitinib

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each ml solution contains 5 mg ruxolitinib (as phosphate).

**3. LIST OF EXCIPIENTS**

Contains propylene glycol, E 216 and E 218.

**4. PHARMACEUTICAL FORM AND CONTENTS**

Oral solution

1 bottle of 60 ml + 2 oral syringes + press-in bottle adapter

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Oral use

Read the package leaflet before use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP

After opening use within 60 days.

**9. SPECIAL STORAGE CONDITIONS**

Do not store above 30°C.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited

Vista Building

Elm Park, Merrion Road

Dublin 4

Ireland

**12. MARKETING AUTHORISATION NUMBER(S)**

|  |  |
| --- | --- |
| EU/1/12/773/017 | 1 bottle + 2 oral syringes + press-in bottle adapter |

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

Jakavi 5 mg/ml

**17. UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC

SN

NN

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING**

**BOTTLE LABEL**

**1. NAME OF THE MEDICINAL PRODUCT**

Jakavi 5 mg/ml oral solution

ruxolitinib

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each ml solution contains 5 mg ruxolitinib (as phosphate).

**3.** **LIST OF EXCIPIENTS**

Contains propylene glycol, E 216 and E 218.

**4. PHARMACEUTICAL FORM AND CONTENTS**

Oral solution

60 ml

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Oral use

Read the package leaflet before use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8.** **EXPIRY DATE**

EXP

Opened:

After opening use within 60 days.

**9. SPECIAL STORAGE CONDITIONS**

Do not store above 30°C.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited

**12. MARKETING AUTHORISATION NUMBER(S)**

|  |  |
| --- | --- |
| EU/1/12/773/017 | 1 bottle + 2 oral syringes + press-in bottle adapter |

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

**17. UNIQUE IDENTIFIER – 2D BARCODE**

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

**B. PACKAGE LEAFLET**

**Package leaflet: Information for the patient**

**Jakavi 5 mg tablets**

**Jakavi 10 mg tablets**

**Jakavi 15 mg tablets**

**Jakavi 20 mg tablets**

ruxolitinib

**Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.**

1. Keep this leaflet. You may need to read it again.
2. If you have any further questions, ask your doctor or pharmacist.
3. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
4. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
5. The information in this leaflet is for you or your child – but in the leaflet it will just say “you”.

**What is in this leaflet**

1. What Jakavi is and what it is used for

2. What you need to know before you take Jakavi

3. How to take Jakavi

4. Possible side effects

5. How to store Jakavi

6. Contents of the pack and other information

**1. What Jakavi is and what it is used for**

Jakavi contains the active substance ruxolitinib.

Jakavi is used to treat adult patients with an enlarged spleen or with symptoms related to myelofibrosis, a rare form of blood cancer.

Jakavi is also used to treat adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.

Jakavi is also used to treat:

- children aged 28 days and older and adults with acute graft versus host disease (GvHD).

- children aged 6 months and older and adults with chronic GvHD.

There are two forms of GvHD: an early form called acute GvHD that usually develops soon after the transplantation and can affect skin, liver and gastrointestinal tract, and a form called chronic GvHD, which develops later, usually weeks to months after the transplantation. Almost any organ can be affected by chronic GvHD.

**How Jakavi works**

Enlargement of the spleen is one of the characteristics of myelofibrosis. Myelofibrosis is a disorder of the bone marrow, in which the marrow is replaced by scar tissue. The abnormal marrow can no longer produce enough normal blood cells and as a result the spleen becomes significantly enlarged. By blocking the action of certain enzymes (called Janus Associated Kinases), Jakavi can reduce the size of the spleen in patients with myelofibrosis and relieve symptoms such as fever, night sweats, bone pain and weight loss in patients with myelofibrosis. Jakavi can help reduce the risk of serious blood or vascular complications.

Polycythaemia vera is a disorder of the bone marrow, in which the marrow produce too many red blood cells. The blood becomes thicker as a result of the increased red blood cells. Jakavi can relieve the symptoms, reduce spleen size and the volume of red blood cells produced in patients with polycythaemia vera by selectively blocking enzymes called Janus Associated Kinases (JAK1 and JAK2), thus potentially reducing the risk of serious blood or vascular complications.

Graft versus host disease is a complication which occurs after transplantation when specific cells (T cells) in the donor’s graft (e.g. bone marrow) do not recognise the host cells/organs and attack them. By selectively blocking enzymes called Janus Associated Kinases (JAK1 and JAK2), Jakavi reduces signs and symptoms of the acute and the chronic forms of graft-versus-host disease leading to disease improvement and survival of the transplanted cells.

If you have any questions about how Jakavi works or why this medicine has been prescribed for you, ask your doctor.

**2. What you need to know before you take Jakavi**

Follow all your doctor’s instructions carefully. They may differ from the general information contained in this leaflet.

**Do not take Jakavi**

- if you are allergic to ruxolitinib or any of the other ingredients of this medicine (listed in section 6).

- if you are pregnant or breast‑feeding (see section 2 “Pregnancy, breast-feeding and contraception”).

**Warnings and precautions**

Talk to your doctor or pharmacist before taking Jakavi if:

* you have any infections. It may be necessary to treat your infection before starting Jakavi.
* you have ever had tuberculosis or if you have been in close contact with someone who has or has had tuberculosis. Your doctor may perform tests to see if you have tuberculosis or any other infections.
* you have ever had hepatitis B.
* you have kidney problems or you have or have ever had liver problems because your doctor may need to prescribe a different dose of Jakavi.
* you have ever had cancer, in particular skin cancer.
* you have or have had heart problems.
* you are 65 years of age or older. Patients aged 65 years and older may be at increased risk of heart problems, including heart attack, and some types of cancer.
* you are a smoker or have smoked in the past.

Talk to your doctor or pharmacist during your treatment with Jakavi if:

* you experience fever, chills or other symptoms of infections.
* you experience chronic coughing with blood-tinged sputum, fever, night sweats and weight loss (these can be signs of tuberculosis).
* you have any of the following symptoms or if anyone close to you notices that you have any of these symptoms: confusion or difficulty thinking, loss of balance or difficulty walking, clumsiness, difficulty speaking, decreased strength or weakness on one side of your body, blurred and/or loss of vision. These may be signs of a serious brain infection and your doctor may suggest further testing and follow-up.
* you develop painful skin rash with blisters (these are signs of shingles).
* you have any skin changes. This may require further observation, as certain types of skin cancer (non-melanoma) have been reported.
* you experience sudden shortness of breath or difficulty breathing, chest pain or pain in upper back, swelling of the leg or arm, leg pain or tenderness, or redness or discoloration in the leg or arm as these can be signs of blood clots in the veins.

**Children and adolescents**

This medicine is not intended for use by children or adolescents aged below 18 years, who have the disease myelofibrosis or polycythaemia vera because it has not been studied in this age group.

For the treatment of graft-versus-host disease, Jakavi can be used in patients 28 days and older.

**Other medicines and Jakavi**

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. While you are taking Jakavi you should never start a new medicine without checking first with the doctor who prescribed Jakavi. This includes prescription medicines, non-prescription medicines and herbal or alternative medicines.

It is particularly important that you mention medicines containing any of the following active substances, as your doctor may need to adjust the Jakavi dose:

* Some medicines used to treat infections:
* medicines used to treat fungal diseases (such as ketoconazole, itraconazole, posaconazole, fluconazole and voriconazole)
* antibiotics used to treat bacterial infections (such as clarithromycin, telithromycin, ciprofloxacin, or erythromycin)
* medicines to treat viral infections, including HIV infection/AIDS (such as amprenavir, atazanavir, indinavir, lopinavir/ritonavir, nelfinavir, ritonavir, saquinavir)
* medicines to treat hepatitis C (boceprevir, telaprevir).
* A medicine to treat depression (nefazodone).
* Medicines to treat high blood pressure (hypertension) and chest tightness, heaviness or pain (chronic angina pectoris) (mibefradil or diltiazem).
* A medicine to treat heartburn (cimetidine).
* A medicine to treat heart disease (avasimibe).
* Medicines used to stop seizures or fits (phenytoin, carbamazepine or phenobarbital and other anti-epileptics).
* Medicines used to treat tuberculosis (TB) (rifabutin or rifampicin).
* A herbal product used to treat depression (St. John’s wort (*Hypericum perforatum*)).

Talk to your doctor if you are not sure if the above applies to you.

**Pregnancy, breast-feeding and contraception**

*Pregnancy*

- If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

- Do not take Jakavi during pregnancy (see section 2 “Do not take Jakavi”).

*Breast-feeding*

- Do not breastfeed while taking Jakavi (see section 2 “Do not take Jakavi”). Ask your doctor for advice.

*Contraception*

- Taking Jakavi is not recommended for women who could become pregnant and who are not using contraception. Talk to your doctor about how to use appropriate contraception to avoid becoming pregnant during treatment with Jakavi.

- Talk to your doctor if you become pregnant while using Jakavi.

**Driving and using machines**

If you experience dizziness after taking Jakavi, do not drive or use machines.

**Jakavi contains lactose and sodium**

Jakavi contains lactose (milk sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.

This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.

**3. How to take Jakavi**

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

Before you start treatment with Jakavi and during treatment, your doctor will do blood tests to find the best dose, to see how you are responding to the treatment and whether Jakavi is having an unwanted effect. Your doctor may need to adjust the dose or stop treatment. Your doctor will carefully check if you have any signs or symptoms of infection before starting and during your treatment with Jakavi.

**Myelofibrosis**

* Adults: The recommended starting dose is 5 to 20 mg twice daily. The maximum dose is 25 mg twice daily.

**Polycythaemia vera**

* Adults: The recommended starting dose is 10 mg twice daily. The maximum dose is 25 mg twice daily.

**Acute and chronic graft versus host disease**

* Children 6 years to less than 12 years old: The recommended starting dose is 5 mg twice daily.
* Children 12 years and older and adults: The recommended starting is 10 mg twice daily.

An oral solution is available if you have difficulty swallowing the whole tablet and for children less than 6 years old.

You should take Jakavi every day at the same time, either with or without food.

Your doctor will always tell you exactly how many Jakavi tablets to take.

You should continue taking Jakavi for as long as your doctor tells you to.

**If you take more Jakavi than you should**

If you accidentally take more Jakavi than your doctor prescribed, contact your doctor or pharmacist immediately.

**If you forget to take Jakavi**

If you forget to take Jakavi simply take your next dose at the scheduled time. Do not take a double dose to make up for a forgotten dose.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

**4. Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Most of the side effects of Jakavi are mild to moderate and will generally disappear after a few days to a few weeks of treatment.

**Myelofibrosis and polycythaemia vera**

**Some side effects could be serious**

**Seek medical help immediately prior to taking the next scheduled dose if you experience the following serious side effects:**

Very common (may affect more than 1 in 10 people):

* any sign of bleeding in the stomach or intestine, such as passing black or bloodstained stools, or vomiting blood
* unexpected bruising and/or bleeding, unusual tiredness, shortness of breath during exercise or at rest, unusually pale skin, or frequent infections - possible symptoms of blood disorder
* painful skin rash with blisters - possible symptoms of shingles (*herpes zoster*)
* fever, chills or other symptoms of infections
* low level of red blood cells (*anaemia*), low level of white blood cells (*neutropenia*) or low level of platelets (*thrombocytopenia*)

Common (may affect up to 1 in 10 people):

* any sign of bleeding in the brain, such as sudden altered level of consciousness, persistent headache, numbness, tingling, weakness or paralysis

**Other side effects**

Other possible side effects include the following listed below. If you experience these side effects, talk to your doctor or pharmacist.

Very common (may affect more than 1 in 10 people):

* high level of cholesterol or fat in the blood (*hypertriglyceridaemia*)
* abnormal liver function test results
* dizziness
* headache
* urinary tract infections
* weight gain
* fever, cough, difficult or painful breathing, wheezing, pain in chest when breathing - possible symptoms of pneumonia
* high blood pressure (*hypertension*), which may also be the cause of dizziness and headaches
* constipation
* high level of lipase in the blood

Common (may affect up to 1 in 10 people):

* reduced number of all three types of blood cells: red blood cells, white blood cells, and platelets (*pancytopenia*)
* frequently passing wind (*flatulence*)

Uncommon (may affect up to 1 in 100 people):

* tuberculosis
* recurrence of hepatitis B infection (which can cause yellowing of the skin and eyes, dark brown-colored urine, right-sided stomach pain, fever and feeling nauseous or being sick).

**Graft-versus-host disease (GvHD)**

**Some side effects could be serious**

**Seek medical help immediately prior to taking the next scheduled dose if you experience the following serious side effects:**

Very common (may affect more than 1 in 10 people):

* signs of infections with fever associated with:
* muscle pain, skin redness, and/or difficulty breathing (*cytomegalovirus infection*)
* pain when urinating (urinary tract infection)
* fast heart rate, confusion and rapid breathing (sepsis, which is a condition associated with an infection and widespread inflammation)
* frequent infections, fever, chills, sore throat or mouth ulcers
* spontaneous bleeding or bruising - possible symptoms of thrombocytopenia which is caused by low levels of platelets

**Other side effects**

Very common (may affect more than 1 in 10 people):

* headache
* high blood pressure (*hypertension*)
* abnormal blood test results, including:
* high level of lipase and/or amylase
* high level of cholesterol
* abnormal liver function
* increased level of a muscle enzyme (increased blood creatine phosphokinase)
* increased level of creatinine, an enzyme which may indicate that your kidneys are not functioning properly
	+ - low counts of all three types of blood cells: red blood cells, white blood cells, and platelets (*pancytopenia*)
* feeling sick (nausea)
* tiredness, fatigue, pale skin - possible symptoms of anaemia which is caused by low level of red blood cells

Common (may affect up to 1 in 10 people):

* fever, muscle pain, pain or difficulty urinating, blurred vision, cough, cold or difficulty breathing - possible symptoms of infection with BK virus
* weight gain
* constipation

**Reporting of side effects**

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in [Appendix V](https://www.ema.europa.eu/documents/template-form/qrd-appendix-v-adverse-drug-reaction-reporting-details_en.docx). By reporting side effects you can help provide more information on the safety of this medicine.

**5. How to store Jakavi**

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton or blister after “EXP”.

Do not store above 30°C.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

**6. Contents of the pack and other information**

**What Jakavi contains**

1. The active substance of Jakavi is ruxolitinib.
2. Each 5 mg Jakavi tablet contains 5 mg of ruxolitinib.
3. Each 10 mg Jakavi tablet contains 10 mg of ruxolitinib.
4. Each 15 mg Jakavi tablet contains 15 mg of ruxolitinib.
5. Each 20 mg Jakavi tablet contains 20 mg of ruxolitinib.
6. The other ingredients are: microcrystalline cellulose, magnesium stearate, colloidal anhydrous silica, sodium starch glycolate (see section 2), povidone, hydroxypropylcellulose, lactose monohydrate (see section 2).

**What Jakavi looks like and contents of the pack**

Jakavi 5 mg tablets are white to almost white round tablets with “NVR” debossed on one side and “L5” debossed on the other side.

Jakavi 10 mg tablets are white to almost white round tablets with “NVR” debossed on one side and “L10” debossed on the other side.

Jakavi 15 mg tablets are white to almost white oval tablets with “NVR” debossed on one side and “L15” debossed on the other side.

Jakavi 20 mg tablets are white to almost white elongated tablets with “NVR” debossed on one side and “L20” debossed on the other side.

Jakavi tablets are supplied in blister packs containing 14 or 56 tablets or multipacks containing 168 (3 packs of 56) tablets

Not all packs may be marketed in your country.

**Marketing Authorisation Holder**

Novartis Europharm Limited

Vista Building

Elm Park, Merrion Road

Dublin 4

Ireland

**Manufacturer**

Novartis Farmacéutica S.A.

Gran Via de les Corts Catalanes, 764

08013 Barcelona

Spain

Novartis Pharmaceutical Manufacturing LLC

Verovškova ulica 57

1000 Ljubljana

Slovenia

Novartis Pharma GmbH

Roonstrasse 25

90429 Nuremberg

Germany

Novartis Pharma GmbH

Sophie-Germain-Strasse 10

90443 Nuremberg

Germany

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

|  |  |
| --- | --- |
| **België/Belgique/Belgien**Novartis Pharma N.V.Tél/Tel: +32 2 246 16 11 | **Lietuva**SIA Novartis Baltics Lietuvos filialasTel: +370 5 269 16 50 |
| **България**Novartis Bulgaria EOODТел.: +359 2 489 98 28 | **Luxembourg/Luxemburg**Novartis Pharma N.V.Tél/Tel: +32 2 246 16 11 |
| **Česká republika**Novartis s.r.o.Tel: +420 225 775 111 | **Magyarország**Novartis Hungária Kft.Tel.: +36 1 457 65 00 |
| **Danmark**Novartis Healthcare A/STlf.: +45 39 16 84 00 | **Malta**Novartis Pharma Services Inc.Tel: +356 2122 2872 |
| **Deutschland**Novartis Pharma GmbHTel: +49 911 273 0 | **Nederland**Novartis Pharma B.V.Tel: +31 88 04 52 111 |
| **Eesti**SIA Novartis Baltics Eesti filiaalTel: +372 66 30 810 | **Norge**Novartis Norge ASTlf: +47 23 05 20 00 |
| **Ελλάδα**Novartis (Hellas) A.E.B.E.Τηλ: +30 210 281 17 12 | **Österreich**Novartis Pharma GmbHTel: +43 1 86 6570 |
| **España**Novartis Farmacéutica, S.A.Tel: +34 93 306 42 00 | **Polska**Novartis Poland Sp. z o.o.Tel.: +48 22 375 4888 |
| **France**Novartis Pharma S.A.S.Tél: +33 1 55 47 66 00 | **Portugal**Novartis Farma ‑ Produtos Farmacêuticos, S.A.Tel: +351 21 000 8600 |
| **Hrvatska**Novartis Hrvatska d.o.o.Tel. +385 1 6274 220 | **România**Novartis Pharma Services Romania SRLTel: +40 21 31299 01 |
| **Ireland**Novartis Ireland LimitedTel: +353 1 260 12 55 | **Slovenija**Novartis Pharma Services Inc.Tel: +386 1 300 75 50 |
| **Ísland**Vistor hf.Sími: +354 535 7000 | **Slovenská republika**Novartis Slovakia s.r.o.Tel: +421 2 5542 5439 |
| **Italia**Novartis Farma S.p.A.Tel: +39 02 96 54 1 | **Suomi/Finland**Novartis Finland OyPuh/Tel: +358 (0)10 6133 200 |
| **Κύπρος**Novartis Pharma Services Inc.Τηλ: +357 22 690 690 | **Sverige**Novartis Sverige ABTel: +46 8 732 32 00 |
| **Latvija**SIA Novartis BalticsTel: +371 67 887 070 |  |

**This leaflet was last revised in**

**Other sources of information**

Detailed information on this medicine is available on the European Medicines Agency website: <https://www.ema.europa.eu>

**Package leaflet: Information for the patient**

**Jakavi 5 mg/ml oral solution**

ruxolitinib

**Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.**

1. Keep this leaflet. You may need to read it again.
2. If you have any further questions, ask your doctor or pharmacist.
3. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
4. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
5. The information in this leaflet is for you or your child – but in the leaflet it will just say “you”.

**What is in this leaflet**

1. What Jakavi is and what it is used for

2. What you need to know before you take Jakavi

3. How to take Jakavi

4. Possible side effects

5. How to store Jakavi

6. Contents of the pack and other information

**1. What Jakavi is and what it is used for**

Jakavi contains the active substance ruxolitinib.

Jakavi is used to treat:

- children aged 28 days and older and adults with acute graft versus host disease (GvHD).

- children aged 6 months and older and adults with chronic GvHD.

There are two forms of GvHD: an early form called acute GvHD that usually develops soon after the transplantation and can affect skin, liver and gastrointestinal tract, and a form called chronic GvHD, which develops later, usually weeks to months after the transplantation. Almost any organ can be affected by chronic GvHD.

**How Jakavi works**

Graft versus host disease is a complication which occurs after transplantation when specific cells (T cells) in the donor’s graft (e.g. bone marrow) do not recognise the host cells/organs and attack them. By selectively blocking enzymes called Janus Associated Kinases (JAK1 and JAK2), Jakavi reduces signs and symptoms of the acute and the chronic forms of graft-versus-host disease leading to disease improvement and survival of the transplanted cells.

If you have any questions about how Jakavi works or why this medicine has been prescribed for you, ask your doctor.

**2. What you need to know before you take Jakavi**

Follow all your doctor’s instructions carefully. They may differ from the general information contained in this leaflet.

**Do not take Jakavi**

- if you are allergic to ruxolitinib or any of the other ingredients of this medicine (listed in section 6).

- if you are pregnant or breast‑feeding (see section 2 “Pregnancy, breast-feeding and contraception”).

**Warnings and precautions**

Talk to your doctor or pharmacist before taking Jakavi if:

* you have any infections. It may be necessary to treat your infection before starting Jakavi.
* you have ever had tuberculosis or have been in close contact with someone who has or has had tuberculosis. Your doctor may perform tests to see if you have tuberculosis or any other infections.
* you have ever had hepatitis B.
* you have kidney problems or you have or have ever had liver problems because your doctor may need to prescribe a different dose of Jakavi.
* you have ever had cancer, in particular skin cancer.
* you have or have had heart problems.
* you are 65 years of age or older. Patients aged 65 years and older may be at increased risk of heart problems, including heart attack, and some types of cancer.
* you are a smoker or have smoked in the past.

Talk to your doctor or pharmacist during your treatment with Jakavi if:

* you experience fever, chills or other symptoms of infections.
* you experience chronic coughing with blood-tinged sputum, fever, night sweats and weight loss (these can be signs of tuberculosis).
* you have any of the following symptoms or if anyone close to you notices that you have any of these symptoms: confusion or difficulty thinking, loss of balance or difficulty walking, clumsiness, difficulty speaking, decreased strength or weakness on one side of your body, blurred and/or loss of vision. These may be signs of a serious brain infection and your doctor may suggest further testing and follow-up.
* you develop painful skin rash with blisters (these are signs of shingles).
* you have any skin changes. This may require further observation, as certain types of skin cancer (non-melanoma) have been reported.
* you experience sudden shortness of breath or difficulty breathing, chest pain or pain in upper back, swelling of the leg or arm, leg pain or tenderness, or redness or discoloration in the leg or arm as these can be signs of blood clots in the veins.

**Other medicines and Jakavi**

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. While you are taking Jakavi you should never start a new medicine without checking first with the doctor who prescribed Jakavi. This includes prescription medicines, non-prescription medicines and herbal or alternative medicines.

It is particularly important that you mention medicines containing any of the following active substances, as your doctor may need to adjust the Jakavi dose:

* Some medicines used to treat infections:
* medicines used to treat fungal diseases (such as ketoconazole, itraconazole, posaconazole, fluconazole and voriconazole)
* antibiotics used to treat bacterial infections (such as clarithromycin, telithromycin, ciprofloxacin, or erythromycin)
* medicines to treat viral infections, including HIV infection/AIDS (such as amprenavir, atazanavir, indinavir, lopinavir/ritonavir, nelfinavir, ritonavir, saquinavir)
* medicines to treat hepatitis C (boceprevir, telaprevir).
* A medicine to treat depression (nefazodone).
* Medicines to treat high blood pressure (hypertension) and chest tightness, heaviness or pain (chronic angina pectoris) (mibefradil or diltiazem).
* A medicine to treat heartburn (cimetidine).
* A medicine to treat heart disease (avasimibe).
* Medicines used to stop seizures or fits (phenytoin, carbamazepine or phenobarbital and other anti-epileptics).
* Medicines used to treat tuberculosis (TB) (rifabutin or rifampicin).
* A herbal product used to treat depression (St. John’s wort (*Hypericum perforatum*)).

Talk to your doctor if you are not sure if the above applies to you.

**Pregnancy, breast-feeding and contraception**

*Pregnancy*

* If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
* Do not take Jakavi during pregnancy (see section 2 “Do not take Jakavi”).

*Breast-feeding*

* Do not breastfeed while taking Jakavi (see section 2 “Do not take Jakavi”). Ask your doctor for advice.

*Contraception*

* Taking Jakavi is not recommended for women who could become pregnant and who are not using contraception. Talk to your doctor about how to use appropriate contraception to avoid becoming pregnant during treatment with Jakavi.
* Talk to your doctor if you become pregnant while using Jakavi.

**Driving and using machines**

If you experience dizziness after taking Jakavi, do not drive, ride a bike/scooter, use machines, or take part in other activties that need alertness.

**Jakavi contains propylene glycol**

This medicine contains 150 mg of propylene glycol in each ml of oral solution.

If your child is less than 5 years old, talk to your doctor or pharmacist before giving them this medicine, in particular if they use other medicines that contain propylene glycol or alcohol.

**Jakavi contains methyl parahydroxybenzoate and propyl parahydroxybenzoate**

May cause allergic reactions (possibly delayed).

**3. How to take Jakavi**

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

Before you start treatment with Jakavi and during treatment, your doctor will do blood tests to find the best dose, to see how you are responding to the treatment and whether Jakavi is having an unwanted effect. Your doctor may need to adjust the dose or stop treatment. Your doctor will carefully check if you have any signs or symptoms of infection before starting and during your treatment with Jakavi.

You should take Jakavi twice daily at approximately the same time every day. Your doctor will inform you of the correct dose for you. Always follow the instructions given by your doctor. Jakavi can be taken either with or without food. You can drink water afterwards to ensure that the whole dose is swallowed.

You should continue taking Jakavi for as long as your doctor tells you to.

For detailed instructions on how to use the oral solution, see “Instructions for use” at the end of this leaflet.

Jakavi tablets are available for patients above 6 years old who are able to swallow tablets whole.

**If you take more Jakavi than you should**

If you accidentally take more Jakavi than your doctor prescribed, contact your doctor or pharmacist immediately.

**If you forget to take Jakavi**

If you forget to take Jakavi simply take your next dose at the scheduled time. Do not take a double dose to make up for a forgotten dose.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

**4. Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Most of the side effects of Jakavi are mild to moderate and will generally disappear after a few days to a few weeks of treatment.

**Some side effects could be serious**

**Seek medical help immediately prior to taking the next scheduled dose if you experience the following serious side effects:**

Very common (may affect more than 1 in 10 people):

* signs of infections with fever associated with:
* muscle pain, skin redness, and/or difficulty breathing (*cytomegalovirus infection*)
* pain when urinating (urinary tract infection)
* fast heart rate, confusion and rapid breathing (sepsis, which is a condition associated with an infection and widespread inflammation)
* frequent infections, fever, chills, sore throat or mouth ulcers
* spontaneous bleeding or bruising - possible symptoms of thrombocytopenia which is caused by low levels of platelets

**Other side effects**

Very common (may affect more than 1 in 10 people):

* headache
* high blood pressure (*hypertension*)
* abnormal blood test results, including:
* high level of lipase and/or amylase
* high level of cholesterol
* abnormal liver function
* increased level of a muscle enzyme (increased blood creatine phosphokinase)
* increased level of creatinine, an enzyme which may indicate that your kidneys are not functioning properly
* low counts of all three types of blood cells: red blood cells, white blood cells, and platelets (*pancytopenia*)
* feeling sick (nausea)
* tiredness, fatigue, pale skin - possible symptoms of anaemia which is caused by low level of red blood cells

Common (may affect up to 1 in 10 people):

* fever, muscle pain, pain or difficulty urinating, blurred vision, cough, cold or difficulty breathing - possible symptoms of infection with BK virus
* weight gain
* constipation

**Reporting of side effects**

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in [Appendix V](https://www.ema.europa.eu/documents/template-form/qrd-appendix-v-adverse-drug-reaction-reporting-details_en.docx). By reporting side effects you can help provide more information on the safety of this medicine.

**5. How to store Jakavi**

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton or bottle after “EXP”.

Do not store above 30°C.

After opening use within 60 days.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

**6. Contents of the pack and other information**

**What Jakavi contains**

1. The active substance of Jakavi is ruxolitinib.
2. Each ml solution contains 5 mg ruxolitinib.
3. The other ingredients are: propylene glycol (E 1520) (see section 2), citric acid anhydrous, methyl parahydroxybenzoate (E 218) (see section 2), propyl parahydroxybenzoate (E 216) (see section 2), sucralose (E 955), strawberry flavour, purified water.

**What Jakavi looks like and contents of the pack**

Jakavi 5 mg/ml oral solution comes as a clear, colourless to light yellow solution, which may have some small colourless particles or a small amount of sediment in it.

Jakavi oral solution is available in amber glass bottles with a white polypropylene child-resistant screw cap closure.

Packs containing one bottle of 60 ml oral solution, two 1 ml oral syringes and one press-in bottle adapter.

**Marketing Authorisation Holder**

Novartis Europharm Limited

Vista Building

Elm Park, Merrion Road

Dublin 4

Ireland

**Manufacturer**

Novartis Farmacéutica S.A.

Gran Via de les Corts Catalanes, 764

08013 Barcelona

Spain

Novartis Pharma GmbH

Roonstrasse 25

90429 Nuremberg

Germany

Novartis Pharma GmbH

Sophie-Germain-Strasse 10

90443 Nuremberg

Germany

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

|  |  |
| --- | --- |
| **België/Belgique/Belgien**Novartis Pharma N.V.Tél/Tel: +32 2 246 16 11 | **Lietuva**SIA Novartis Baltics Lietuvos filialasTel: +370 5 269 16 50 |
| **България**Novartis Bulgaria EOODТел.: +359 2 489 98 28 | **Luxembourg/Luxemburg**Novartis Pharma N.V.Tél/Tel: +32 2 246 16 11 |
| **Česká republika**Novartis s.r.o.Tel: +420 225 775 111 | **Magyarország**Novartis Hungária Kft.Tel.: +36 1 457 65 00 |
| **Danmark**Novartis Healthcare A/STlf.: +45 39 16 84 00 | **Malta**Novartis Pharma Services Inc.Tel: +356 2122 2872 |
| **Deutschland**Novartis Pharma GmbHTel: +49 911 273 0 | **Nederland**Novartis Pharma B.V.Tel: +31 88 04 52 111 |
| **Eesti**SIA Novartis Baltics Eesti filiaalTel: +372 66 30 810 | **Norge**Novartis Norge ASTlf: +47 23 05 20 00 |
| **Ελλάδα**Novartis (Hellas) A.E.B.E.Τηλ: +30 210 281 17 12 | **Österreich**Novartis Pharma GmbHTel: +43 1 86 6570 |
| **España**Novartis Farmacéutica, S.A.Tel: +34 93 306 42 00 | **Polska**Novartis Poland Sp. z o.o.Tel.: +48 22 375 4888 |
| **France**Novartis Pharma S.A.S.Tél: +33 1 55 47 66 00 | **Portugal**Novartis Farma ‑ Produtos Farmacêuticos, S.A.Tel: +351 21 000 8600 |
| **Hrvatska**Novartis Hrvatska d.o.o.Tel. +385 1 6274 220 | **România**Novartis Pharma Services Romania SRLTel: +40 21 31299 01 |
| **Ireland**Novartis Ireland LimitedTel: +353 1 260 12 55 | **Slovenija**Novartis Pharma Services Inc.Tel: +386 1 300 75 50 |
| **Ísland**Vistor hf.Sími: +354 535 7000 | **Slovenská republika**Novartis Slovakia s.r.o.Tel: +421 2 5542 5439 |
| **Italia**Novartis Farma S.p.A.Tel: +39 02 96 54 1 | **Suomi/Finland**Novartis Finland OyPuh/Tel: +358 (0)10 6133 200 |
| **Κύπρος**Novartis Pharma Services Inc.Τηλ: +357 22 690 690 | **Sverige**Novartis Sverige ABTel: +46 8 732 32 00 |
| **Latvija**SIA Novartis BalticsTel: +371 67 887 070 |  |

**This leaflet was last revised in**

**Other sources of information**

Detailed information on this medicine is available on the European Medicines Agency website: <https://www.ema.europa.eu>

**Instructions for use**

**Jakavi 5 mg/ml oral solution**

Please read these “Instructions for use” carefully before you start using Jakavi. Your healthcare provider should show you how to measure and give a dose of Jakavi correctly. If you have any questions about using Jakavi talk to your healthcare provider.

1 bottle containing Jakavi oral solution

|  |  |
| --- | --- |
| Your Jakavi pack should contain: | 2 reuseable oral syringes (1 ml size with 0.1 ml graduations)1 bottle adapterDose markingsBlack stopperPlungerBarrelTip |
| **IMPORTANT INFORMATION** |
| * The healthcare provider must determine whether the patient can self-administer the medication or if assistance from a caregiver is necessary.
* **Do not** use the Jakavi oral solution if packaging is damaged, or expiry date has passed.
* **Do not** use the syringe if it is damaged or dose marking scale is faded.
* **Always** use a new oral syringe for each new bottle of Jakavi oral solution.
* If Jakavi oral solution gets on your skin, immediately wash the area well with soap and water.
* If Jakavi oral solution gets in your eyes, immediately rinse your eyes well with cool water.
 |

|  |
| --- |
| **Administration** |
| 1. **Always** wash and dry your hands before measuring and giving a dose of Jakavi oral solution to avoid any potential contamination.If Jakavi oral solution gets on your skin, immediately wash the area well with soap and water.If Jakavi oral solution gets in your eyes, immediately rinse your eyes well with cool water. |
| 2. Check the bottle tamper evident seal is intact and check the expiry date on the bottle label.**Do not** give Jakavi oral solution if the tamper evident seal is broken or the expiry date has passed. |
| 3. Shake the bottle before opening.Remove the child-resistant cap by pushing down on the cap and turning it in the direction of the arrow (anti-clockwise).Write the date of the first opening on the bottle label. | A hand holding a bottle of liquid  Description automatically generated |
| 4. Place the bottle on a flat surface and hold it firmly. With your other hand, insert the adapter into the bottle using your thumb or palm.**Important:** Inserting the adapter may require a high force. Push hard until it is fully inserted. The adapter should be fully flush with the bottle, and you should not be able to see any ridges. | A hand opening a bottle  Description automatically generatedA close-up of two brown bottles  Description automatically generated |
| 5. Push the plunger of the syringe to remove all the air inside. |
| 6. Insert the tip of the syringe into the opening of the bottle adapter.Push down to ensure the syringe is securely attached. |  |
| 7. Carefully turn the bottle upside down and pull down on the plunger until the top of the black stopper lines up with your prescribed dose on the syringe barrel.**Note:** Small air bubbles are ok. | A hand holding a syringe  Description automatically generated |
| 8. Continue to hold the syringe in place and carefully turn the bottle back upright.Remove the syringe from the bottle by gently pulling straight up. | A hand holding a syringe and a bottle  Description automatically generated |
| 9. Check again to be sure that the top of the black stopper is at your prescribed dose.If not, repeat measuring steps again. | A close-up of a thermometer  Description automatically generated |
| 10. Make sure the child is **sitting upright or standing.**Place the end of the syringe inside the mouth with the tip touching inside of either cheek.Slowly push the plunger all the way down to give the prescribed dose of Jakavi oral solution.**WARNING:** Administering to the throat or pushing the plunger too fast may cause choking. | A black and white drawing of a hand holding a pen  Description automatically generated |
| 11. Check there is no Jakavi oral solution left in the syringe. If there is any Jakavi oral solution left in the syringe, administer it.The child can be given a drink of water after administration to ensure that the whole dose of Jakavi oral solution is swallowed.**Note:** If the prescribed dose requires using the syringe twice, repeat the administration steps until the prescribed dose has been administered. |
| 12. **Do not** remove the bottle adapter.Place the child-resistant cap back on the bottle and turn it clockwise to close it.Make sure the cap is securely attached onto the bottle. |

|  |
| --- |
| **Cleaning the syringe** |
| Note: keep your oral syringe separate from your other kitchen items in order to keep it clean. |
| 1. Fill a glass with warm water. |
| 2. Place the syringe into the glass with the warm water.Pull up and then push down on the plunger to pull the water in and out of the syringe 4 to 5 times. |
| 3. Remove the plunger from the barrel.Rinse the glass, plunger and barrel under warm tap water. |
| 4. Leave the plunger and barrel on a dry surface to air dry before next use.**Always** keep the syringe out of reach of children. |

|  |
| --- |
| **Administration via feeding tube** |
| * **Always** talk to your healthcare provider before administering Jakavi oral solution via a feeding tube. Your healthcare provider should show you how to administer Jakavi oral solution via a feeding tube.
* Jakavi oral solution can be administered via a Nasogastric (NG) or Gastric (G) feeding tube of **size French 4** (or greater)and not exceeding **125 cm in length**.
* You may need an ENFIT adapter (not included in pack) to connect the 1 ml syringe to the feeding tube.
* Flush the feeding tube according to the manufacturer’s instructions immediately before and after administering Jakavi oral solution.
 |